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Abstract.
The antiproliferative effects of the tumour suppressor p53 stem from its ability to 
induce either cell cycle arrest or apoptosis and aie regulated by the p300/CBP 
transcriptional co-activator proteins. In order to elucidate the mechanisms of p300 
dependent transcriptional activation of the p53 response, the role of a newly 
identified protein co-factor, termed JMY, that physically associates with p300 was 
examined. JMY effectively assists p300 in p53-dependent fran^activation of 
apoptotic promoting genes. Removal of the proline rich domain in the C-terminus of 
JMY produces a protein that switches the functional outcome of the p53 response 
from apoptosis to cell cycle arrest. Results presented here suggest that JMY 
collaborates with p300 to stimulate p53 apoptosis while the JMYAP isofoiTn 
collaborates with p300 to induce p53 fran.yactivation of and cell cycle
arrest. Thus, the proline rich region of JMY modulates p53’s role as a cell cycle arrest 
or apoptotic inducing protein.
Furtheimore, JMY may functionally impact on the p53 pathway through its ability to 
associate with and influence the activities of human JMY co-activates and
assists p300 in E2F-1 mediated expression of pl4^^ In addition JMY is present in the 
pl4*^^ complex and a functional consequence of the interaction is the displacing of 
the nucleolar population of pl4*^^ into the nucleoplasm.
A tumour derived mutant of pRb, pRbA22, that has lost E2F regulatory activity 
collaborates with JMY in the co-activation of p53-dependent Bax expression, 
suggesting that cells can by-pass the loss of growth control through pRb by
stimulating apoptosis. JMY therefore acts as a potential regulator of the p53 response 
and may represent a novel target for the development of therapeutically useful 
modulators of p53 activity. Defining the mechanism through which JMY and pRb 
collaborate in apoptosis may prove useful in the understanding of the cells response 
to tumourigenesis.
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1. Introduction.
Cells have acquired the ability to divide and replicate in order to allow the 
propagation of the species and to counter the loss of cells by damage. The replication 
of cellular material and DNA, which leads to cell division, takes place through a 
process known as the cell cycle. Understanding the cell cycle is essential in the 
comprehension of human diseases that originate from its breakdown and is vital in 
the search and design of anti-tumour therapies.
The cell cycle is regulated through the activity of transcription factors and their 
associated repressors and activators. The co-ordination of the signals from these 
components determines whether a cell proliferates, differentiates, enters quiescence 
or dies (La Thangue, 1994).
The integration of growth regulating signals occurs at the Gi to S phase boundary 
after which point a cell is committed to divide. The transition from Gi into S phase is 
controlled by a number of critical regulatory proteins that control gene expression, 
such as the transcription factors p53 and E2F (La Thangue, 1994; Levine, 1997). In 
addition these critical factors are themselves regulated by cellular proteins such as the 
tumour suppressor pRb and the transcriptional co-activator p300/CBP (Torchia et aL, 
1998; Weinberg, 1995; Shikama et a l, 1997). The cellular importance of p53, pRb, 
and p300/CBP is emphasised by the observations that viral proteins that maintain 
proliferation directly interfere with their functions.
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Under conditions where the integrity of the genome has been compromised the cells 
cycle is an’ested. The failure of cells with unstable genomes to arrest is a defining 
point in the formation of cancer cells. Cellular mechanisms have evolved that repair 
damaged genomes but under conditions where the damage response is unable to 
initiate a recovery a second more potent mechanism that prevents the proliferation of 
cells has arisen, namely apoptosis. Apoptosis plays an indispensable role during 
development to eliminate unwanted potentially dangerous cells and consequently the 
mechanisms that control the apoptotic response are highly conserved (Burns and El- 
Deiry, 2000).
Additional, new, members involved in the regulation of the cell cycle and apoptotic 
pathways are continually being identified and with every discovery a more detailed 
understanding of the cell cycle emerges. Discussed here in more detail are the known 
functions of the cell cycle regulators, p53, p300/CBP, ARE and pRb,
20
1-1. p53, the cellular gatekeeper for 
growth and apoptosis.
1-1.1. Introduction.
A key regulator of cellular growth and neoplasia is the tumour suppressor p53. The 
gross over-expression of p53 witnessed in a variety of tumours regardless of the 
transforming agent and cell type underlies the vital importance of p53 in genome 
stability (Rotter et aL, 1981; Rotter, 1983).
p53 is a multi-functional protein that executes a vaiiety of cellular outcomes in order 
to maintain a healthy cell. Numerous studies have elucidated a role for p53 in growth 
arrest, apoptosis and differentiation and defined p53 as a DNA damage-inducible 
protein that participates in genomic repair (Cross et ah, 1995; Wells, 1996).
The inactivation of wild-type p53 promotes genomic instabilities and is a key event in 
the formation of cancer cells. The high frequency of p53 mutations observed in 
human tumours clearly helps define p53 as the “guardian of the genome” (Levine, 
1997).
1-1.2. Characteristics of p53.
The p53 gene is highly mutated in human cancer, with approximately 50% of 
tumours displaying a loss of p53 function as a result of germline mutations (Hollstein 
et aL, 1991; Greenblatt et aL, 1994). Many tumour types show deletion of one p53 
gene allele and mis-sense mutation in the other (Hollstein et aL, 1994). The high 
frequency of mutations in p53 alleles lead to the discovery that p53 is a heritable
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germ line mutated gene. Individuals suffering from Li-Fraumeni syndrome that aie 
predisposed to cancer carry a germ line mutation in p53 (Donehower and Bradley, 
1993). In addition individuals with independently arising neoplasms often display 
germ line mutations in the p53 locus.
Species and mutational comparisons identified that the vast majority of mis-sense 
mutations in p53 are clustered at hot spot regions in the highly conserved core 
domain. The hot spot regions are comprised primarily of amino acids that 
incapacitate p53 sequence specific DNA binding and underpin p53’s ability to 
suppress tumourigenesis. The hot spot amino acids Arg248 and Arg273 directly 
contact DNA while Argl75, Arg245, Gly249, Arg273 and Arg282 are responsible for 
stabilising the structure of the DNA binding interface (Levine, 1997) (Figure 1.1a).
p53 is more susceptible to mis-sense mutations than nonsense mutations which 
suggests that p53 mutants that retain selective functions are advantageous to tumour 
cells. Consistent with the advantage of p53 mutations in tumour cells is the 
observation that mutant p53 introduced into p53 negative cells aids tumourigenesis 
(Dittmer et aL, 1993). In addition to the gain of function observed by mutant p53 the 
proteins is also able to disrupt cellular growth control by affecting the activity of the 
wild-type protein. In agreement, oligomerization domain mutations in p53 that 
dominate wild-type p53 function are negative in cell cycle control as a result of their 
inability to form tetramers (Unger et aL, 1993).
p53, in keeping with the observation that many oncogenes and tumour suppressor 
genes are arranged into families, is itself one member of a family. p53 has two known
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family members, namely p63 and p73 (Kaghad et a l, 1997; Yang et al., 1991). 
Interestingly p63 and p73 show more similarity to each other than to p53. Common to 
all three family members is the high number, large size and organisation of their non­
coding introns (Soussi and May, 1996; Marin and Kaelin, 2000).
The p53 family of proteins is enlarged by the ability of all the family members to 
undergo splicing events that produce functionally distinct proteins. In mouse, two p53 
splice forms are expressed, called normal splice (NS) and alternative splice (AS), 
while both p63 and p73 are multiply spliced (Wu et a l, 1995; Arai et a l, 1986). p63 
can be spliced into a, p, and y forms while p73 has five known fonns namely 
a, P, y, Ô, and e (De Laurenzi et a l, 1998; De Laurenzi et a l,  1999; Zaika et a l, 
1999; Marin and Kaelin, 2000). Additionally a cryptic promoter located in exon three 
is utilised to produce three N-terminal deleted transcripts of p63 (Yang et a l, 1997).
The cloning and sequencing of p53 from a variety of species in combination with 
functional interaction data has enabled a detailed structural analysis of p53. Human 
p53 is encoded by 393 amino acids and has four structurally conserved functional 
domains in addition to a number of other interesting features. The N-terminal 42 
amino acids of p53 constitute its transcriptional activation domain, presumably as a 
result of its ability to contact directly members of the basal transcription machinery 
(Fields and Jang, 1990). The N-terminus is predominantly acidic in nature, however, 
two hydrophobic residues in this region mediate p53’s ability to interact with the 
transcription machinery components TAFn70 and TAFn31 (Lu and Levine, 1995; 
Thut et a l, 1995). The transactivation domain of p53 is also the site targeted by the 
negative regulators ElB-55kDa and MDM2 (Lin et a l, 1994) (Figure 1.1b).
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Active p53 exists as tetramers (dimer of dimers) and the domain that mediates 
oligomerization resides in the C-terminus (Shaulian et al., 1992; Iwabuchi et a l, 
1993; Wang et a l, 1994a) (Figure 1.1b). Interestingly, as a result of allosteric 
interactions between the core domain and the oligomermization domain through a 
flexible linker, p53 can also form multiples of tetramers (Stenger et a l, 1994).
p53 binds to specific DNA sequences through its central core domain (Zauberman et 
a l, 1993) (Figure 1.1b). A tetrahedrally co-ordinating Zn^ "^  atom in the core domain 
confers the self-folding and sequence specific binding properties of p53 (Pavletich et 
a l, 1993; Wang et a l, 1993). Analysis of multiple genomic p53 target sites has 
defined the consensus site 5 ' -PuPuPuC(^/T)(^/A)GPyPyPy-3 ' for tetrameric p53 
binding (Strurzbecher and Deppert, 1994).
The highly basic, extreme, C-terminus of p53 negatively regulates the specific 
binding of p53 to its consensus site and can also non-specific ally bind DNA and 
RNA (Hupp et a l, 1992; Pavletich et a l, 1993; Wang et a l, 1993) (Figure 1.1b). The 
ability of the C-terminal domain of p53 to recognise nucleotide mismatches, 
insertions and deletions to either sterically or allosterically alter the sequence specific 
binding capacity of p53 is undoubtedly an important feature of p53 (Levine, 1997). 
C-terminal domain associated catalysis of DNA and RNA re-association underlies the 
involvement of p53 in the mismatch repair process.
p53’s functional diversity has been attributed to its ability to interact with a large 
number of different cellular proteins (Figure 1.1c). p53 interacts with the single
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stranded binding protein RP-A and the interaction is believed to inhibit RP-A binding 
and stimulation of single stranded DNA condensation (Dutta et al., 1993). The 
interaction of the RNA polymerase subunit TFnH with p53 results in the loss of its 
helicase activity and a modulation of its function in nucleotide excision repair (Wang 
et al., 1995b). The Wilms’ tumour suppressor gene product W Tl also interacts with 
p53. W Tl abrogates p53-mediated transcription to suppress apoptosis (Maheswaian 
et al., 1995). In addition to the factors discussed above, p53 binds to and utilises a 
lai’ge number of transcriptional co-activator proteins, one such member being 
p300/CBP (Avantaggiati et al., 1997; Gu et a l, 1997; Lill et a l,  1997b).
In the N-terminus of p53 there are five copies of the SH3 (Src homology domain 3) 
binding motif P-X-X-P. A potential role of the polyproline domains is in the 
regulation and binding of p53 to SH3 signal transduction domain containing proteins. 
Consistent with the proposed role of p53 as a SH3 domain binding protein and signal 
transduction cascade target is the ability of the SH3 domain containing c-Abl protein 
to stimulate and activate a p53-dependent cell cycle arrest (Goga et a l, 1995). 
Interestingly, mutations in the P-X-X-P motifs have been detected in patients 
suffering Li-Fraumeni syndrome and correlates with the reduced ability of p53 in 
these suffers to induce apoptosis and cell cycle anest (Sun et a l, 1996; Walker and 
Levine, 1996).
In addition to the sequence and structural features discussed above p53 also has a 
number of other interesting features, including potential sites that can be modified by 
phosphorylation and acétylation (Privies, 1998; Soutogloou et a l, 2000). The high
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level of evolutionary conservation of p53 together with its structural characteristics 
underlies p53’s vital cellular importance.
1-1.3. p53 mediated transcription.
In most cells p53 is a latent, short-lived protein with a rapid turnover rate. 
Consequently, in order for p53 to perform a specific function it must receive signals 
that alter its half-life. Several types of cellular stresses such as y-inadiation, UV 
irradiation, nucleotide depletion and chemical damage all activate p53 function either 
by post-translationally stabilising p53 or increasing its profile of expression. 
Consistent with the activation of p53 in response to DNA damage is the observation 
that transgenic mice defective in nucleotide excision repair display an elevated level 
of p53 (MeWhir gr aZ., 1993).
Given that divergent forms of DNA damage result in an identical cellular outcome it 
is possible that the cellular mechanisms that sense DNA damage cross-talk and 
converge on p53. Supportive of such a role for p53 is the observation that cells 
defective in the ATM gene product, that senses DNA damage, display a delayed p53 
accumulation response following their treatment with ionising radiation (Kastan et 
a l, 1992).
The p53 response is also activated as a result of hypoxia. An interesting possibility is 
that tumour cells, as they reach a critical size, begin to undergo a p53 response that 
holds the tumour in a non-metastatic state (Graeber et a l, 1996). The anti-angiogenic 
factor thrombospondin-1 is induced by p53 suggesting the existence of a feedback 
mechanism of p53 activation in tumours. Thrombospondin reduces the blood supply
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to tissues, which concurrently activates the p53 hypoxia response which in turn will 
feedback and activate thrombospondin expression (Sun et ah, 1999).
The ability of p53 to specifically bind DNA elements in the reporters of many cell 
cycle genes clearly demonstrates that p53 is a bona fide transcription factor. The 
gadd45 gene, that encodes a protein which modulates PCNA function and is involved 
in nucleotide excision repair, is induced by p53 in response to DNA damage (Kastan 
et ah, 1991; Smith et ah, 1994). Induction of GADD45 by p53 stimulates a growth 
aiTest phenotype to presumably allow damage repair.
Interestingly, p53 was also shown to induce the expression of the MDM2 proto­
oncogene that, in turn, can repress p53 transcription by promoting its degradation 
(Momand et ah, 1992). The mdm2 gene contains two distinct potential p53 
responsive promoters, PI is responsible for basal MDM2 expression and P2 is 
involved in the activated p53 response (Barak et ah, 1994). MDM2 gene expression 
is elevated following the radiation induced DNA damage stabilisation of p53 (Barak 
and Oren, 1992; Barak et ah, 1994) (Figure 1.2b).
The exposure of cells to a vaiiety of DNA damaging agents led to the identification 
of as a p53 responsive gene (El-Deiry et ah, 1993). The ability of
p2 iWafi/cipi inhibit cyclin-dependent kinases and thereby influence pRb 
phosphorylation is the mechanism by which p53 stimulates Gi arrest (Gu et ah,
1993). The treatment of human fibroblasts with radiation confirmed that 
expression and inhibition of the cell cycle was p53-dependent (Dulic et ah, 1994) 
(Figure 1.2c).
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The regulation of cellular apoptosis by the proto-oncogene Bcl-2, that prevents 
apoptosis, and its homologous protein Bax, that accelerates apoptosis, were studied in 
relation to p53 transcriptional activation (Oltvia et a l, 1993). The Bcl-2 family of 
proteins can be divided into pro-survival members such as Bcl-2, B c1-X l, Bcl-w and 
CDE9 and pro-apoptotic members such as Bax, Baf and Bid (Burns and El-Deiry, 
1999). The Bcl-2 family members form heterodimers, and it is the relative ratio of the 
survival versus apoptotic factors that determines whether the cell lives or dies. The 
anti-apoptotic members of the Bcl-2 family inhibit cyctochrome c release from the 
mitochondria which prevents Apaf-1 activation of initiator capase 9. The over­
expression of p53 in a murine leukaemia cell line resulted in an increase in Bax 
expression and further analysis demonstrated that the actual gene promoter contains 
four potential consensus p53 sites. Physiologically p53 appears to specifically 
activate Bax in the context of p53-dependent apoptosis (Miyashita et a l, 1994a; 
Miyashita and Reed, 1995) (Figure 1.2a).
The insulin-like growth factor binding protein 3 (IGF-BP3) that inhibits mitogenic 
signalling by the insulin like growth factor (IGF-1) is effectively induced by p53 
(Buckbinder et a l, 1995). The induction of IGF-BP3 occurs in response to DNA 
damage and lowers the receptiveness of cells to mitogenic signals (Levine, 1997). 
Given that IGF-BP3 protects cells from c-Myc induced p53-dependent apoptosis it 
has been proposed to act as a survival factor that sensitises cells to apoptotic signals.
The cyclin G gene is also transcriptionally activated by p53 although the functional 
significance of this over-expression is unknown (Zauberman et a l, 1995).
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Interestingly in transient transfection assays the pRb promoter is dose-dependently 
p53 responsive, with high levels of p53 being repressive, and low levels activating 
(Shiio et aL, 1992; Osifchin et ah, 1994).
The N-termihal p53 polyproline domain is essential for efficient growth suppression 
and transcription of the PIG3 (p53 induced gene 3) promoter but is dispensable for 
the transcriptional activation of mdm2 and box (Walker and Levine,
1996). Conflicting evidence exists as to the ability of the polyproline region to affect 
p53’s DNA binding affinity. The polyproline domain of p53 is believed to mediate 
p53’s role in non-specific transcriptional repression, production of reactive oxygen 
species (ROS), and apoptosis but not its role in growth airest (Sakamuro et a l, 1997; 
Venot et a l, 1998).
An interesting feature of p53 is its ability to repress both cellular and viral promoters 
that do not contain a consensus p53 site (Ginsberg et a l, 1991; Subler et al., 1992; 
Jackson et al., 1993). p53’s non-specific repressive activity relies on both its N- and 
C- termini and is TATA box promoter dependent (Subler et al., 1992; Mack et a l, 
1993; Sang et al., 1994). p53’s ability to repress transcription may be an indirect 
consequence of activation domain binding factor competition. Consistent with such a 
model is p53’s ability to repress the human hspVO promoter as a consequence of its 
ability to bind and sequester the transcription factor CBF (CCAAT binding factor) 
(Agoff et a l, 1993). p53’s ability to act as a transcriptional repressor is also 
highlighted by its ability to repress a large number of genes following p53 induction 
(Polyak et a l, 1997). One such gene encodes the microtubule-associated protein 
MAP4 (Murphy et a l, 1996).
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1-1.4. p53 induced cell cycle arrest.
The constitutive over-expression of wild-type p53 abrogates oncogene-mediated 
transformation and inhibits the growth of various tumour cell types (Eliyahu et al., 
1989; Finlay et al., 1989; Baker et al., 1990; Diller et al., 1990). p53 inhibits cell 
cycle progression by holding cells in Gi which allows time for the assessment of the 
DNA integrity of the cell before a commitment to divide, that helps maintain the 
genetic stability of the cell (Levine, 1997). Consequently the level of p53 is directly 
induced upon the treatment of cells with DNA damaging agents (Kastan et al., 1991).
The ability of p53 to cause Gi an'est is mediated by its ability to reduce the activity of 
the cyclin-dependent kinases that promote gene expression. p53 induction of the 
cyclin dependent kinase inhibitor in response to DNA damage in human
fibroblasts is the major event that mediates Gi aiTest. (Dulic et al., 1994). 
universal inhibition of the cyclin dependent kinases is mediated by its interaction with 
the cyclin fold and inhibition of CAK (CDK activating kinase) phosphorylation. 
Inactivation of cyclin/cdk’s results in the hypophosphorylation of pRb which in turn 
represses the key cell cycle regulatory transcription factor E2F (Figure 1.2c). 
Interestingly however p53 transcriptionally inactive mutants are still able to induce a 
Gi arrest and deficient mice develop normally (Deng et a l, 1995).
Additionally, mouse embryonic fibroblasts (MEF’s) that are rb'’' can still undergo a 
radiation stimulated p53 mediated Gi an'est supporting a role of p53 not only in pRb 
regulation but also in the regulation of the other pocket protein family members 
namely, pl07 and pl30 (Slebos et al., 1994). The ability of p53 to mediate a Gi arrest 
is, however, pivotal to the stability and regulation of the genome.
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When mitotic spindle inhibitors, such as nocodazole, are added to cells in the 
presence of p53 cells arrest in G2 /M (Vikhanskaya et al., 1994; Cross et al., 1995). 
The ability of p53 to G2/M anest cells is believed to be a consequence of p53’s role 
as a centrosome number and spindle checkpoint controlling protein (Fukasawa et a l,
1996). In support of p53’s role as a spindle formation regulator is the observation that 
p53'^' cells and embryos from p53 knockout mice display a high degree of 
aneuploidy, tetraploidy and octaploidy (Harvey et a l, 1993; Cross et a l, 1995). 
Indeed, p53 directly associates with centrosomes (Brown et a l, 1994).
In addition to its role in cell cycle arrest p53 has been linked to a Gasl associated Go 
arrest. Gasl is a membrane protein that is expressed during G q  and functions in 
maintenance of the G q  phenotype. p53’s role in signalling, in a transcriptionally 
independent manner, may be the mechanism that p53 utilises to mediate a Gasl 
associated G q  aiTest (Del-Sal et a l, 1995; Ruaro et a l, 1997).
The flattened senescence like phenotype observed in some p53-induced cells 
indicates that the p53 response is cell type specific. The levels of p53 and 
increase as cells age and senesce, and interestingly p53'^' cells escape a senescence 
check point and go on to form aneuploid immortalised cells (Bond et a l, 1995). The 
transient Gi arrest or permanent senescence like arrest associated with p53 activation 
outlines two of the mechanisms that the cell has evolved to prevents its proliferation 
with an unstable genome (Gottlieb and Oren, 1996).
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In addition to repression of the cell cycle machinery, another way that p53 may 
prevent cell cycle progression is through the inhibition of DNA replication. p53 
interacts with the replication associated protein, RP-A, and stimulates gadd45 
transcription. GADD45 can bind and inhibit PCNA’s (proliferating cell nuclear 
antigen) role in replication. The p53 transcriptional target gene can also
inhibit SV40 DNA replication potentially as a consequence of its ability to bind 
PCNA and block its role as a DNA processcivity factor in replication (Flores-Rozas 
et a i, 1994; Waga et a l, 1994). The importance of in DNA damage-
inducible Gi arrest has been confiimed by the deficiency of p2V'' MEF’s to undergo 
a Gi aiTest in response to DNA damage (Deng et al., 1995). These observations 
clearly show that the molecular mechanism of p53 mediated cell cycle anest may be 
either direct through the action of inhibitors such as or indirect through
proteins such as PCNA.
1-1.5. Induction of apoptosis bv p53.
The introduction of p53 into cells can also induce a programmed cell death or 
apoptotic phenotype (Yonish-Rouach et al., 1991). p53’s role in apoptosis was 
confirmed by the finding that p53'^' mouse thymocytes and intestinal stem cells, 
unlike wild-type cells, are unable to undergo radiation induced apoptosis (Clai'ke et 
al., 1993; Lowe et al., 1993; Menitt et al., 1994). p53’s role as a cell death inducer is 
however stimuli specific as p53'^~ thymocytes undergo a normal apoptotic response 
following their treatment with glucocorticiods or T cell receptor stimulants (Clarke et 
a l, 1993; Lowe et a l, 1993).
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Consistent with the role of p53 in apoptosis, the introduction of p53 into quiescent 
cells produces an apoptotic response (Lowe and Ruley, 1993; Howes et ah, 1994). 
Adenoviral E l A and the Papilloma virus E7 proteins both induce p53-dependent 
apoptotic pathways (Vaux et al., 1994). Both E lA  and E7 stabilise p53 but 
conversely in the normal viral life cycle the anti-proliferative viral ElB and E6 
proteins are expressed simultaneously with E lA  and E7. The co-expression of ElB 
and E6 results in the prevention of apoptosis while simultaneously promoting 
proliferation (Reo et al., 1992).
The cellular oncogenes E2F-1 and c-Myc are two other proteins that trigger p53- 
dependent apoptosis (Hermeking and Eick, 1994; Wagner et al., 1994; Wu and 
Levine, 1994). The over-expression of c-Myc in p53''' fibroblasts induces cell cycle 
progression while over-expression in a p53 positive background stimulates apoptosis 
(Hermeking and Eick, 1994). Similarly the over-expression of E2F-1 can induce a 
p53 apoptotic response (Qin et a l, 1994).
Given that p53-dependent apoptosis can occur in the presence of the RNA and 
protein synthesis inhibitors, actinomycin D and cycloheximide, it is possible that 
apoptosis is independent of p53 mediated transcription (Gaelics et al., 1994). In 
addition, p53 mutants, devoid of a transcriptional activation domain when introduced 
into cells, although more slowly than wild-type, still induce apoptosis (Haupt et al., 
1995).
Interestingly, pRb overcomes the anti-apoptotic function of MDM2 but does not 
prevent MDM2 from inhibiting p53-mediated transcription (Hsieh et al., 1999).
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Given that pRb forms a tiimeric complex with p53 and MDM2 it is therefore 
plausible to assume that p53 transcriptional activation is dispensable for apoptosis 
(Hsieh et a l, 1999). The ability of p53 and pRb to cross-talk in the regulation of 
apoptosis points to a cellular mechanism by which apoptosis is tightly regulated by 
the two tumour suppressors, p53 and pRb.
However certain cell systems appear to require an intact p53 transcriptional activation 
capacity in order to induce apoptosis (Sabbatini et al., 1995b). Consistent with the 
rran^activation domain of p53 being necessary for the effective induction of 
apoptosis is the ability of p53 to transcriptionally activate bax expression (Miyashita 
and Reed, 1995). Bax protein expression accelerates apoptosis by overcoming the 
anti-apoptotic effects of Bcl-2. Interestingly and consistent with p53’s role as a 
transcriptional repressor, p53 overexpressing cells display a lower level of the anti- 
apoptotic factor Bcl-2 (Miyashita et al., 1994a; Miyashita et al., 1994b).
Interestingly although bax is a p53 responsive gene that stimulates apoptosis a 
number of studies demonstrated that bax expression was dispensable for p53 
mediated apoptosis (Knudson et al., 1995). Another protein potentially involved in 
p53 mediated apoptosis is the tumour necrosis factor receptor superfamily member 
Fas/APOl. The binding of the Fas/APOl receptor ligand FasL stimulates F ADD 
binding (Fas-associated death domain) and the autocatalysis and activation of caspase 
8, which results in apoptosis. Even through Fas/APOl is transcriptionally and non- 
transcriptionally stimulated by p53 it is not essential for p53-dependent apoptosis 
(Fuchs et al., 1997; Bennett et al., 1998).
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Consequently additional genes that participate in the DNA damage induced p53 
apoptotic response have been identified. The gene encoding, the cathepsin-D aspartyl 
protease that contributes to cytokine mediated apoptosis, KILLER/DR5 a pro- 
apoptotic inducing member of the tumour necrosis related factor receptor family 
(TRAIL), PA26 a novel member of the G ADD family, Wipl a type 2C phosphatase, 
A28-RGS14 a GTPase activating protein, PAG608 a nuclear zinc finger protein and a 
human homologue of the Drosophila sina gene have all been implicated in the p53 
apoptotic pathway (Nemani et aL, 1996; Buckbinder et a l, 1997; Fiscella et a l, 
1997; Israeli et a l, 1997; Wu et a l, 1997; Wu et a l, 1998; Velasco-Miguel et a l, 
1999).
The pro-apoptotic caspase cascade activating TRAIL receptors (TNF-related 
apoptosis inducing ligand) KILLER/DR4 and /DR5 function is counteracted by the 
anti-apoptotic or decoy receptors TRED (truncated intracellular domain) and 
TRUNDD (truncated death domain). Interestingly p53 also induces the expression of 
TRID and TRUND which provides a mechanism by which p53 modulates its own 
apoptotic response (Bums and El-Deiry, 1999).
Recently the serial analysis of gene expression identified a number of p53 induced 
genes (PIG’s) involved in the oxidative stress response of p53 (Polyak et a l, 1996). 
The PIG3 gene identified by Polyak et a l  (1996) encodes an apoptosis inducing 
protein based on its homology with a plant apoptotic promoting protein NADPH 
quinone oxidoreductase.
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The ability of p53 to induce apoptosis is clearly cell type specific and depending on 
the stimuli received can be transcriptionally dependent or independent. Furthermore it 
appears that p53 not only acts as an activator but also potentially as a repressor in the 
induction of apoptosis.
1-1.6. Differentiation and development.
The ability of p53 to induce cell cycle arrest and apoptosis is well documented but 
additionally p53 may also be involved in differentiation and development. A number 
of differentiation associated markers are expressed following a rise in the level of p53 
in hematopoietic cells (Feinstein et ah, 1992; Aloni-Grinstein et ah, 1995). 
Furthermore the level of p53 mRNA is increased alongside the level of differentiation 
markers (Aloni-Grinstein et al., 1993). p53 has been linked with the differentiation of 
a number of cellular tissue, namely hematopoitic cells, skeletal muscle cells, 
epithelial cells, central nervous system cells and thyroid neoplasms. Interestingly the 
level of p53 in different cell types seems to bestow p53’s role in differentiation, with 
a decrease in p53 responsible for differentiation in some linagaes while an increase is 
responsible in others.
p53’s role in development is further emphasised by the observation that a fraction of 
female p53'^~ mice embryos, that predominantly develop normally, display neural 
tube closure defects (Donehower et al., 1992; Sah et al., 1995), Consistent with a role 
for p53 in neural development is the finding that the central nervous system 
regulatory gene, PAX5, is a regulator of p53 gene expression (Stuart et a l, 1995). In 
particular the regulation of p53 and its family members as a result of alternative
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splicing especially in the C-tenninal non-specific DNA binding domain has been 
associated with differentiation control.
1-1.7. Cell cycle arrest or apoptosis.
The regulatory event that governs the decision to undergo apoptosis or cell cycle 
aiTest in response to p53 expression is unknown. However the apoptotic and cell 
cycle aiTest functions of p53 appear to be mutually exclusive functions as p53 
mutations that retain apoptotic function but have lost growth arrest capabilities ai’e 
found in tumours. Several factors have been proposed to play a role in shifting the 
balance between growth arrest and apoptosis including; cell type, the presence of 
survival factors and the presence of oncogenes (Gottlieb and Oren, 1996; Bums and 
El-Deiry, 1999).
Following the induction of a p53 mediated Gi anest the cell is held in a position that 
allows time for potentially damaging genetic events to be repaired. If components in 
the mechanistic pathway of p53 mediated Gi arrest are deregulated or abrogated the 
cell will then undergo apoptosis. Thus p53-dependent apoptosis may be the favoured 
outcome when Gi amest is not possible or can not be maintained long enough. 
Consistent with the loss of Gi anest being a controlling mechanism in p53 mediated 
apoptosis is the observation that DA-1 inadiated cells undergo replicative DNA 
synthesis and cell cycle re-entry prior to apoptosis (Gottlieb and Oren, 1996).
The extent and severity of the cellular shock appears to be the major controlling event 
in growth anest versus apoptosis. If the cell can not repair its genetic lesions then 
apoptosis ensues to prevent tumourigenesis.
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1-1.8. Modulation of p53 function.
The high-risk Papilloma virus E6 protein inhibits p53 sequence specific transcription 
by promoting p53 degradation through the ubiquitin proteasome pathway (Wemess et 
a l, 1990; Lechner et al., 1992; Gu et al., 1994; Mansur et al., 1995; Thomas et al.,
1995). The adenovirus ElB  proteins, 55kDa and 19kDa, both effectively promote 
transformation in co-operation with E lA  by inhibiting p53 mediated apoptosis (Rao 
et al., 1992; Lowe and Ruley, 1993). The 55kDa ElB  protein acts as a non-specific 
transcriptional repressor that binds to and prevents p53 transcription (Yew et al.,
1994). Adenoviral ElB 19kDa component is believed to prevent apoptosis by 
mimicking Bcl-2 function (Sabbatini et a l, 1995a).
p53 was first identified through its ability to bind the Simian virus 40 large T antigen 
(Lane and Crawford, 1979; Linzer and Levine, 1979). SV40 large T binds to the 
central DNA binding core domain of p53 to prevent DNA binding and transcriptional 
activation (Farmer et al., 1992). As a result of SV40 binding to p53 the stability of 
p53 is increased which may contribute to the abrogation of p53’s apoptotic function.
In addition to the viral proteins discussed above a number of other viral proteins 
interact with p53. The hepatitis B virus X protein, human cytomegla vims IE84 
protein and the Epstein-Barr vims (EBV) protein BZLFl all bind p53 and inhibit its 
rmn^activation capacity (Speir et al., 1994; Wang et a l, 1994b; Zhang et a l, 1994). 
Clearly the interaction and abrogation of p53 function imposed by viral proteins is an 
important event in the viral life cycle and the maintenance of viral infection.
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The MDM2 protein that was originally identified by virtue of its amplification in a 
transformed mouse cell line also interacts with p53. (Fakharzadeh et al., 1991; 
Momand et al., 1992). MDM2 inhibits p53-mediated transcription by binding to the 
transaoiivaiion domain of p53 and promoting its ubiquitin dependent degradation 
(Oliner et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997). Ubiquitin is a 76 
amino acid protein that when attached to substrate proteins at free lysine residues 
marks them for 26S proteasome degradation (Momand et al., 2000). p53 proteolysis 
mediated by MDM2 corresponds to a transfer of a ubiquitin molecule from the C~ 
terminus of MDM2 to p53. Consequently the C-terminus of MDM2 is essential in the 
mediation of p53 degradation and mutants of p53 that are unable to bind MDM2 are 
constitutively more stable (Haupt et al., 1997; Honda et al., 1997; Kubbutat et a l,
1997).
MDM2’s ability to stimulate p53 degradation stems not only from its inherent E3 
ubiquitin ligase activity but also from its ability to shuttle p53 to the cytoplasm (Roth 
et a l, 1998; Tao and Levine, 1999a). MDM2 contains both a nuclear import (NLS) 
and export signal (NES) and so is constantly shuttled between the nucleus and 
cytoplasm (Roth et a l, 1998). It is this shuttling capability of MDM2 that allows the 
effective transport of p53 to the cytoplasm and its subsequent degradation. 
Interestingly p53 itself contains a nuclear export signal that is masked after 
tetramization and activation (Stommel et a l, 1999). In addition MDM2 interacts with 
p300 and p53 simultaneously to mediate p53 degradation (Grossman et a l, 1998). 
Presumably MDM2 utilises all its inherent activities in the regulation of p53.
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Interestingly MDM2 and p53 function in an auto-regulatory feedback loop. p53 
stimulates MDM2 expression which in turn degrades and down-regulates p53, which 
then subsequently leads to a reduction in the level of MDM2. The in vivo importance 
of the MDM2/p53 regulatory loop is emphasised by the rescue of the mice embryonic 
lethality phenotype of mdm2'^' when crossed with p53'^' mice (Jones et a l, 1995; 
Montes de Oca Luna et al., 1995).
MDM2’s ability to interact with p53 is undoubtedly an important regulatory step in 
p53 control. The p53/MDM2 interaction is directly regulated by the covalent 
phosphorylation and acétylation of p53 and indirectly through the actions of proteins 
such as p 14/19^^^ (Chin et al., 1998; Prives, 1998). Interestingly, MDM2, in 
response to ionising radiation, is phosphorylated in an ATM dependent manner by 
DNA-PK (Momand et al., 2000). This implies that ionising radiation which triggers 
an ATM/DNA-PK phosphorylation cascade results in the modification of both 
MDM2 and p53, that in turn regulates MDM2’s association with p53 (Momand et al., 
2000).
The oncogenic properties of MDM2 stem not only from its ability to prevent a p53 
mediated response but also from its ability to activate the E2F directed transcription 
of S-phase promoting genes (Martin et al., 1995; Xiao et ah, 1995). Given that many 
tumours with MDM2 mutations retain wild-type p53 it is feasible to assume that 
inactivation of p53 or MDM2 is a mutually exclusive event in tumour formation.
The MDM2 family member, MDMX, although structurally almost identical to 
MDM2 can not substitute for MDM2 in early embryonic development (Shvarts et al..
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1996). MDMX can from stable heterdimers with MDM2 through its ring finger 
domain and is also able to associate with p53 (Tanimura et a l, 1999). The functional 
significance of MDMX function on p53 action are two fold, firstly p53 can be nuclear 
retained but transcriptionally inactivated when complexed with MDMX and secondly 
p53 can be stabilised and transcriptionally activated as a result of MDMX 
dimérisation with MDM2 (Jackson and Berberich, 2000). The regulation of p53’s 
level and localisation by MDMX and MDM2 indicates a mechanism for the 
regulation of p53 function in cells.
1-1.9. Modification of p53.
Two distinct serine/threonine rich domains in the N- and C-termini of p53 are 
extensively post-translationally modified by phophorylation (Figure 1.1b). The 
kinases responsible for p53 phosphorylation are the DNA dependent protein kinase A 
(DNA-PK), ATM/ATR, casein kinase I and II (CKI, CKII), protein kinase C (PKC), 
mitogen activated protein (MAP), Chkl/Cdsl and the UV induced kinases JNKl and 
raf-1. (Milne et a l, 1992; Milne et a l, 1994; Takenaka et a l,  1995; Woo et a l, 1998; 
Chebab et a l, 2000; Shiel et a l, 2000). Interestingly p53 is also a substrate for the 
cyclin dependent kinases, cyclin B/cdc2, and cyclin A/cdk2, both of which stimulate 
the sequence specific binding property of p53 (Ko and Prives, 1996). Casin kinase II 
phosphorylation of p53 also results in an increase in sequence specific binding of p53 
to DNA (Hupp and Lane, 1994).
Intriguingly, ATM kinase is induced following DNA damage and this induction runs 
alongside p53 activation and N-terminal phosphorylation (Banin et a l, 1998; Canman 
et a l, 1998). Additionally, atm^' cells show delayed phosphorylation and activation
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of p53 following y-irradiation but not UV inadiation suggesting that ATM is 
important for signalling to p53 in a DNA damage specific manner (Siliciano et al.,
1997). However, the prolonged exposure of atm^' cells to y-irradiation does 
eventually lead to the N-terminal phosphorylation of p53 suggesting that other stress 
activated kinases can substitute for ATM.
Potentially, a mechanistic function of p53’s N-terminal phosphorylation is the loss of 
its negative regulation by MDM2. Shieh et al. (1997) demonstrated that DNA 
damage-induced N-terminal phosphorylation weakens the association of MDM2 with 
p53 and consequently stimulates transcriptional activation. Additionally DNA 
damage and stalled replication activates the Chkl and Cdsl kinases which 
functionally phosphorylate the N-teiTninus of p53 to dissociate MDM2 (Chehab et 
at., 2000; Shiel et al., 2000). The actions of Chkl and Cdsl on p53 result in p53 
stabilisation and Gi arrest.
C-terminal phosphorylation of p53 actives the DNA binding capacity of p53 and is 
associated with a loss in C-terminal auto-repression. The C-terminus of p53 
negatively regulates the sequence specific binding activity of p53 by interacting with 
the central core domain (Hupp et al., 1995). In addition the C-terminus has a non­
specific damaged induced DNA binding capacity that can allosterically stimulate the 
sequence specific binding of p53 to DNA (Bayle et al., 1995; Jayaraman and Prives,
1995). The C-terminus of p53 is believed to maintain p53 in a latent form but upon 
either single stranded DNA binding or phosphorylation its ability to inhibit DNA 
binding is lost, which results in sequence specific p53 transcription. Interestingly the
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C-terminus of p53 is phosphorylated in response to UV but not ionising irradiation 
(Kapoor and Lozano, 1998; Lu et a l, 1998).
Conversely, phosphatases that act on p53 have been proposed as regulators of its 
function. The C-terminal protein kinases C phosphorylation site on p53 is actually 
dephosphorylated following the treatment of cells with ionising irradiation 
(Waterman et al., 1998). Dephosphorylation of this region induces a conformational 
change that correlates with an increase in the sequence specific binding of p53 
(Prives, 1998). Indeed, the dephosphorylation of the C-terminus of p53, following an 
ATM response to ionising radiation, creates a consensus site for 14-3-3 proteins 
(Waterman et a l, 1998).
A second potent mechanism of p53 modification is acétylation. C-terminal 
acétylation of p53, by p300, induces a transcriptionally active DNA bound form of 
p53 (Gu and Roeder, 1997; Sakaguchi et a l, 1998). Presumably the post-translational 
acétylation of lysine residues in the C-terminus of p53 counteracts there highly 
positively charge and removes their negative affect on p53’s sequence specific DNA 
binding activity.
The ability of p53 to function in the DNA repair mechanism of cells is consistent 
with the nuclear localisation of p53. It is conceivable that latent cytoplasmic p53 is 
activated and transported or translocated to the nucleus where it then regulates the 
cell cycle. The ability of viral and cellular oncogenes to influence p53 localisation 
and function also occurs through the regulation of p i4/19^^^ (deStanchina et a l, 
1998; Palmero et a l, 1998). p i4/19^^^ is induced by viral oncoprotein and cellular
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oncogenes, that deregulate the cell cycle, and functions to induce p53 by interfering 
with the MDM2/p53 pathway (Chin et a l, 1998; Sharpless and DePinho, 1998). p53 
regulation by the p 14/19^^ is a highly co-ordinated process that goes even further to 
underlie the cellular importance of p53.
1-1.10. Conclusions.
The role of p53 as the “guardian of the genome” is associated with its ability to 
enforce either cell cycle checkpoint an'est or in cases where the cell is unable to 
recover apoptosis (Levine, 1997) (Figure 1.3). Given the high level of germline 
mutations in cancer cells that either directly or indirectly target p53’s role its 
importance in the maintenance and development of the healthy cell is seemingly 
unquestionable.
Even through p53 has been widely studied many of the environmental and cellular 
mechanisms that activate it remain unknown. Furthermore, the roles of 
phosphorylation, and acétylation are only now becoming understood. Recently, 
proteins which help mediate p53’s function are becoming known and it is with the 
understanding of these proteins that p53’s cellular activity will be unravelled.
Clearly the ability to fully understand p53’s activation pathway will prove of 
insurmountable benefit in the design of drugs for the treatment of cancer.
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Figure 1.1. Structural and functional interactions of p53.
a). Diagram representing the amino acid mis-sense mutational frequency of human 
p53. Indicated are the core domain hot spot mutations Argl75, Arg248 and Arg273.
b). A diagrammatic representation of human p53. Indicated are the N-terminal 
transactivation domain (Blue), the central DNA binding core domain (yellow), the 
C-terminal non-specific DNA/RNA binding domain (grey), the nuclear localisation 
signal (Green) and the oligomerisation domain (Purple). The red boxes I, II, III, IV 
and V represent the evolutionarily conserved regions. The binding regions for the 
indicated cellular and viral proteins are shown together with the phosphorylation 
sites for DNA-PK, CKI, CKII, CDK’s and PKC (Gottlieb and Oren, 1996; Levine, 
1997; Prives et a l, 1998).
c). Proteins that have a functional relationship with p53. Some of the viral and 
cellular proteins that interact with p53 and their functional outcomes are listed.
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Figure 1.2. Model of p53 transcription activation.
The activation of p53 by cellulai' stimuli or external DNA damaging events 
promotes the activation and tetramerisation of p53. The active p53 tetramer can 
either activate the expression of apoptotic promoting proteins such as Bax (a), 
stimulate the expression of that promotes cell cycle Gi arrest (c), or self
regulate its own level through the expression of MDM2 (b). The exact mechanism 
that controls the outcome of p53’s activation whether it is apoptosis or cell cycle 
anest is unknown.
The over-expression of Bax changes the composition of the Bcl-2 family 
heterodimers that in turn alters the cells pro- to anti-apoptotic signal ratio. The high 
level of Bax stimulates apoptosis (Bums and El-Deiry, 1999; Miyashita et ah, 
1994a; Miyashita and Reed, 1995).
p2 lWafi/C'pi binds and inhibits the activity of the cyclin/cdk enzyme complexes. The 
inactive cyclin/cdk complexes no longer promote the phosphorylation and release 
of pRb’s repression of E2F. Consequently the expression directed through E2F, of 
the S-phase promoting genes is suppressed and cell cycle arrest occurs at the Gi 
phase (El-Deiry et al., 1993; Gu et al., 1993).
The up regulation of MDM2, directed by p53 acting on the P2 responsive promoter, 
leads to a down regulation in the level of p53 which in turn leads to a reduction in 
the level of MDM2. MDM2 and p53 levels are therefore auto-regulatory (Barak 
and Oren, 1992; Barak et al., 1994).
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Figure 1.3. p53-dependent pathways of apoptosis and cell cycle arrest.
Summary of the molecular mechanisms that p53 uses to induce either apoptosis or 
cell cycle aiTCst. p53 is activated following the cellular response to a variety of 
stresses and it is this activation of p53 that viral proteins such as E lA  target and 
prevent. Many of the cellular events and proteins that p53 influences are indicated 
(blue) and their downstream mechanisms of action outlined.
p53’s induction of Gi anest is primarily associated with induction of 
expression that in turn impacts on the pocket protein regulatory pathway as 
indicated. In addition p53 can induce cell cycle arrest in both G2/M and Go via its as 
yet poorly understood roles in centrosome formation and Gasl expression 
respectively
The induction of apoptosis following the stimulation of p53 occurs in response to a 
variety of genetic stresses and involves the actions of a number of p53 responsive 
genes. The level and extent of gene activation required for p53 mediated induction 
of apoptosis is poorly understood, however it is clear that p53 induced apoptosis 
takes place through the sequential and cumulative effects of the genes which it 
activates.
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1-2. The p300/CBP family of 
transcriptional co-activators.
1-2.1. Introduction,
p300 and CBP belong to a family of versatile transcriptional co-activators that 
function as regulators of a number of cellular processes; including proliferation, 
differentiation and apoptosis (Giordano and Avantaggiati, 1999). p300 and CBP were 
originally identified by their ability to interact with the adenovirus E lA  and the 
transcription factor CREB proteins respectively (Whyte et al., 1989; Chrivia et al., 
1993; Eckner et a l, 1994).
It is believed that co-activators, such as p300 and CBP, facilitate transcription by 
promoting the interactions between sequence specific activators and the RNA 
polymerase II transcription machinery (Roeder, 1996). The ability of p300/CBP to 
physically interact with an assorted number of activators and the basal transcription 
machinery components, together with topological factors such as RNA helicase A 
clearly supports its role as a transcriptional co-activator (Imhof et a l, 1997; Nakajima 
et a l, 1997; Sang et a l, 1997; Kim et a l, 1998; Felzien et a l, 1999).
The over-expression of p300 or CBP in cellular systems results in the transcriptional 
activation of both viral and cellular enhances and promoters which utilise a wide 
body of transcription factors (Lundbiad et a l, 1995; Janknecht and Hunter, 1996; 
Shikama et a l, 1997; Giordano and Avantaggiati, 1999). CBP, for instance, acts as a 
transcriptional co-activator of cAMP responsive elements as a consequence of its
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ability to directly bind the transcription factor CREB. CREB is induced, by protein 
kinase A stimulated KID domain phosphorylation, to bind the cAMP response 
element (CRE) from where it recruits CBP to activate the transcription of target genes 
(Chrivia et a l, 1993).
In addition to the multi-faceted interaction capacity of p300/CBP the protein also 
possesses an intrinsic enzymatic histone acetyltransferase activity (HAT). The HAT 
activity of p300/CBP equally contributes to its ability to act as a transcriptional co­
activator (Bannister and Kouzarides, 1996; Ogryzko et al., 1996a).
The cellular significance of p300/CBP is highlighted by the observation that 
p300/CBP may function as a tumour suppressor. Mutations in p300/CBP have been 
detected in a range of tumour types and genetic disorders, such as epithelial 
malignancies and Rubinstein-Taybi syndrome (Giles et al., 1998; Gayther et al., 
2000).
1-2.2. P300/CBF.
The transcriptional co-activators p300 and CBP share a high degree of homology and 
genetic evidence suggests that the two proteins perform both overlapping and unique 
functions (Arany et al., 1995) (Figure 1.4a). p300 and cbp are both highly conserved 
genes in multi-cellular organisms with orthologs in organisms as diverse as human, 
Drosophila and Caenorhabditis elegans (Akimaru et al., 1997). In particular the 
functional domains in p300 and CBP show a very high degree of sequence homology 
with each other (Figure 1.4a). The Bromodomain, the cysteine/histidine rich domains 
(CHI, CH2 and CH3) and the KIX domain are all regions of high homology.
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Interestingly the p300/CBP family of co-activators is known to contain at least two 
other members, namely p270 and p400. The functions of p270 and p400 have not yet 
been reported but p270 is a known component of the mammalian Swi/Snf complex 
(Dallas et a l, 1998; Giles et a l, 1998).
The functional domains in p300/CBP thus far identified have a number of interesting 
features. The central Bromodomain, which is highly conserved in all known 
mammalian HAT proteins, in alliance with the CH2 and CH3 domains encompasses 
the acetyltransferase activity of p300/CBP (Bannister and Kouzarides, 1996; Ogryzko 
et a l, 1996a) (Figure 1.4a). The KIX, CHI and CH3 domains in p300/CBP mediate 
its protein interactions and are the regions targeted by viral proteins (Shikama et a l,
1997). It is the modular organization of p300/CBP that imparts its ability to act as a 
transcriptional co-activator as it allows the formation of muti-meric transcription 
mediating complexes. To this end both the N- and C-termini of p300/CBP are known 
to possess transaciiwation properties (Figure 1.4a).
The overlap in function seen between p300 and CBP is highlighted by the embryonic 
phenotype of p300'^', cbp''' and p300^''\cbp'^'' knock out mice. They all show similar 
neural tube closure, growth, and embryonic lethality defects (Yao et a l, 1998). The 
close overlap seen between the phenotypes of cbp^'' mice and RTS patients whom 
lack one cbp allele also suggests that p300 and CBP carry out dose-dependent 
functions. Consistent with these observations is the fact that a population of p300^'' 
\cbp^‘' mice suffer embryonic lethality as a consequence of the reduced level of 
p300/CBP (Tanaka et a l, 1997). Given that the level of p300/CBP in cells is limited
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and that its absence is an inducer of lethality in embryonic mice, it is believed that the 
physical distribution and redistribution of p300/CBP by controlling signals is what 
permits its varied and wide ranging cellular influences (Torchia et a l, 1998; Yao et 
a l, 1998).
The ability of p300 and CBP to perform unique non-overlapping cellular functions 
has been demonstrated using ribozyme technology that specifically inactivates one 
member of the family. The ribozyme study demonstrated that p300 but not CBP was 
responsible for retinoic acid induced F9 embryonic carcinoma cell differentiation 
(Kawasaki et a l, 1998). In addition the ability of ionising radiation to induce 
apoptosis is impaired in p30O^'' cells but remains unaffected in CBP deficient cells 
(Yuan et a l, 1999). Consistent with these observations is the ability of p30O^'' mice 
but not cbp^'' mice to retain a normal hematopoeitic differentiation phenotype and the 
fact that CREB function is unaffected in p300''' mice that show impaired retinoic acid 
induced transcription (Kung et al., 1999).
Together these observations suggest that transcriptional co-activators, such as p300 
and CBP, perform synergistic functions in the regulation of cellular gene 
transcription. Interestingly and consistent with their family status it is also recognized 
that both p300 and CBP do however perform unique tasks that can not be 
compensated by the other family members.
1-2.3. Transcription and d300/CBP.
The formation of a molecular bridge by p300/CBP is highlighted by its ability to 
interact with a wide variety of transcription factors and basal transcription machinery
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components, namely TBP, TFnB, TFnE, and TFnF (Imhof et a l, 1997; Sang et al., 
1997; Felzien et al., 1999) (Figure 1.4b). p300/CBP’s ability to allow the cross-talk 
of transcription factors with the RNA polymerase II holoenzyme is undoubtedly a 
cellular mechanism by which it regulates transcription (Roeder, 1996).
p300/CBP’s role in transcription is in part connected with its ability to act as a rate- 
limiting factor. The rate-limiting level of p300/CBP is highlighted by hormone 
dependent transcriptional activation that utilises p300/CBP to indirectly inhibit 
mitogen activated transcription factors such as AP-1. p300/CBP is also utilised by 
p53 in the repression of TRE regulated promoters (Kamei et al., 1996; Avantaggiati 
et al., 1997; Shikama et al., 1997). Interestingly p300/CBP association with the 
mitogen regulated S6 kinase pp90*^ ®^  has been linked with the repression of CREB 
dependent transcription during Ras signaling (Nakajima et a l, 1996). The 
physiological induction of differentiation and block of proliferation by hormone 
treatment intriguingly points to competition for p300/CBP as the determining factor 
in differentiation versus proliferation. Furthermore the transcription factor E2F-1 
blocks p53 transaciivaûon in a p300/CBP dependent manner (Lee et ah, 1998).
p300/CBP’s role as co-activator that responds to a wide range of signal transduction 
pathways to specifically promote a cellular outcome is well documented. It would 
appear that a major regulatory event involved in p300/CBP mode of action is 
promoter specific targeting and it is this promoter specific targeting that viral 
oncoproteins, such as E lA  and SV40 large T, employ in order to induce proliferation 
and not differentiation.
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The ability of p300/CBP to form a large nuclear co-activator protein complex is also 
associated with its ability to act as a transcriptional co-activator (Korzus et al., 1998; 
Westin et al., 1998; Xu et al., 1999). Signal transduction pathways that induce a 
number of different cellular outcomes potentially regulate p300/CBP’s ability to 
recruit and be recruited to specific promoters (Carey 1998; Kim et al., 1998; Korzus 
et al., 1998; Xu et al., 1999). The ability of p300/CBP to recruit factors such as 
p50/p65, NFkB, P/CAF and HMGI (high mobility group proteins) to the human 
interferon enhancer (INFp) provides credence to the role of p300/CBP as a complex 
protein recruiter (Kim et al., 1998; Munshi et al., 1998).
The recruitment of p300/CBP into a transcriptional enhancer element complex is 
further complicated by its intrinsic HAT activity. p300/CBP is also found complexed 
with the cellular HAT’s, P/CAF (p300/CBP associated factor), SRC-1 (steroid 
receptor co-activator 1) and PCIP (p300 cellular interacting protein) (Yang et al., 
1996; Chen et ah, 1997; Spencer et al., 1997). It is attractive to speculate that the 
different HAT’s present in the DNA bound co-activator complex confer target 
specificity and mediate the cellular outcome. In support of co-activator HAT specific 
roles the INFp enhancer is known to require p300/CBP mediated acétylation of 
HMG-1 for transcriptional termination (Munshi et al., 1998). It is therefore plausible 
to associate HAT activities with functional specificity and to assume that co­
ordination of the antagonistic or synergistic effects of acétylation are a mechanism by 
which transcription is regulated.
DNA is highly wound and compressed into nucleosomes that consist of octomers of 
histone H2A, H2B, H3 and H4. The acétylation of histones, on lysine tails.
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neutralizes the attractive charges in the nucleosome and is associated with a hyper­
relaxed chromosome structure and active transcription (Brownell and Allis, 1996; 
Grunstein, 1997; Hassig and Schrieber, 1997; Wade et al., 1997) (Figure 1.5). The 
co-activation of transcription has been linked to p300/CBP’s HAT activity, that 
preferentially acetylates histone H3 and H4, although the acétylation of H2A and 
H2B still occurs in vitro (Bannister and Kouzarides, 1996; Ogryzko et al., 1996a). 
Interestingly the HAT activity of p300/CBP shows promoter specificity, with the 
adenovirus major late (AdML) and E4; but not ElB or SV40 promoters, requiring the 
HAT activity of p300/CBP for co-activation (Martinez-Balbas et at., 1998). The 
ability of p300/CBP to acetylate nuclosomes and histones in vivo still remain unclear.
Both p300/CBP and its associated factor P/CAF utilise their HAT activity in the 
acétylation of non-histone targets such as p53, E2F, c-Myb, MyoD, GATA-1, EKLF 
and HNF-4 (Gu and Roeder, 1997; Boyes et al., 1998; Sakaguchi et al., 1998; Zhang 
and Bieker, 1998; Liu et al., 1999; Sartorelli et al., 1999; Martinez-Baibas et al., 
2000; Marzio et al., 2000; Soutogloou et al., 2000; Tomita et al., 2000). The 
acétylation of p53 and E2F-1 neutralizes positive charges on the e-amino group of 
lysine residues. This promotes a charge induced conformational change that leads to 
an increase in sequence specific DNA binding and potentially transcriptional 
activation (Gu and Roeder, 1997; Gu et al., 1997; Liu et al., 1999; Martinez-B albas et 
a l, 2000). Further to these observations, Lambert et al. (1998) demonstrated that 
ionising radiation induces the phosphorylation of p53, that in turn increases its 
affinity and consequently acétylation by p300/CBP.
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Another functional significance of p300/CBP HAT activity is in the acétylation of the 
H3V-Tat protein. HIV-Tat protein acétylation induces transcription of the HIV-1 LTR 
by enhancing its binding to the Tat associated kinase CDK9/P-TEFb (Keiman et aL, 
1999). Interestingly one report of p300/CBP protein acétylation suggests a role for 
HAT activity in transcriptional down-regulation. The acétylation of the dTCF (T-cell 
factor) transcription factor by p300/CBP inhibits its association with the beta 
catenin/Armadillo co-activator and therefore transcription activation of the 
WntAVingless genes (Waltzer and Bienz, 1998).
Interestingly p300/CBP undergoes auto-acetylation and is able to acetylate the basal 
transcription machinery components TFnEp and TFnF (Imhof et aL, 1997). The 
functional significance of p300/CBP HAT activity in these situations however is 
unclear'.
Clearly the ability of p300/CBP to acetylate core histones and members of the 
transcriptional apparatus, as well as transcription factors is closely associated with its 
role as a transcriptional co-activator. Further studies that elucidate the pattern of 
protein acétylation in gene regulation will aid in the true identification of the 
importance of post-translation acétylation in gene transcription.
1-2.4. Differentiation, proliferation and apoptosis bv p300/CBP.
The adenovirus E lA  protein is a multi-functional pleiotropic protein that mediates its 
biological effects through its ability to modulate the activity, either directly or 
indirectly, of target genes. The ability of E lA  to block differentiation, in a wide 
variety of lineage’s such as myogenesis, neurogenesis and karatinocyte differentiation
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correlates with its ability to inactivate enhancer activity in a p300/CBP dependent 
manner (Stein et aL, 1990; Puri et aL, 1997a; Puri et aL, 1997b). Consistently, E lA ’s 
increase of YYl transcriptional activity involves the loss of p300/CBP mediated 
transcriptional repression (Lee et aL, 1995). E lA ’s ability, through its N-teiminus 
and CHI region, to bind p300/CBP and promote S-phase entry and cell cycle 
progression clearly supports p300/CBP’s role as a mediator of the cell cycle (Whyte 
et aL, 1989; Stein et aL, 1990; Yaciuk and Moran, 1991; Arany et aL, 1995).
The requirement of p300 and CBP for both cellular proliferation and differentiation is 
highlighted by the inability of mutant ElA, that is unable to bind p300, to induce 
transformation and the embryonic lethality of p300~'' knock out mice due to defective 
cardiac myocyte differentiation (Wang et aL, 1995a; Yao et aL, 1998). In addition 
knock out mice studies have also defined a role for p300/CBP in the differentiation of 
haematopoietic tissues (Eckner et aL, 1996b).
Both p300/CBP and the associated protein, P/CAF, were shown by their ability to 
induce MyoD dependent transcription, to promote cell cycle withdrawal in muscle 
and B cells. The regulation of the myogenic factors such as myogenin and MEF2 
(Mycoyte enhancer factor 2) in differentiation is also controlled by p300/CBP (Yuan 
et aL, 1996; Puri et aL, 1997a; Puri et aL, 1997b; Sartorelli et aL, 1999). Interestingly 
the HAT domain of p300 is not essential for MyoD dependent transcription although 
P/CAF’s HAT activity is (Sartorelli et aL, 1999).
Consistent with the role of p300/CBP in differentiation is the observation that 
inactivation of Caenorhabditis elegans cbp-1 gene, that is homologous to p300/CBP,
56
leads to severe neuronal cell differentiation defects (Shi and Mello, 1998). The 
differentiation defects seen in cbp-1 knockouts can be overcome by the use of 
deacetylase inhibitors, which directly links HAT activity and suppression of 
deacetylases with p300/CBP differentiation regulation (Shi and Mello, 1998). The 
ability of p300/CBP to participate in cellular differentiation strongly supports its 
ability to act as a tumour suppressor.
A role for p300/CBP in cellular proliferation was initially suspected given that p300''' 
embryos and p300''' MEF’s proliferate slower than wild-type and are significantly 
smaller with a phenotype reminiscent of senescent cells (Yao et al., 1998). More 
detailed studies demonstrated that p300/CBP directly mediates E2F-1 transcriptional 
activation (Trouche et a l, 1996). In addition the ability of E lA  to bind p300 under 
conditions that promote DNA synthesis illustrates an interesting model whereby ElA  
prevents p300 induced cellular differentiation while simultaneously using p300 to 
stimulate cellular proliferation (Stein et a l, 1990). Given that p300/CBP also 
associates with a number of cellulai* HAT proteins, namely P/CAF, SRC-1 and PCIP 
it is plausible to assume that transcription factors and viral oncoproteins utilise a 
multiple HAT containing complex in order to stimulate transcription (Yang et a l, 
1996; Chen et a l, 1997; Brown et a l, 2000).
The analysis of p300 and CBP deficient cells indicated that the ionising radiation 
induced cellular shock response is impaired in p300 knock out cells but not CBP 
deficient cells (Yuan et ah, 1999). The inability of retinoic acid induced apoptosis to 
occur in p300/CBP deficient cells together with the ability of E lA  to sequester 
p300/CBP and block p53-dependent apoptosis provides an interesting link of
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p300/CBP with apoptosis (Kawasaki et aL, 1998). T-cell antigen receptor (TCR) 
induced thymocyte apoptosis triggered by calcium dependent signaling and 
MEF2/NFAT (nuclear factor of activated T cells) mediated transcription also utilises 
p300 (Youn et aL, 2000). Interestingly studies on the cell cycle effects of p300 and 
p53 showed that p300/CBP induced a p53 mediated Gi arrest together with E2F-1 
dependent apoptosis (Lee et aL, 1998). Together these results suggest a role for p300 
in p53 and E2F-1 dependent mechanisms of cell cycle arrest and apoptosis, possibly 
as a cellular shock responder.
p300/CBP is also involved in the cellular mechanisms that control DNA damage 
repair as the expression of the human proliferating cell nuclear antigen (PCNA) 
requires p300/CBP. PCNA in response to serum and mitogenic growth factors is 
required for 5 polymerase activity and DNA replication and repair (Lee and 
Mathews, 1997). Furthermore p300/CBP as a consequence of its interaction with p53 
can induces the expression of the p53 responsive genes, mdm2, Wafl/Cipl and bax 
(Avantaggiati et aL, 1997; Gu et aL, 1997; Lill et aL, 1997a). Thomas and White 
(1998) demonstrated that p53 mediated transcription of mdm2 is dependent on 
p300/CBP and proposed a model in which p300 regulation of MDM2 levels, through 
p53, determines whether the physiological response of p53 is growth anest or 
apoptosis.
As MDM2 is known to regulate p53’s stability it was interesting to recognize that 
p300 can mediate the formation of a p53/MDM2/p300 ternary complex in which p53 
is targeted for degradation (Grossman et aL, 1998). The inability of MDM2 mutants, 
that retain p53 binding but have lost p300 binding capabilities, to degrade p53 clearly
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points to p300 as a mediator of p53/MDM2 dependent degradation (Grossman et al., 
1998). Taken together it appears that p300/CBP plays a dual role, in one hand as a 
p53 transcriptional co-activator and in the other as a regulator of p53 stability.
Clearly p300/CBP and their family members appear to be key regulators of cell 
development, differentiation and proliferation. It would seem plausible to assume the 
exact cellulai’ consequence of a p300/CBP response, whether it is proliferation, 
apoptosis or differentiation, will be a tightly controlled process depending on both the 
level of p300/CBP and also the stimuli that p300/CBP is exposed to.
1-2.5. Functional regulation of p300/CBP.
p300/CBP are phosphorylated in a cell cycle regulated fashion, with 
hypei*phosphoryled forms being observed during mitosis (Yaciuk and Moran, 1991). 
The treatment with retinoic acid or the introduction of E lA  into F9 cells, both of 
which induce differentiation, also induces p300 phosphorylation (Kitabayashi et al., 
1995). Interestingly although E lA  stimulates p300 hyperphosphorylation, probably 
through cyclin/CDK recruitment, the SV40 large T antigen that binds to the same 
region of p300 as E lA  is associated with and induces p300 hypophosphorylation 
(Banerjee et al., 1994; Eckner et al., 1996a). The cyclin dependent kinases cdk2 and 
cdc2 are known to phosphorylate p300 in vivo (Banerjee et a l, 1994). The 
bromodomain and associated HAT activity of p300/CBP is potentially a target of 
phosphorylation, as the similar bromodomain in GCN5 is known to undergo 
repression as a result of DNA-PK phosphorylation (Bariev et al., 1998).
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Perkins et al. (1997) determined that p300 was negatively regulated by cyclin E/cdk2 
and that expression, induced by p300, inhibited this regulation pathway.
The inhibition of cyclinE/cdk2 by results in p300 increasing NFkB
mediated transcriptional activation. The ability of to act in a positive
feedback loop on p300/CBP cyclin E/cdk2 action proposes the existence of a 
potential Gi/S phase checkpoint involving p300/CBP (Missero et al., 1995; Perkins et 
al., 1997).
A role for p300/CBP in signal transduction was demonstrated when CBP was defined 
as a target for the MAPK (mitogen activated protein kinases) and PKA (protein 
kinase A) phosphorylation cascades (Janknecht and Hunter, 1996). Both MAPK and 
PKA were shown to upregulate CBP transcriptional co-activation potential. 
Undoubtedly p300 and CBP are both targets for a large and varied number of signal 
transduction pathways.
The ability of p300/CBP to acetylate histone tails in a cell cycle regulated fashion, 
with a peak in HAT activity at the Gi/S transition, points to a functionally important 
mechanism of p300/CBP (Ait-Si-Ali et al., 1998). Indeed p300/CBP’s HAT activity 
is potentially regulated and stimulated upon phosphorylation by the cyclinE/cdk2 
complex. Interestingly ElA  is believed to affect p300/CBP acétylation function in a 
dose-dependent manner, with low levels enhancing and high level suppressing the 
acétylation activity of p300/CBP (Ait-Si-Ali et al., 1998; Chakravarti et a l, 1999; 
Hamamori et al., 1999).
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1-2.6. d300/CBP in human diseases.
A number of clinical observations have defined a role for p300/CBP as a tumour 
suppressor given that mutations in p300/CBP are closely linked to tumour formation 
and progression. The congenital autosomal dominant Rubinstein-Taybi syndrome that 
is characterised by mental retardation, skeletal abnormalities and an increased 
incidence of neoplasia is associated with a inactivating germline mutation of one cbp 
allele (Petrij et ah, 1995). The predisposition of RTS patients to cancer, given that 
only one cbp allele is deleted, point to a gene-dosage role for CBP in normal 
development and suggests that p300 can not rescue CBP insufficiency. Furthermore, 
cbp'^'' mice aie phenotypic ally similar to RTS patients as they show an abnormal 
skeletal development pattern with the developmental consequences being dependent 
on the genetic background (Tanaka et ah, 1997). The role of p300/CBP is further 
underscored by the link with RTS of two other congenital malformation syndromes, 
namely Greig cephalosyndactyly syndrome and Saethre-Chotzen syndrome. Both 
these congenital malformations, although not directly as a result of genetic p300/CBP 
alterations, are associated with p300/CBP development pathway disturbances (Giles 
et ah, 1998).
Interestingly the p300 gene is subjected to bi-allelic inactivating somatic mutations in 
a number of gastric and colon cancers (Muraoka et ah, 1996). In 80% of examined 
glioblastomas a loss of heterozygosity (LOH) markers at the p300 gene locus on 
chromosome 22ql3 have been observed. Similarly a loss of heterozygosity around 
the cbp gene locus is associated with hepatocellular carcinomas (Sakai et ah, 1992). 
The observation that cbp'^'' mice are prone to haematologic malignancies as a result of 
defects in haematopoietic differentiation suggests that CBP is a tumour suppressor.
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In a study of human cancer cell lines by Gayther et aL (2000) a number of p300 
truncation mutations were observed in epithelial cancers, together with p300 somatic 
in-frame insertions in primary breast cancer and mis-sence alterations in colorectal 
cancers. Taken together these observations clearly demonstrate that p300/CBP 
behaves as classic tumour suppressor protein and is consistent with the ability of viral 
proteins such as E lA  and SV40 large T to target and antagonize p300/CBP function.
The p300/CBP gene locus, in addition to germline mutations is subject to somatic 
translocations that are associated with various types of malignancies. The acute 
myeloid leukaemia associated translocation t(8;16)(pll;pl3) results in a disruption of 
the cbp and moz genes and in at least one case a MOZ-CBP fusion protein (Bonow et 
aL, 1996; Giles et aL, 1998). MOZ is a protein of unknown function although based 
on its homology with the mammalian Tip60 protein (human immunodeficiency virus 
tat-interacting protein) and the yeast silencing protein SAS2 (something about 
silencing) is has been assigned as a putative acetyltransferase with potentially a gene 
silencing role (Reifsnyder et aL, 1996). The 5’-MOZ-CBP-3’ fusion protein retains 
the HAT domain from both proteins but is no longer able to act as a nuclear receptor 
co-activator, this alters CBP mediated transcriptional control and is at least in part 
responsible for transformation.
Another translocation event associated with CBP that arises, as a consequence of 
anti-cancer chemotherapeutic treatments, such as the topoisomerase II inhibitors 
etoposides, is known to occur in chronic myeloid leukaemia and myelodysplastic 
syndrome. The translocation results in the fusion of CBP to the mixed lineage
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leukaemia (m/Z) gene product. MLL is believed to function as a chromatin modulator 
and Swi/Snf complex component based on its SET domain homology and likeness to 
the Drosophila trithorax group genes (Sobulo et aL, 1997; Taki et aL, 1997). A p300- 
MLL in frame fusion protein has also been identified in therapy related acute myeloid 
leukaemia (Ida et aL, 1997).
The ability of CBP-MOZ, p300-MLL and CBP-MLL to contribute to hematological 
malignancy through their gain of function and presumably inactivation of un- 
reanange CBP or p300 provides a mechanism whereby an uncontrolled and 
deregulated cell cycle results. Given that MLL and MOZ as well as p300/CBP are 
associated with chromatin remodeling it is plausible to assume that the translocation 
events produce an altered acétylation pattern that presumably contributes to their 
oncogenic activity (Giles et aL, 1998).
Additional to chromosomal aben'ations p300/CBP are also involved with the products 
of some leukaemogenic chromosomal translocation events. p300/CBP is known to 
function as a transcriptional co-activator in the induction of differentiation by the 
leukaemia-associated transcription factors AML-1 and TAL-1 (Kitabayashi et aL, 
1998; Huang et aL, 1999).
The underlying genetic instability of sequences within the p300/cbp alleles together 
with the susceptibility of the genes to translocations, inversions and deletion as well 
as the ability of the proteins to interact with the p53 tumour suppressor and E2F 
oncogene clearly supports the importance of p300/CBP in human malignancies.
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1-2.7. Conclusions.
The cellular, transcriptional co-activator, role of p300/CBP is clearly not as simple as 
first believed given that both proteins display contradictory transcriptional properties. 
The paradoxical functions of p300/CBP on proliferation and differentiation 
highlight’s the potential for cross-talk between the separate cellular systems.
However, the absolute requirement for p300/CBP in the actions of many transcription 
factors underlies their importance in the control of cell growth and differentiation. 
Given the function of p300 and CBP as interconnecting proteins that regulate 
transcription by integrating signaling pathways their importance in cellular control is 
indisputable. Elucidating p300/CBP’s role in the regulation of a cells fate will not 
only benefit our understanding of the cell cycle but will help in the design of new cell 
cycle related therapies.
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Figure 1.4. Schematic representation of p300 and CBP.
a). The alignment of human CBP and p300. The CHI, CH2 and CH3 regions are 
indicated (Red) together with other areas of high homology. Percentages refer to 
amino acid identity between the two proteins. The region encompassing the 
acetyltransferase activity of p300 and CBP is indicated (Yellow) together with the N- 
and C-terminal rra/i^activation domains (Green) (Giles et aL, 1998). The N-terminal 
nuclear hormone receptor binding domain is indicated (Blue) together with the 
central Bromodomain (Grey).
b). Functional interaction domains in p300/CBP. Indicated are the binding domains 
for the previously identified factors that interact with p300/CBP. The N-terminal 
nuclear hoiTnone receptor-binding region is indicated (Blue) together with the 
cysteine/histidine rich regions, CHI, CH2, and CH3 (Red). Also indicated are the 
central Bromodomain (Grey) and the N-terminal CREB binding KIX domain 
(Janknecht and Hunter, 1996; Shikama et aL, 1997).
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Figure 1.5. Co-activator function.
a). A diagrammatic representation of transcriptional repression. As a result of 
particulai' cellulai’ stimuli or a lack of stimuli a co-repressor complex is targeted to 
genetic promoter elements where it actively represses transcription. Co-repressor 
complexes, which contain histone deacetylases (HDAC’s), promote the condensation 
of DNA and histones into nucleosomes. The nucleosome contains a highly 
condensed inaccessible DNA topology and as a result the level of transcription in 
such a situation is basal.
b). Transcription factors (TF’s) actively recruit the co-activator complex that 
contains p300/CBP, to the gene locus. The co-activator complex acetylates the 
histone tails (Red) that results in a loss of charge and a breakdown of the nucleosome 
topology. The altered chromatin integrity now allows the entry of RNA polymerase 
n  transcription machinery components such as TBP and TFyB, which results in the 
active induced transcription of target genes. The ability of the co-activator complex 
to acetylate the basal transcription component may in addition help activated 
transcription. Interestingly the TAFn250 component of the transcription machinery 
has intrinsic HAT activity so the activation of gene transcription may proceed 
exponentially once begun (Mizzen et ah, 1996).
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1-3. The INK4a/ARF locus and its two 
gene products.
1-3.1. Introduction.
Growth control in mammalian cells is facilitated by the retinoblastoma (pRb) protein 
regulating exit from the Gi phase and the p53 protein that triggers growth arrest and 
apoptotic events in response to cellular stress. Consequently the loss of cell cycle 
control by the inactivation of the pRb and p53 pathways appears to be a vital step in 
the rite of passage for all cancer cells. The lNK4a/ARF locus and its gene products 
stand at the nexus of both these cell cycle growth controlling pathways (Chin et ah, 
1998).
The INK4a/ARF locus encodes p i a n  inhibitor of cyclin D-dependent kinases 
and p 14/19'^^^ which blocks MDM2 inhibition of p53 activity. It is therefore not 
suiprising that the INK4a/ARF locus is one of the most frequently mutated genes in 
cancer irrespective of the tumour type (Sharpless and DePinho, 1998).
1-3.2. T\ve^INK4a/ARF locus.
The INK4a/ARF locus, which stretches over ~20Kb, is located at position p21 on the 
short arm of chromosome 9 in humans, and the cognate loci on chromosome 4 in 
mouse and 5 in rat (Sharpless and DePinho, 1998; Stott et ah, 1998). The 9p21 
chromosomal hot spot region is frequently subject to deletions and point mutations in 
a broad spectrum of cancer types ranging from familial melanomas to non-small lung 
carcinomas (Caldas et ah, 1994; Kamb, 1995). ink4a/arf^' locus knock out mice
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exhibit a cancer prone phenotype and fibroblasts from these mice have an enhanced 
potential for spontaneous immortalization and are efficiently transformed by 
activated Ras (Serrano et a l, 1996). Together these observations point clearly to the 
INK4a/ARF locus as a bona fide tumour suppressor (Chin et a l, 1998; Kamijo et a l, 
1999b).
Two transcripts, which are driven by distinct promoters that encode two functionally 
separate potential tumour suppressor proteins, are expressed from the INK4a/ARF 
locus, the p l 6 ^^ "^^ “ CDK inhibitor and the p i4/19^^^ protein (Quelle et a l, 1995). 
Within the INK4a/ARF locus there are four exons, E l (3, E2 and E3 encode 
pl4/pl9'^^^ and E l a , E2 and E3 encode p i Splicing of exon 1(3 to exon 2
allows translation to continue in the - 1  reading frame relative to p l 6 ^^ "^ % giving rise 
to a 132 amino acid protein termed pl4**^ in humans or a 169 amino acid pl9*^^ 
protein in mouse (Figure 1.6). The mouse pl9*^^ and human pl4*^^ proteins 
although functionally almost identical show only a 50% identity over the region of 
overlap (Stott et a l, 1998).
The ability of the pl4/19"^^^ and p l 6 ^^ "^^ “ proteins to be encoded by distinct reading 
frames within a common coding sequence, such that the two products share no amino 
acid identity, although common in viruses and bacteria is an exceedingly rare event in 
eukaryotes where an evolutionarily advantage as yet remains unclear (Quelle et a l, 
1995). The observation that the INK4a/ARF locus is the genetic target for specific 
mutational events which affect only one member of the gene locus gives credence to 
the finding that each protein monitors a separate essential cellular function (Quelle et 
a l, 1995; Kamijo et a l, 1997; Gardie et a l, 1998).
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1-3.3. lNK4a/ARF Expression.
Neither nor are expressed during mouse embryonic development, but
upon culture mouse fibroblasts begin to express both p i a n d  p i9^^^. The 
distinct spacial expression pattern of p l 6 ^^ "^  ^ and p i4/19^^^ observed during both 
mouse and human development and ageing suggests that the transcriptional 
regulation of the two products differ (Quelle et ah, 1995; Zindy et ah, 1997). In fact 
differential controlled expression of p l 6 ^^ "^^  ^and p i4/19^^^ is born out by the ability 
of cells to control promoter specific transcription of E l a  and E ip  independently of 
each other.
The high levels of CpG islands present within both the p l 6 ^^ "^  ^ and p i4/19^^^ 
promoters are a characteristic of many cellular house keeping genes (Robertson and 
Jones, 1998). It is these CpG islands, as a consequence of hyper-methylation, that are 
often associated with tumour-derived promoter silencing. However the presence of 
Spl sites, within the INK4a and ARF  promoters, may maintain the expression of both 
proteins under physiological cellular conditions by a mechanism that retains the 
promoters in an unmethylated form (Robertson and Jones, 1998).
In p53'^' cell lines or in cells in which p53 has been functionally compromised by the 
over expression of MDM2 the level of p l4 ^ ^  is significantly elevated (Quelle et ah, 
1995). Studies performed on p53 over expression in a number of cell lines showed 
that p53 itself is able to down regulate transcription from both the pl4*^^ and 
pj^ i^NK4 a pj-omoters (Robertson and Jones, 1998; Stott et al., 1998). Consistent with 
these observations is the up regulation of p i4^^^expression by the viral proteins HPV
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E 6  and SV40 large T, both of which deregulate p53 (Hara et a l, 1996; Stott et a l, 
1998). These observations propose the existence of an auto regulatory feedback loop, 
reminiscent for that of p53 and MDM2, in which p53 levels are controlled by p l4 ^ ^ , 
whose expression is in turn controlled by p53. As yet the modulation of mouse 
PI9 ARF yy levels remains to be documented.
Interestingly the TATA less p 14/19^^^, but not the p l 6 ^^"^“ promoter, in a region 
upstream of exon ip , contains several potential consensus E2F sites. The p i4"^^ 
promoter contains at least four potential negative strand E2F binding sites, two of 
which are high affinity while two are poor matches (Roberston and Jones, 1998). 
pigARP only two high affinity E2F sites, one negative and one positive strand
coded (Inoue et a l, 1999).
Initial studies demonstrated the potential of E2F to induce pl4/19*^^ expression 
(Bates et a l, 1998; Roberston and Jones, 1998; Inoue et a l, 1999). Over expression 
of E2F-1 activates the transcription of pl4"^^^mRNA in a transcriptionally-dependent 
but non cell cycle regulated manner (Bates et a l, 1998; Inoue et a l, 1999). 
Specificity studies carried out on the E2F family members indicated that E2F-1 and 
E2F-2, but not E2F-3 to E2F-5, were able to increase pl9*^^ mRNA levels 
(DeGregori et a l, 1997). The induction of p 14/19^^^ mRNA expression by E2F is 
paralleled by a marked increase in the level of pl4^^^ protein, although to date there 
is no indication whether this corresponds to a change in stability of p l4 /19^^  or an 
increase in translation (Bates et a l, 1998). It is interesting to note that pRb has been 
shown to repress p i 6 ^^"^“ expression under certain cellular circumstances (Moran, 
1993).
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The influence of E2F on the p i4/19^^^ pathway provides a mechanism whereby 
proliferative oncogenic stimuli are detected in such a way that cell cycle arrest or 
apoptosis is induced through p53. E2F deregulation via the activation of oncogenes, 
such as Ras or c-Myc, results in the activation of p53 and the enhanced expression of 
p 14/19^^^. Such a model, linking E2F to p53 activation, is strongly supported by the 
ability of pl4**^ mutant tumours to tolerate the retention of wild-type p53 (Bates et 
al., 1998). Given that the regulation of p 14/19^^^ and p i e x p r e s s i o n  occurs 
through both p53 and pRb, via E2F, it is feasible to assume that both pathways cross 
talk, with p53 being the dominant component for pl4yi9*^^ and pRb the dominant 
partner for p l 6 ^ "^^“ (Robertson and Jones, 1998) (Figure 1.6).
The polycomb group of proteins, comprises a set of proteins that maintain the stable 
expression of specific target genes, such as homeo-box cluster genes, during 
development (Gould, 1997). The Bmi-1 oncognene is a member of the polycomb 
group which acts as a specific transcriptional repressor (Van Lohuizen et al., 1991; 
Van der Lugt et al., 1994). In addition to the severe neurological defects seen in W /- 
r ' '  mice, MEF’s from these animals exhibit an impaired S phase entry and premature 
senescence phenotype (Jacobs et al., 1999a). The impaired S phase and early 
senescence observed in MEF’s from these animals con*esponds to a highly elevated 
level of both the INK4a/ARF locus products. Over expression of Bmi-1 down 
regulates the expression of both p i 6 ^ "^^  ^and p i9^^^ in bmi-F^' mice which results in 
fibroblast immortalisation. The full rescue of the proliferation defects and early 
senescence onset together with the loss of the neurological defects in bmi-F’'',ink4d‘' 
mice clearly point to Bmi-1 as an important regulator of INK4a/ARF expression in 
development and cell cycle regulation (Jacobs et al., 1999a). Bmi-1 clearly functions
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by suppressing both the p l 6 ^^ "^^ VpRb and pl9^^^/MDM2/p53 pathways, thereby 
allowing progression through the cell cycle.
Insertional mutagenesis in transgenic mice with c-Myc identified Bmi-1 as a 
collaborator in the onset of B-cell lymphomas (Haupt et al., 1991; Alkema et al.,
1997). Given that myc'’' mice are embryonic lethal, and that c-Myc over expression 
induces apoptosis and tumourigenesis, the importance of c-Myc in proliferation and 
differentiation during embryogenesis is unquestionable (Davis et al., 1993; 
Prendergast, 1999). Myc induced apoptosis is both p53 and pl9*^^ transcription 
dependent (Zindy et al., 1998) and is prevented by Bmi-1 over expression (Jacobs et 
al., 1999b). The synergistic and dose-dependent increase in proliferation and decrease 
in apoptosis observed between Bmi-1 and c-Myc indicates that their co-operation in 
oncogenic transformation is mediated by the ability of Bmi-1 to prevent Myc 
activation of pl9^^^ (Jacobs et al., 1999b).
The pl9*^^ promoter has been shown to contain a single responsive consensus site 
for the transcription factor and potential tumour suppressor DMPl. Enforced 
expression of DMPl in mouse fibroblasts induces cell cycle arrest (Inoue and Shen\
1998). It is via the induced expression of pl9^^^ that DMPl exerts its p53-dependent 
anti-proliferative effects (Inoue et al., 1999). Studies performed on dmpV’' animals 
suggests that p i9^^^ function is in fact compromised but not eliminated, in the 
absence of DMPl, raising the possibility that DMPl contributes but is not essential 
for pl9*^^ regulation (Inoue et al., 2000).
72
DMPTs ability to bind DNA and drive transcription is lost in the presence of over 
expressed D-type eye lins, in the absence of CDK’s. It is therefore possible to assume 
that D-type cyclins can act negatively on the cell cycle through repression of p i9^^^ 
expression, as well as positively through the release of E2F-pRb repression.
The tumour suppressor BRCAl is able to trigger transcription by both p53-dependent 
and independent pathways. Interestingly neither pl4 '^ '^^‘ cells nor p l 9 '^F/- ]y[EF’s are 
able to induce p53 stabilisation in response to BRCA-1 over-expression 
(Somasundaram et al., 1999). BRCAl s ability therefore to stabilise p53 is p i4/19*^^ 
dependent. It has also been noted that the level of pl4**^ mRNA is substantially 
increased following BRCAl introduction into cells, although the mechanism of such 
induction remains unclear (Somasundaram et al., 1999). Given that BRCAl 
transcription is itself activated by E2F it is attractive to imagine other potential 
synergistic pathways that act on pl4/19^^^ expression (Wang et a l, 2000).
Other potential regulators of p l4 /19^^  expression and their potential consequences 
include co-activators such as p300, that regulates MDM2 and co-activates E2F. In 
addition to the regulators of ARF expression previously discussed undoubtedly the 
Ap-1 and YYl sites present in the pl4**^ promoter have a significant but as yet 
unknown role (Roberston and Jones, 1998).
1-3.4.
Mutational analysis revealed that p l 6 ^ "^^  ^is commonly mutated or deleted in human 
cancer, in particular in pancreatic adenocarcinoma and melanomas, with some 
mutations mapping specifically to exon l a  (Hussussian et a l, 1994; Sharpless and
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DePinho, 1998). Interestingly mutations in cdk4, which abrogate function,
are also found in melanomas further strengthening the observation that the p l 6 ^^ "^^ -^ 
cdk interaction plays a role in tumour susceptibility (Zuo et al., 1996).
p^ i^NK4 a first identified by its ability to block cell passage from Gi into S phase, 
as a consequence of the inhibition of cyclin D-dependent cdk4/6 kinase activity 
(Serrano et al., 1993). The inhibition of cdk4/6 leads to the hypophosphorylation of 
pRb that in turn represses E2F and blocks G% progression and exit (Figure 1.6). 
Crystallographic studies of p i 6 ^ "^^  ^bound to cdk6  demonstrated that binding distorts 
the cyclin binding site and prevents ATP binding (Russo et al., 1998). The lack of 
pRb and plb^^ '^ '^  ^mutations in the same tumour together with the observation that Rb' 
'' cells generally display very high levels of p l 6 ^^ "^  ^indicates the lack of a selective 
advantage in deregulation of two genes in the same pathway.
1-3.5. d 14/ 19^”^.
Structurally pl4/19^^^ is a highly basic protein that shares no homology with known 
proteins in the databases and lacks any decisive functional protein motifs (Quelle et 
al., 1995). p l4 /19^^  can induce cell cycle arrest in a p53-dependent cdk-independent 
manner as cells-lacking p53 aie refractory to pl4/19'^^^ arrest (Pomerantz et a/.,1998; 
Zhang et a l, 1998; Kurokawa et a l, 1999).
Given the ability of pl4^^^ to suppress MDM2/Ras induced transformation it was 
suspected that pl4^^^ induced cell cycle arrest by preventing MDM2 mediated p53 
ubiquitin degradation. Studies have demonstrated that pl4**^ activates p53 by 
binding and sequestering MDM2 into nuclear bodies where it is unable to target p53
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for nuclear export and degradation (Zhang and Xiong, 1999) (Figure 1.6). Expression 
of p 14/19^^^ exon Ip alone (amino acids 1-64) is sufficient to stabilise p53, stimulate 
p53-dependent transcription of and mdm2, and induce cell cycle arrest
(Kamijo et ah, 1998; Stott et ah, 1998; Zhang et ah, 1998). Indeed p 14/19^^^, via at 
least two independent exon ip  encoded sequences, interacts directly with the central 
acidic domain of MDM2 at a site overlapped by the p300 binding domain but distant 
from the p53 site (Momand et ah, 1992; Zhang et ah, 1998; Zhang and Yiong, 1999; 
Weber et ah, 1999; Lohrum et ah, 2000a; Midgley et ah, 2000;). Given that p300 
complexed with MDM2 may mediate ubiquitination of p53 and its subsequent 
degradation (Grossman et ah, 1998). It is plausible to assume that p 14/19^^^ may 
compete with p300 for MDM2 in a manner that reduces degradation dependent down 
regulation of p53, simultaneously releasing p300 to act as a p53 transcriptional co­
activator.
Although p 14/19^^^ is functionally devoid of any previously characterised domain, 
regions within the protein have been shown to confer its characteristic nucleolar 
localisation. Nucleolar localisation of pl4/19^^^ under basal conditions is poorly 
understood, although nucleolar structures are known sites of rDNA localisation, 
rRNA synthesis and ribosomal assembly (Scheer and Weisenburger, 1994; Fomproix 
et ah, 1998).
Nucleolar localisation of pl4/19'^^^ is imposed by specific sequence motifs present 
within both exon ip  and exon 2 of the protein (Weber et ah, 1999; Zhang and Xiong,
1999). Within the nucleolar localisation coding region from exon 2 of p l4 /19^^ a 
number of mutational events have been noted, ranging from microdeletions to single
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nucleotide insertions, which would presumably affect both localisation and 
consequently function of p 14/19^^^ (Soufir et aL, 1998; Holland et a l, 1999). Recent 
observations have identified basic amino acid stretches present in both the N- and C- 
terminal of p l4 /19^^  as being important for nucleolar localisation. Such basic amino 
acid stretches are also found in RNA binding proteins as well as the human 
immunodeficiency viral proteins Rev and Tat, where they mediate an impoitin p 
interaction (Henderson and Percipalle, 1997; Rizos et a l, 2000). The identification of 
these regulatory domains suggests that p 14/19^^^ may be a multi-functional protein 
participating in several aspects of the controlled growth of cells.
Mutational analysis revealed that the formation of p53-MDM2-pl4^^^ nuclear 
bodies, within which p53 is stabilised, requires to some degree the presence of the 
nucleolar localisation signal encoded by exon 2 (Zhang and Xiong, 1999). The 
presence of nuclear bodies and their function as yet remains unclear, although it is 
interesting to speculate that they are sites of DNA synthesis or are regions involved in 
structure-related events. The importance of nucleolar localisation on p 14/19^*^ 
function is further highlighted by the presence of a second potential nucleolar 
localisation signal (NuLS) within the exon ip  encoded N-terminus which although 
less efficiently is still able to drive p53 stabilisation (Lohrum et aL, 2000a; Midgley 
et aL, 2000). Murine p l9 ^ ^  differs from human pl4*^^ in that pl9^^^ appears not to 
form nuclear bodies with p53 and MDM2 but to actually sequester and retain MDM2 
but not p53 into the nucleolus of cells (Weber et aL, 1999).
In addition to the nuclear structures formed by the interaction of p i4/19^^^ with 
MDM2 it appears that MDM2 itself can be sequestered, or located into the nucleolus.
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As a result of its interaction with a cryptic nucleolar localisation signal within
the C-terminus of MDM2 is revealed that is effective in promoting MDM2 nucleolar 
localisation (Weber et ah, 1999; Lohrum et ah, 2000a; Lohrum et ah, 2000b).
The ability of MDM2 to regulate the cellular level of p53 is a direct consequence of 
its ability to undergo nucleo-cytoplasmic shuttling (Roth et ah, 1998). It is the 
targeting of p53 to the cytoplasmic proteasome by MDM2 that is blocked by 
p i4/19^^^, which tethers MDM2 into nuclear structures (Tao and Levine, 1999b). As 
MDM2 nuclear export is dependent upon its interaction with exportin-1 (CRM-1) and 
Ran-GTP it is feasible to assume that p 14/19^^^ effects these interactions either 
directly by holding MDM2 or indirectly through an as yet undefined secondary 
modification mechanism (Freedman and Levine, 1998).
pl4*^^ was originally believed not to participate in the p53 DNA damage response 
(Zhang et ah, 1998). However studies performed by Khan et ah (2000) demonstrated 
that pl9^^^^ responds, in a p53-dependent manner, to microtubule disruption and 
ionising radiation, whereas ribonucleotide depletion and actinomycin induced RNA 
synthesis inhibition were completely independent of p i9^^ . Clearly these specific 
roles for p 14/19^^^ in the DNA damage response require clarification.
The direct interaction of the p i9^^^ exon ip  encoded N-terminal domain (amino 
acids 1-62) with p53 was demonstrated, and although the interaction can occur in a 
DNA context it does not increase the affinity of p53 for its consensus site (Kamijo et 
ah, 1998). Mutant forms of p53, that exhibit a prolonged half life and have a reduced
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affinity for MDM2, and the stress activated kinase JNK show an increased affinity for 
p i4/19^^^ (Buschmann et a l, 2000).
The forced induction of pl9^^^ in mouse fibroblasts causes a p53-dependent Gi and 
G2 /M atTest in the cell cycle (Kurokawa et ah, 1999). Fibroblasts that express high 
levels of pl9*^^ prior to Gi arrest show high mobility forms of pl9*^^ that may 
conespond to either p i9^^^ degradation inteimediates or post-translational 
intermediates (Kurokawa et ah, 1999). Cells expressing high levels of pl9*^^ retain 
high molecular weight forms of p53 (Pomerantz et aL, 1998) that possibly coiTespond 
to polyubiquitinated forms. Given this observation it is foreseeable that pl9^^^ might 
not inhibit MDM2 mediated ubiquitination but instead might prevent the degradation 
of ubiquitinated p53.
piqARF reduces the level of pRb phosphorylation and forces pRb into a 
hypophosphorylated form. The induction of pRb hypophosphorylation corresponds 
with the ability of p i9 ^ ^  to down-regulate cdk activity, p i9 ^ ^  down-regulates the 
activity of cdk 2 and 4 by reducing the level of cyclin A, B 1 and E. Interestingly the 
level of the mid Gi cyclin, D l, is increased by p i9"^ ^^  as well as the p53 induced gene 
p2 iVRa///op7 \yhich functionally inhibits cyclin D/cdk complex kinase activity. The 
increased expression of cyclin D and p21^^^^^ '^^  ^ as a consequence of pl9^^^ alters 
the cellular composition of the cyclin/cdk complexes in such a way that usually 
undetected cyclin cdk complexes become prominent (Labaer et ah, 1997; Kurokawa 
et aL, 1999). The p27^^^ cyclin dependent kinase inhibitor is down regulated by 
piqARF together with the cdc2  kinase, which is absolutely required for G2/M
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progression. The repression of cdc2 expression may provide a mechanism by with 
which pl9^^^ induces G2/M cell cycle arrest (Kurokawa et ah, 1999).
mdm2 gene expression, as a consequence of p53 stabilisation, is upregulated by 
p i4/19^^^, but interestingly the stability of MDM2 in complex with p i9^^^ is 
reduced (Zhang et a l, 1998; Kurokawa et a l, 1999; Zhang and Xiong, 1999). The 
exact mechanism by which MDM2 stability in complex with p i9"^ ^^  is reduced is 
unknown, although it is potentially by the cytoplasmic proteasome pathway in an 
analogous way to p53 stability regulation by MDM2.
pj^yg important function in the p53 mediated pathways involved in Gi 
arrest, but several lines of evidence point to mechanisms by which p i9^^^ can induce 
cell cycle arrest via a p53 independent mechanism (Kurokawa et a l, 1999; Caiuero et 
a l, 2 0 0 0 ).
1-3.6. Oncogenes and pl4/19^^.
Given that p 14/19^^^ shows little or no response to DNA damaging conditions it is 
interesting to note the response to oncogenic stimuli. The oncogenes Ras, Myc and 
E l A are all able to induce a p i 4/19^^ response (de Stanchina et a l, 1998; Palmero 
et a l, 1998). Interestingly Ras can also elicit and make use of the tumour
suppressor in order to aiTest cells (Serrano et a l, 1997). The enforced expression of 
pl4^^^ induces cell cycle arrest however in the presence of E l A or Myc cells 
undergo apoptosis (deStanchina et a l, 1998; Zindy et a l, 1998). E lA  requires both 
the capacity to bind pRb and p300 in order to induce cellular apoptosis, so it is 
possible that pl4/19^*^^ activation is a consequence of these activities (de Stanchina
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et al., 1998). The action of oncogenes in the targeting of p i4/19^^^ is further 
emphasised by the observation that p 14/19“'^ '^ ' cells are resistant to E2F-1 induced 
apoptosis (Zindy et al., 1998).
The ability of the Abel son virus (Ab-MLV) oncoprotein to induce pre-B cell 
transformations is a direct consequence of loss of p53 function. The normal cellular 
defence mechanism against v-Abl appears to be governed by p i9^^^, given that Ab- 
MLV induces c-Myc and Ras expression that in turn induce p l9 ^^(Z o u  et al., 1997; 
Radfar gr a/., 1998).
The actions of oncogenes on and p i9^^^ together with the lack of a clear
involvement in the DNA damage response of the two proteins implies that the 
lNK4a/ARF locus may be a specific cellular controlling mechanism against the 
actions of oncogenic stimuli.
1-3.7. Roles of and pl4/19^^ in senescence.
Senescence is the loss of the ability to proliferate after the completion of a finite 
number of cellular divisions and is characterised by a growth arrest, apoptotic 
resistance and an altered spectrum of differentiation phenotypes (Campisi, 1996; 
Campisi, 1997). A loss of, or shortening of, telomeres from eukaryotic chromosome 
ends results in an inability to induce DNA replication and a senescence phenotype 
(Campisi, 1996; Campisi, 1997; Bodnar et al., 1998). The senescence phenotype has 
also been shown to be induced under conditions of DNA damage, the introduction of 
deacetylase inhibitors and by oncogenic forms of Ras and Raf (Ogryzko et al,, 1996b; 
Sen’ano et al., 1997; Chen et al., 1998). As senescence entails an irreversible growth
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arrest it has been suggested as a fail-safe program that curtails tumouri genesis and 
age related pathologies. The growth an-est associated with senescence is closely 
associated with the down regulation of many cell cycle associated genes, such as c- 
fos, Cdc2, cyclin A and E2F1, and the up regulation of growth inhibitors like 
and p2 lW»«'api (Alcorta et a i, 1996; Hara et a l,  1996; Stein et a l,  1999).
Viral oncoproteins immortalise cells, by inactivating the telomere length checkpoint 
control system which prevents the initiation of senescence, as a consequence of their 
ability to target the cellular proteins, p53 and pRb (Chen et a l, 1998). Consistent 
with the role of pRb and p53 as mediators of senescence is the observation that both 
p2 iWafi/cipi p2^ iNK4a able to induce premature senescence phenotypes when 
expressed in human fibroblasts (McConnell et aL, 1998). A role for p i i n  
senescence is further enforced in that primary cultured cells express increasing 
amounts of as they approach senescence and inactivation of
prevents Ras induced senescence (Hara et a l, 1996; Haber, 1997).
Introduction of transcriptionally active E2F-1 into human fibroblasts is able to induce 
a senescence like phenotype in a p53 and pl4^^^ dependent manner. Given that E2F 
induces p l4 ^ ^  expression and the introduction of p i4^^^ into fibroblasts produces a 
senescence phenotype it is likely that E2F’s ability to induce a senescence phenotype 
is at least in part due to its ability to upregulate p i4^^^ (Kamijo et a l, 1999a; Dimri 
et a l, 2000). The senescence phenotype is therefore to a degree controlled by p i4^^^, 
although not maintained by induced expression from E2F, as E2F levels are low in 
senescence cells, possibly as a consequence of the low level of Bmi-1 expression seen 
in senescence cells (Jacobs et a l, 1999a).
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Camero et al. (2000) performed an elegant study using anti-sense knock out vectors 
in which they examined the role of both pl9^^^ and in senescence and cell
cycle arrest. Interestingly pl9^^^ could, in a p53 independent fashion, negatively 
regulate the cell cycle. The p53 independent mechanism of cell cycle arrest by p i9^^^ 
was lost upon pRb inactivation, and required MDM2. It was demonstrated that 
piqARF jnore effective at inducing senescence than p i a s  p i9^^^ deficient 
cells can proliferate with high levels of p i b u t  cells without p i c a n  not 
proliferate with high levels of p i9^^^. It is interesting to speculate that p i 9^ *^" and 
pj^ giNK4a developed as a mechanism by which senescence is activated by
targeting both p53 and pRb not only potentially directly but also through MDM2 
(Yap et at., 1999; Carnero et at,, 2000; Lloyd, 2000).
1-3.8. Conclusions.
The lNK4a/ARF locus and its two gene products, pl6^^"^^ and p 14/19^^^, both play a 
key role in regulating the cell cycle check point controlling proteins, p53 and pRb. 
pl i^NK4a j.^ j.gg^ g pRb pathway to induce a cell cycle arrest and p i4/19^^^ the 
MDM2/p53 pathway (Figure 1.6). The transcription of two unrelated genes from the 
same genetic locus such that both function to mediate the same cellular consequences 
has undoubtedly come about through a genetic selection event. The reason for such 
conservation in genetic information in mammalian cells is unknown but will prove an 
exciting avenue for future research.
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Figure 1.6. The INK4a/ARF locus and its two gene products.
Diagram of the exon organisation of the INK4a/ARF locus. Alternative splicing of 
E ip  to E2 gives rise to p 14/19^^^ and transcription driven from E l a  forms the GDI 
pl i^NK4a pl4/19'^^^ neutralises MDM2 to stabilise p53 that in turn results in
p53 mediated cell cycle arrest as a result of induction of genes such as p21^^^^ ‘^^ ^^  ^
pl6^^K4a inhibits the phosphorylation of pRb by directly inhibiting cyclin/CDK 
activity that in turn results in the repression of E2F and cell cycle arrest (Chin et al., 
1998).
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1-4. The Retinoblastoma tumour 
suppressor protein (pRb).
1-4.1. Introduction.
The retinoblastoma tumour suppressor gene {rb} is frequently mutated in a broad 
spectrum of human tumours, including retinoblastoma, osteosarcoma, and prostate, 
breast and lung carcinomas (Weinberg, 1995; Sherr, 1996). In addition, a number of 
genes, such as and cyclin D l that regulate pRb function are also frequently
associated with tumour progression (Caldas et al., 1994; Kamb et ah, 1995; Hall and 
Peters, 1996). The high frequency of mutations in the pathway that controls pRb 
activity underscores the importance of this tumour suppressor pathway in 
tumouri genesis. More precisely loss of pocket protein function, either through 
mutagenesis, viral infection or phosphorylation results in the de-regulation of the E2F 
transcription factor family and is a major step in the loss of cell cycle control and 
tumour formation (Dyson, 1998).
pRb’s cellular importance is highlighted by the plethora of interactions, with 
transcription factors, kinases, phosphatases, structural proteins and deacetylases 
which it uses to suppress cell cycle progression. Clearly the role of pRb in 
suppressing growth, facilitating differentiation and inhibiting apoptosis defines pRb 
as a master regulator of the cell (Sellers and Kaelin, 1996; Dyson, 1998).
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1-4.2. Rb family.
The retinoblastoma gene (Rb) located on chromosome 13 encodes a llOkDa nuclear 
phosphoprotein that behaves as a classical tumour suppressor protein (Lee et ah, 
1987; Riley et a l, 1994). pRb is frequently inactivated in a variety of tumour types 
and sporadic or familial inherited inactivating mutations in both copies of the rb gene 
are associated with retinoblastoma (Friend et a l, 1986). Single allelic mutations in 
the rb gene predisposes suffers not only to retinoblastoma but also tumours such as 
osteosarcomas and fibrosarcomas (Horowitz et a l, 1990; Riley et a l,  1994).
pRb is a member of a family of proteins termed “the pocket proteins” that includes 
pl07 and pl30 (Ewan et a l, 1991; Hannon et a l, 1993; Weinberg, 1995; Whyte, 
1995). The pocket protein family members are highly homologous proteins and their 
genes are highly conserved in multi-cellular organisms. The family share a region of 
very high homology termed the pocket region and it is this region that is targeted by 
the negative cell cycle viral regulators, SV40 large T, E l A and E7 (La Thangue, 
1994; Chow and Dean, 1996).
The pocket region of pRb, pl07 and pl30 mediates many of the cellular binding 
properties of the proteins and is essential for their growth suppression properties. An 
LXCXE binding region imparts the ability of many cellular proteins that contain 
LXCXE motifs such as, hi stone deacetyl ases (HDAC’s) and cyclin D to interact with 
the pocket proteins (Kaelin, 1999). Viral oncoproteins such as ElA , E7 and SV40 
large T also contain LXCXE motifs in their protein sequence and similarly it is this 
region that mediates their interactions with pocket proteins (Dyson and Harlow, 1992; 
Moran, 1993). The pocket region that encompasses the LXCXE motif is also
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responsible for the interaction of pRb with the transcription factor E2F. In addition 
pRb utilises its C-terminal pocket region to mediate interactions with the cellular 
proteins MDM2 and c-Abl. The binding of c-Abl to pRb prevents ATP binding and 
abrogates pRb’s growth an'est function as a consequence of a loss in c-Abl’s kinase 
activity (Welch and Wang, 1993; Welch and Wang, 1995). Conversely pRb binding 
to MDM2 inhibits its anti-apoptotic function (Martin et al., 1995; Xiao et a l, 1995; 
Hsieh et al., 1999) (Figure 1.7a).
To date only the pRb member of the pocket protein family has been observed to be 
mutated in tumour cells. The generation of knockout mice has indicated that pRb, 
pl07 and pl30 perform both distinct and overlapping functions in the regulation of 
cellular proliferation (Hurford et al., 1997). rb knockout mice are embryonic lethal 
while plOT^' or p i 30' '^ mice are normal and survive to term (Clarke et al., 1992; 
Jacks et al., 1992; Lee et al., 1992). rb'''' mice suffer from the defective differentiation 
of many tissues and an increased level of apoptosis and embryonic fibroblasts from 
these animals display inappropriate S-phase entry (Herrera et al., 1996). Specifically, 
it appears that p i07 and p i30 in a rb' '^ background are unable to compensate for the 
loss of pRb with respect to the differentiation and proliferation of certain tissue types. 
The unique tumour suppressor status of pRb is also highlighted by pl0T^’;pl30^^' and 
pl07'^^'',pl30'^' mice that develop normally and show no increase in the level of 
tumour formation.
The non-lethal phenotype of pl07 and pl30 knockouts is potentially due to functional 
redundancy between the two family members and in agreement pl0T^'\pl30'^' mice 
die in utero due to cartilage and bone malformation (Cobrinik et al., 1996).
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Interestingly the overlap in function of the pocket protein family is highlighted by the 
observation that rb^ '^ mice, that do not develop retinoblastoma, when crossed with 
plOT^' mice, to generate rb^^'\plOT^' mice, begin to suffer from retinal dysplasia (Lee 
et a l, 1996). In addition rb'^'\plOT^' mice die at an earlier stage in utero than rb' '^ 
mice (Lee et al., 1996).
Given these observations it is interesting to speculate that pl07 and p i30 are essential 
cellular genes and that mutations in their regulatory mechanisms are intolerable even 
in tumour cells. Potentially the physiological role of pl07 and pl30 in tumourigenesis 
is confined to mutational events that inactive their functions as regulators of gene 
expression while maintaining other necessary functions they perform. In agreement 
such mutations are found in the pocket protein regulatory protein, pl6^^ "^^  ^ (Caldes et 
al., 1994; Kamb et a l, 1995; Koh et a l, 1995; Hall and Peters, 1996).
1-4.3. Cell cycle regulation by pRb.
pRb acts as a potent negative regulator of cellular proliferation through its ability to 
regulate the activity of a variety of nuclear proteins and transcription factors such as 
E2F (Weinberg, 1995). E2F is a heterodimeric transcription factor that consists of an 
E2F and DP component which regulates the transcription of a number of target genes 
involved in DNA replication, chromosomal replication and cell cycle control. Distinct 
cellular mechanisms control the timing of E2F target gene activation potentially by 
ordering the family composition of the E2F/DP DNA binding complexes (Bandara et 
a l, 1993; La Thangue, 1994; de La Luna et a l, 1996; Allen et a l, 1997). E2F target 
genes involved in DNA replication include DNA polymerase a, thymidine kinase 
(TK), dihydrofolate reductase (DHFR) and cdc6, and those involved in cell cycle
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regulation include cyclin A, cyclin E, cyclin D l, pl07, cdc2, E2F-1, E2F-4, E2F-5 
and p 14/19"^^  ^(La Thangue, 1994; Adams and Kaelin, 1995; Kaelin, 1999).
The E2F family consists of six members all of which display different affinities for 
the pocket protein family members. Each member of the E2F family, except E2F-6, 
contains a domain for DNA binding, heterodimerisation and ^ransactivation (Dyson, 
1998; Helin, 1998). E2F’s role as an S-phase promoting gene inducer is dependent on 
its DNA binding and /ra^z^activation domains. The rraw^activation domain in the E2F 
proteins is the region that mediates their binding to the regulatory pocket proteins. 
E2F-1, -2 and -3 have a high affinity for pRb in contrast, E2F-4 and E2F-5 
preferentially bind to pl07 and pl30. The interaction of pocket proteins with the E2F 
or DP partners alone is week however the interaction with the heterodimer is highly 
stable (Bandara et al., 1993; Helin et al., 1993). pl07/pl30 E2F complexes are more 
evident in differentiated or quiescent cells while pRb/E2F complexes are most 
evident during cyclin cells, particularly at the Gi/S phase transition.
In addition to their role in the up-regulation of transcription E2F’s also play a role in 
transcriptional repression. Promoter analysis demonstrated that during Go and early 
Gi E2F’s are found on promoters in complex with pocket proteins, and that this 
complex is repressive (Tommasi and Pfeifer, 1995; Zwicker et al., 1996; Yasuhiko et 
al., 2000). Also the mutational analysis of a number of E2F responsive promoters, 
such as those encoding B-Myb, E2F-1, E2F-2 and cyclin E, demonstrated that E2F’s 
absence actually leads to an increase in transcription (Dalton, 1992; Lam and Watson, 
1993; Geng et al., 1996; Helin, 1998). It therefore appears that the primary function
of E2F on certain promoters is to negatively regulate transcription, potentially by 
acting as a pocket protein recruiter.
As well as pRb’s role in E2F mediated transcription it can also negatively regulate the 
Ets-family transcription factor members, Elf-1 and PU.l and additionally through a 
RCE region (retinoblastoma control element) in the c-fos promoter can repress TK 
expression (Kim et al., 1991; Pietenpol et al., 1991; Hagemeier et al., 1993; Wang et 
a l, 1993).
An interesting feature of pRb is its ability to interact with the transcription apparatus 
associated factor TFuD via the TAFn250 component (Shao et a l, 1995; Shao et a l, 
1997). pRb interacts with TAFn250 through multiple domains and the interaction 
inhibits TAFn250 kinase activity but not its cell cycle regulatory HAT activity 
(Siegert and Robbins, 1999; Dunphy et a l, 2000). The ability of pRb to inhibit 
TAFii250 enzymatic kinase activity points to an additional mechanism by which pRb 
can regulate the cell cycle by directly modulating the functions of the basal 
transcription machinery.
The ability of viral proteins such as SV40 large T antigen and adenoviral E l A to 
transform cells is to some extent dependent on their ability to overcome the growth 
suppressive activities of pRb (Hu et a l, 1990; Bandara and La Thangue, 1991; 
Chellappan et a l, 1991; Zamanian and La Thangue, 1992). The binding of pRb by 
viral proteins results in the appearance of free E2F and an increase in E2F 
transcriptional activity (Hu et a l, 1990; Vous den, 1995). Interestingly E lA  can also
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stimulate the binding of pRb to the transcriptional co-activator p300, but as yet the 
functional significance of the pRb/p300 interaction is unknown (Wang et al., 1995a).
1-4.4. pRb regulation of E2F.
pRb in a hypophosphorylated form binds to E2F in a DNA bound context to regulate 
E2F transcriptional activity primarily during the Go and Gi stages of the cell cycle. 
The binding of pRb to E2F inactivates E2F ?ra«.sactivation, which prevents gene 
expression and cell cycle progression. Cyclin/cdk complexes release pRb repression 
of E2F, liberate free E2F and promote cell cycle progression (Figure 1.7b). Notably, 
pRb residues that are required for its binding to E2F and consequent inhibition of 
fraTT^activation are frequently found mutated in human tumours (La Thangue, 1994).
E2F’s transcriptional activity is potentially regulated in a number of ways by pRb 
(Dyson, 1998). The most direct way that pRb regulates E2F transcription is through 
its ability to bind and block the function of the transcriptional activation domain of 
E2F (Weintraub et ah, 1995). The pRb in the pRb/E2F complex also inhibits the 
recruitment of the transcriptional initiation complex by E2F (Ross et al., 1999). In 
addition pRb can recruit enzymes that inhibit E2F’s transcriptional activation. pRb 
binds to the hi stone deacetyl ase family of enzymes (HD AC’s) which catalyses the 
deacetylation of histones and condensation of the nucleosome that leads to 
transcriptional repression (Brehm et al., 1998; Luo et a l,  1998; Magnaghi-Jaulin et 
a/.,1998; Brehm and Kouzarides, 1999).
The ability of pRb to bind the chromosome remodelling complex Swi/Snf is another 
potential mechanism by which it represses E2F mediated transcription (Zhang et al..
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2000). Interestingly the pRb/HDAC complex is also bound by the Swi/Snf complex, 
which presents an interesting model in which it is the component of the pRb complex 
and not simply pRb that mediates its repressive activity of target genes. In agreement 
the pRb/Swi/Snf complex can repress cyclin A and cdc2 gene expression but not 
cyclin E or E2F-1 expression (Zhang et aL, 2000). Furthermore pRb has a potential 
role in the recruitment of a eo-repressor complex through its ability to bind RbAp48 
and RbAp46. RbAp48 and RbAp46 are components of the SIN3 co-repressor 
complex (Hassig et al., 1997; Hassig and Schrieber, 1997)
The pocket proteins are also able to regulate the level of E2F mediated transcription 
by indirectly effecting the level of E2F protein (Dyson, 1998). Un-phosphorylated 
pRb protects E2F from ubiquitin mediated SCF like proteolysis and thereby 
maintains a steady state level of E2F (Hateboer et al., 1996; Dyson, 1998; Marti et 
al., 1999).
Interestingly, pRb also regulates the apoptotic function of E2F. Specifically E2F-1, 
and not the other E2F family members, when overexpressed in a pSS'''' or p53'^ '^  ^
background can induce apoptosis (Qin et a l, 1994; Hsieh et a l, 1997; Phillips et al., 
1997). The mechanism of E2F-1 induced apoptosis at least in part occurs through the 
death receptor pathway and involves the inactivation of anti-apoptotic signals such as 
NF-kB (Phillips et al., 1999). More specifically, E2F-1 stimulates p i4/19^^^ 
expression that in turn releases MDM2’s suppression of p53 apoptotic function 
(Sharpless and DePinho, 1998).
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The cellular properties of E2F are dependent on its localisation, given that its nuclear 
localisation is vital for transcriptional activation. The localisation of E2F into the 
nucleus is in pait controlled by its DP partner molecule and is cell cycle regulated (de 
La Luna et al., 1996; Magae et al., 1996; Linderman et al., 1997). Conceivably the 
expression of the DP component may be vital in transcriptional control.
1-4.5. Transcriptional activation and pRb.
Under certain cellular circumstances pRb has actually been shown to augment the 
transcriptional activation of certain transcription factors (Sellers and Kaelin, 1996). 
pRb’s role as an activator has been linked with ATF2’s transcriptional activation of 
the TGF-P2 and pRb promoters (Kim et al., 1992). NF-IL6 in co-operation with pRb 
shows an increase in DNA binding affinity and transcription directed from the 11-6 
promoter (Chen et ah, 1996b). The pocket region of pRb has also been shown to 
mediate an interaction with c-Jun, and this interaction stimulates c-Jun transcriptional 
activity (Need et al., 1998). Interestingly the complexes between pRb and c-Jun are 
only visible in terminally differentiated cells and those re-entering the cell cycle after 
serum starvation (Need et al., 1998).
pRb also binds to the potential transcriptional co-activators and nucleosome 
remodelers BRM and BRGl to activate promoters containing glucocorticoid 
responsive elements (Dunaief et a l, 1994; Singh et a l, 1995). The exact role of pRb 
in these interactions is not fully understood but potentially it may involve the 
stabilisation of the protein DNA binding interface (Sellers and Kaelin, 1996)
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The ability of pRb to positively regulate transcription depends, in most cell systems, 
on the integrity of the pRb pocket. Given that the pocket region of pRb is frequently 
mutated in human tumours it is conceivable that pRb’s up-regulation of transcription 
is also required for its suppression of tumourigenesis (Sellers and Kaelin, 1996).
1-4.6. pRb phosphorylation.
The cell cycle repressive activity of pRb is directly regulated by its phosphorylation 
status (Mittnacht, 1998). In the active repressive state, such as in Go, pRb is Un- or 
hypophosphorylated and during cell cycle progression pRb is successively 
phosphorylated to become inactive. The phosphorylation of pRb is a highly 
orchestrated process and corresponds with an increase in the expression of cyclins 
and a up-regulation of cyclin dependent kinase (cdk’s) activity (Hatakeyama et a l, 
1994; Lundberg and Weinberg, 1998). Dephosphorylation of pRb is carried out by 
phosphatases such as PP-1 and occurs in mitosis (Mittnacht, 1998) (Figure 1.7b).
pRb is phosphorylated on a number of potential S/T-P motifs throughout its sequence 
(Figure 1.7a). Interestingly, the in vivo phosphorylation of pRb by individual 
cyclin/cdk complexes helps confer the specific functions of pRb. Cell cycle 
progression and loss of pRb’s repressive function involves the sequential activation 
of cyclin D/cdk4, cyclin D/cdk6, cyclin E/cdk2 and cyclin A/cdk2 complex during 
late Gi and S phases (Hatakeyama et al., 1994; Sherr and Roberts, 1995; Pines, 1995; 
Whyte, 1995; Lundberg and Weinberg, 1998) (Figure 1.7b). The phosphorylation of 
pRb during Gi in response to mitogenic signals involves the activation of cyclin 
D/cdk4 and cyclinD/cdk6. The peak in cyclin E observed at the Gi/S phase transition
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corresponds to a hyperphosphorylated and non-repressive inactive pRb molecule 
(Sherr and Roberts, 1995) (Figure 1.7b).
pRb’s phosphorylation controls the repressive activity of pRb by disrupting its 
tertiary structure and therefore its ability to interact with its partner molecules such as 
HDAC’s and E2F (Knusden and Wang, 1996; Vivette et al., 1999). In particular the 
C-terminus of pRb is believed to interfere with the interaction capacity of the pocket 
region of pRb through a lysine rich patch (Harbour et a l, 1999). Several studies have 
demonstrated the existence of pRb/E2F complexes in both the S-phase and Gg/M 
phase of the cell cycle although the functional significance of such complexes is 
unknown (Schwarz etaL, 1993)
The phosphorylation of pRb is negatively regulated by the cyclin dependent kinase 
inhibitors, p27“ P> (Harper et a l ,  1993; Serrano et
a l, 1993; Xiong et a l, 1993; Sherr and Roberts, 1995; Weinberg, 1995). The 
expression of the cyclin dependent kinases inhibitors correlates with the repressive 
function of pRb and is associated with their ability to directly influence pRb 
phosphorylation status. The high frequency of mutation in the INK4a and lNK4b gene 
products helps highlight pRb’s role in the suppression of tumourigenesis (Sharpless 
and Depinho, 1998).
The cell cycle promoting molecules c-Myc and Ras also impart their functions on the 
pRb pathway. Over-expression of Ras and c-Myc promotes the accumulation of 
active cyclin/cdk complexes that coincides with a loss of p27^^* function 
(Alevizopoulos et a l, 1997; Leone et a l, 1997). It therefore appears that the
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inactivation of pRb function by growth promoting signals is an important 
intermediary step in cell cycle progression.
1-4.7. pRb as an anti-apoptotic protein.
E2F-l’s introduction into rb' '^ cells induces inappropriate S-phase entry and apoptosis 
via both p53-dependent and independent mechanisms (Qin et al., 1994; Almansan et 
al., 1995; Hsieh et al., 1997; Phillips et al., 1997). The induction of apoptosis by 
E2F-1 is overcome by the co-expression of pRb or MDM2 and is dependent on pRb 
ability to bind E2F-1 (Hsieh et al., 1997; Wang, 1997; Loughran and La Thangue, 
2000). The ability of E2F-1 to induce apoptosis is transcriptionally independent as 
mutant forms of E2F-1 that are devoid of the transcriptional activation domain retain 
the ability to drive apoptosis (Hsieh et al., 1997). However the DNA binding function 
of E2F-1 is an absolute requirement for apoptosis (Phillips et al., 1997). The 
regulation of E2F-1 apoptotic function by pRb is confirmed by the high levels of 
apoptosis observed in rb' '^ mice tissues and by the resistance of e2f'\rb'^' cells to 
apoptotic inducing signals (Yamasaki et al., 1996; Yamasaki et al., 1998). In addition 
E l A, which functionally inactivates pRb also induces apoptosis.
Conversely pRb has also been shown to promote p53’s apoptotic function by the 
inhibition of MDM2 function (Hsieh et al., 1999). Given that the C-terminus of pRb, 
which binds MDM2, is cleaved by an Interleukin Ip-converting enzyme like protease 
(ICE-like) in response to TNF induced apoptosis, the role of pRb in apoptosis is 
potentially regulated by its interaction with MDM2 (Reinder et ah, 1996). In support, 
the cleavage of the C-terminus of pRb is blocked by Ced-3/ICE inhibitors that
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prevent apoptosis (Bing and Don, 1996). It is interesting to speculate that MDM2 
regulates apoptosis through its ability, at least in part, to modulate pRb function.
1-4.8. Terminal differentiation and pRb.
A role for pRb in terminal differentiation was initially suspected given that rb' '^ mice 
display defects in erythriod, neuronal and lens development (Mulligan and Jacks, 
1998; Lipinski and Jacks, 1999). Interestingly the loss of pRb does not affect the 
induction of differentiation but rather its completion and termination, indicating that 
pRb is important in late development. The transcriptional activation of some 
myogenic genes by MyoD also requires the presence of pRb and in addition pRb can 
cooperate with C/EBP to promote adipocyte differentiation (Chen et a l, 1996a; 
Sellers and Kaelin, 1996). Given that mutations in pRb that reduce its ability to bind 
E2F still retain an ability to augment transcription of MyoD dependent genes it is 
presumed that pRb role as a tumour suppressor stems also, in part, from its role in 
differentiation (Gu et al., 1993; Sellers et al., 1998)
1-4.9. Conclusions.
The pRb tumour suppressor is clearly a vital mediator of cell cycle control, that 
responds to both positive and negative signals to regulate proliferation, differentiation 
and apoptosis. pRb modulates the function of a number of transcription factors by 
nature of its ability to assemble an active repressor complex. In addition the ability of 
pRb to bind to chromatin modulators is potentially an important mechanism that 
helps initiate gene transcription.
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The importance of pRb in gene transcription is underlined by its ability to regulate 
Pol I, Pol II and Pol III mediated transcription (La Thangue, 1994; Dyson, 1998; 
Sellers and Kealin, 1996). Indeed the regulation of the components of the pRb 
pathway are the source of numerous studies into the design of anti-proliferative 
drugs.
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Figure 1.7. Structure and function of pRb.
a). Structure of the retinoblastoma protein (pRb). The 16 potential S/T-P 
phosphorylation sites are indicated together with the large pocket domain that 
contains the LXCXE binding motif (green and red regions). The C-terminal pocket 
region is also highlighted (blue). The minimal binding region required for E2F, 
MDM2 and c-Abl aie indicated.
b). Model of pRb regulation. pRb is unphosphorylated in Go and Gi and forms stable 
complexes with the E2F/DP heterodimers. The activities of pRb are controlled at 
least in part by its ability to recruit histone deacetylases and chromatin remodelling 
complexes. In late Gi pRb is hypeiphosphorylated by cyclin/cdk complexes, 
hypeiphosphorylated pRb is unable to associate with E2F/DP and so is unable to 
repress transcription. Transcription driven by E2F helps drive the cell cycle and in 
the M phase pRb is dephosphorylated by PPL
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1-5. Objectives.
The role of co-activators and their associated molecules in the regulation of 
transcription is poorly understood. It is becoming evident that the co-activator 
complex is not simply a collection of proteins that carry out one definite function but 
that the exact composition of the complex determines its function. Specifically, subtle 
changes in the composition of the co-activator complex are likely to be responsible 
for dictating its promoter specific activities and are a vitally important mechanism of 
cellular growth control.
It is clear that the p300 transcriptional co-activator plays an important role in cell 
cycle control. In addition it appears likely that p300/CBP allows cross-talk between 
different controlling pathways in order to bring about a given physiological outcome. 
An important cellular target of p300’s molecular action is the p53 tumour suppressor 
protein.
A definitive question in cell cycle research relates to the physiological role of p300 in 
the regulation of the p53 response and the mechanism that controls the switch 
between the cell cycle arrest and apoptotic functions of p53. In this respect the role of 
a novel protein, JMY that co-operates with p300 in the p53 apoptotic response was 
investigated. Of particular interest was the C-terminal proline rich region of JMY that 
is alternatively spliced to generate a JMY variant that selectively activates the cell 
cycle aiTest function of p53.
99
The cell cycle affect of p53 is regulated by the actions of the p 14/19"^^  ^ tumour 
suppressor proteins. pl4/19^*^^ controls the function of the oncogene MDM2 in order 
to release p53 and promote a cellular effect. As JMY is involved in the p53 response 
another objective of this study was to determine if JMY influenced the p i4/19^^^ 
pathway.
Finally, an additional objective of this research was to dissect the repressive and 
transcriptional activating functions of pRb. Loss of pRb function is believed to be an 
important step in the formation of tumours and significantly pRb tumour mutants 
posses the ability to co-operate with JMY in the tran^activation of p53. This suggests 
a novel mechanism of protection against tumourigenesis that cells have developed in 
circumstances when the crucial pRb growth regulatory pathway has been disabled.
Understanding the nature and function of the JMY/p300 co-activator complex 
response will ultimately help dissect the role of p300 in the p53 response and 
consequently is likely to yield important answers in the understanding of 
tumourigenesis.
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2. Materials and Methods.
2.1. Plasmids.
The following plasmids have been previously described; pCMV-HA-JMY (Shikama 
et a l, 1998), pCMV-Pgal (Zamanian and La Thangue, 1992), pCMV-pl4^^^ (Scott et 
a l, 1998), pCMV-MDM2 (Loughran and La Thangue, 2000), Exon Ip-luc (Bates et 
al., 1998), pBax-luc (Haupt et al., 1995; Friedlander et al., 1996), pWWP-luc (EL 
Deiry et al., 1993), pGADD45-luc (Chen et al., 1995), pMDM2-luc (Haupt et a l, 
1995), pG5Elb-luc (Lee et al., 1998) pCMV-p300 (Eckner et al., 1996a), pCMV- 
(Shikama et a l,  1999), (Shikama et a l,  1999), pCMV-
JMY^-^°" (Shikama et a l, 1999), pCMV-JMY'*®“'“  (Shikama et a l, 1999), pCMV- 
CD20 (Lee et al., 1998), pCMV-p53 (Lee et al., 1998), pCMV-pRb (Zamanian and 
La Thangue, 1992), pCMV-E2Fl (Kaelin et a l, 1992), pCMV-JMY* ''”  (Shikama et 
a l, 1999), pCMV-RbA22 (Zamanian and La Thangue, 1992), pCMV-Gal4-E2F-l“ “^  
‘‘^ ’ (Leee<al„ 1998).
The following plasmids were gratefully received as gifts; pGEXKG-pld''*^'' from 
Sarah Mason, pPIG3-luc and pCMV-p53AP from Dr Dobblestein, pCMV-HDAC-I 
from Dr Schreiber, pTG^-luc from Chang-Woo Lee, pCMV-JMY^^^ from Laurent 
DeLavaine, pCMV-RB^^^’^ ^^  from Ho-Man Chan and JMYAC from Noriko Shikama. 
The N-teiTninal JMY specific antibody and polypeptide were a generous gift from 
Noriko Shikama. Dr N. Shikama isolated and provided the sequencing information 
described for the splice variant clones, JV4 FS'^  ^and JV^FS^^^.
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To construct pCMV-HA-JMYAP the PCR products generated by 3’ RT-PCR were 
cloned into the pCR 2.1 vector (In vitro gen). The clone corresponding to the JMYAP 
variant was digested with Kpnl (site within JMY) and Xbal (site from within pCR 
2.1). The fragment was ligated in frame to a pCMV-2X HA-JMY^"^^^ coding vector 
previously cut with Kpnl and Xbal.
2.2. Transfection.
For transfections all cells were maintained in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% foetal calf serum (FCS) and the antibiotics 
streptomycin (lOmg/ml) and penicillin (lOOU/ml). Cell cultures were maintained in a 
water saturated 5% CO2 atmosphere at 37°C.
Cells were plated out 24 hours prior to transfection at 5x10^ for reporter assays, 1x10*^  
for flow cytometry and immuno-precipitation or 2x10^ for immuno-staining. Plating 
densities were optimized at 70% surface coverage in all cases. Three hours prior to 
transfection, the media was removed and replaced with fresh growth medium. In all 
cases calcium phosphate-DNA precipitation was used. The indicated concentrations 
of plasmid DNA were mixed with a 2M CaCL solution to give a final salt 
concentration of 200mM in a volume appropriate to the plating density. The Solution 
was drop wise added, with agitation, to an equal volume of 2XHBS (50mM HEPES 
pH 7.1, 280mM NaCl and 1.5mM Na2 HP0 4 ) and the mixture incubated at room 
temperature for 30 minutes before addition to cells. The total volume of precipitate 
added was maintained at a constant ratio of 1ml total volume precipitate per 1x10^ 
cells.
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Whenever required pcDNA-3, or pSG-5 backbone vector was used to maintain a 
constant concentration of DNA. All transfections included CMV-Pgal as an internal 
control for transfection efficiency.
12-17 hours post transfection cells were washed three times with 37°C PBS to 
remove excess precipitate and fresh media added. Cells were harvested 30-40 hours 
post transfection.
In cases where trichostatin A was used it was added to cells in fresh growth media at 
a final concentration of 150nM 10 hours before harvesting. Non-treated cells were 
incubated with an equal volume of the solvent used to dissolve the trichostatin A 
(100% ethanol),
2.3. Luciferase and B-galactosidase assays.
For luciferase assays, cells were washed three times with PBS prior to lysis in 500pl 
reporter lysis buffer (25mM Tris-H3 P 0 4  pH 7.8, 2mM 1,2 diaminocyclohexane tetra 
acetic acid, 2mM DTT, 10% glycerol and 1% Triton X-100). The lysed extract was 
centrifuged at 13000rpm for 15 minutes to remove cell debris before luciferase 
activity was measured. Luciferase activity was measured by the addition of 300jil of 
luciferase assay reagent (Promega) to lOOjiil cell extract in a luminometer (Berthold 
Lumant).
Internal control P~galactosidase activity was determined by mixing lOOjiil of cell 
extract with an equal volume of 2X P-galactosidase buffer (200mM sodium 
phosphate buffer pH 7.3, 2mM MgCL, lOOnriM p-mercaptoethanol and 1.33mg/ml O-
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nitrophenyl-P-D-galactopyranoside), The reaction mixtures were incubated at 3TC  
until faintly yellow in colour at which point enzyme activity was quantified by 
measuring the optical density of the mixture at 420nm.
In cases where fold activation and fold repression were calculated the following 
formulas were used:-
 ^Fold activation (rel. reporter) = Activity of reporter. + Activator.
Activity of reporter.
 ^Fold repression by p i4"^ ^^  = Activity of reporter + Activator.
Activity of reporter + activity of activator + p i4^^^
2.4. Immunofluorescence.
Cells transfected, on 35nun glass coverslips, were washed three times in PBS prior to 
fixation in a solution of 4% paraformaldehyde at room temperature for 15 minutes. 
Cells were then washed in PBS and permeabilised in a PBS solution containing 0.2% 
Triton X-100 for 10 minutes at room temperature. Fixed cells were then blocked in a 
10% FCS PBS solution for 10 minutes at room temperature. Primary antibodies in a 
5% FCS PBS solution were then incubated with the cells for 30 minutes at room 
temperature. After washing three times in a PBS 10% FCS solution the secondary 
antibody diluted in a PBS 5% FCS solution was added for 30 minutes at room 
temperature. Anti-mouse, anti-goat, or anti-rabbit IgG conjugated to fluorescein 
isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC) was used for 
detection (Southern Biotechnology Associates Inc). Finally, coverslips were washed 
three times in PBS and once in PBS containing DAPI (4,6-Diamidino-2-
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phenylindole) before mounting on slides with Citifluor (Citifluor Ltd). 
Immunofluorescence was viewed under a fluorescent microscope (Olympus).
In cases where cells were doubly transfected either anti-mouse, anti-goat or anti­
rabbit conjugated to either fluorescein isothiocyanate or rhodamine isothiocyanate 
were used accordingly. Where cellular compartmentalisation was quantified the 
percentage of cells in each cellular localisation was defined relative to the whole 
population examined. Whole cell staining was defined as cells expressing equal 
quantities of protein in the cytoplasm and nucleus. Nucleolar staining was defined as 
dense bodies within the nucleus that correspond to region of highly condensed DNA.
2.5. Flow cytometry.
Flow cytometry analysis was carried out on cells transfected with the indicated 
amounts of plasmid DNA. In all cases cells were transfected with S jL tg  of CD20 
expression vector and captured by monitoring the expression of the cell surface 
protein, CD20. After transfection cells were harvested by treatment with cell 
dissociation solution (Sigma) for 15 minutes at 37°C. Cell were washed in DMEM by 
centrifugation at 2000ipm for 3 minutes and re-suspended in 200|l i 1 of DMEM 
containing 20|l i 1 of a mouse anti-CD20, leu 16, antibody (Becton Dickinson) coupled 
to fluorescein isothiocyanate (FITC). The cell suspension was incubated on ice for 30 
minutes followed by washing in ice cold PBS. Cell pellets were then fixed by the 
dropwise addition of a 50% ethanol/PBS solution and left overnight at 4°C.
Cells were then washed in PBS and re-suspended in 500jil of PBS containing 
propidium iodide (20p,g/ml) and RNase (125U/ml). Flow cytometry was performed
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on a Becton Dickinson fluorescence activated cell sorter. All cell populations were 
analyzed at a rate of 100-200 cells/second to prevent mis-read. To determine the cell 
cycle profiles of transfected populations the intensity of propidium iodine staining 
was analyzed in cell populations that were positive for FITC staining. Using 
CellQuest software, the cell cycle profiles of 10000 transfected cells was ascertained. 
The data presented show a representative example from multiple assays.
2.6. Immuno-precipitation.
Transfected cells were washed twice in PBS and harvested by scraping in TNN buffer 
on ice (50mM Tris-HCl pH 7.4, 120mM NaCl, 5mM EDTA, 0.5% NP-40, 50mM 
NaF, ImM DTT, ImM PMSF, 0.2 mM sodium orthovanedate, leupeptin (0.5 jig/ml), 
bestatin (40|ig/ml), protease inhibitor (0.5p.g/ml), trypsin inhibitor (1.0|xg/ml) and 
aprotinin (0.5jiig/ml)). The cell extract was centrifuged for 10 minutes at lOOOOrpm 
and pre-cleared by incubating with protein-G agarose for 30 minutes at 4°C with 
agitation. The supernatant was harvested and incubated at 4^C with agitation for 1 
hour after the addition of 4p,l of primary antibody. The reaction was continued for a 
further 30 minutes at 4°C following the addition of 50|Li1 of protein-A agarose (50w/v 
slurry). The agarose beads were collected by centrifugation for 30 seconds at 
5000ipm and were subsequently washed three times in TNN reaction buffer. Bound 
proteins were released into 2X SDS loading buffer (250mM Tris-HCl pH 6.8, 20% 
glycerol (v/v), 4% SDS (w/v), 0.1% bromophenol blue (w/v), 200mM DTT, and 5% 
P-mercaptoethanol). The sample was denatured and separated by SDS-PAGE and the 
protein of interest detected by Western blot using a specific antibody.
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2.7. Apoptosis assays.
Transfected S AOS-2 cells were washed and grown in DMEM supplemented with 
0.2% FCS, streptomycin lOmg/ml and penicillin lOOU/ml for 17 hours before 
analysis. Transfected populations of cells were washed and fixed in a 4% 
paraformaldehyde solution for 15 minutes at room temperature, rinsed thoroughly 
and permeabilised in a PBS solution containing 0.1 % Trition X-100 and 0.1% 
sodium citrate for 5 minutes. Cells were then incubated with primary antibody for 30 
minutes in order to assay transfected cells. Cells were then incubated in a Ca^ "*" 
reaction buffer containing fluorescein-dUTP, dNTP and terminal deoxynucleotidyl 
transferase at 37”C for one hour. In addition a secondary antibody was included that 
was tetramethyl rhodamine isothiocyanate (TRITC) labeled in order to allow the 
visualization of transfected cells. Following incubation cells were washed three times 
in PBS and once in PBS containing DAPI (2jig/ml) mounted and viewed under a 
fluorescent microscope (Olympus),
Apoptotic cells were counted in transfected staining cells in order to ensure a 
conelation between transfection and apoptosis. Transfected cells were visualized 
under a red filter and apoptotic cells under a green filter. At least 1000 transfected 
cells were counted in order to obtain representative data. Background apoptosis was 
determined by TUNEL assay alone in the whole population. Percentage stimulation 
was calculated relative to the level of apoptosis in p53 transfected cells.
2.8. Gluthione S-tranferase recombinant proteins.
BL21(DE3)pLysS (Promega) bacterial cultures transformed with the plasmid of 
interest were grown to a mid-logarithmic stage in LB-broth (Sigma). Protein
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expression was induced by the addition of IPTG (isopropyl-p-D- 
thiogalactopyranoside) at a final concentration of 0.5mM for 4 hours at 37°C. During 
protein induction the protease inhibitor PMSF was added to the cultures every 30 
minutes at a final concentration of 0.5mM. Bacterial pellets re-suspended in 10ml’s 
of PBS containing 1% Triton X-100, 0.5 mM PMSF and 50mM DTT were sonicated 
on ice for two 30 second bursts. Bacterial debris was pelletted by centrifugation and 
re-centrifugation at 12000 rpm for 30 minutes at 4”C. 250)41 of a 50% v/v suspension 
of gluthathione-agarose beads were added to the supernatant and the mixture 
incubated, with rotation, at 4°C for one hour. The suspension was washed twice with 
PBS containing 0.5% Np-40 and once with PBS by centrifugation at 4000rpm for 5 
minutes at 4“C. Beads were stored at 4°C in PBS-azide and protein expression 
monitored by coomassie staining after SDS-PAGE.
2.9. In Vitro protein expression.
In vitro protein transcription and translation was carried out using a TNT T7 coupled 
Reticulocyte lysate system (Promega). Luciferase and MDM2 were expressed as 
recommended by the manufacturer. All the JMY constructs were expressed to an 
optimized reaction condition. Briefly; 30)41 of rabbit reticulocyte lysate, 3)41 reaction 
buffer, 3)41 T7 RNA polymerase and 2)41 of RNase inhibitor were added to l)4 g of 
purified plasmid DNA. Expression was initiated by the addition of 6)41 amino acids 
minus methionine mixture and 4 )4 l of ^^ S labeled amino acid mixture (Amersham). 
The reaction volume was maintained at 50)41 by the addition of water and allowed to 
proceed at 30°C for 3 hours. Protein expression was examined by loading the 
indicated amounts of crude inputs onto a SDS-PAGE gel and the level of ^^ S signal 
examined by autoradiography.
108
2.10. Western blot analysis.
Protein expression levels were measured by immobilization of crude extract onto 
nitrocellulose membrane (Inverclyde Biochemicals) followed by detection with 
specific antibodies. Specific goat, mouse or rabbit primary antibodies were used for 
detection of the protein of interest and the signal amplified either by the addition of a 
specific horseradish peroxidase conjugated secondary antibody (1;7500) or a calf 
alkaline phosphatase conjugated secondary antibody (1;5000). Detection was 
achieved using substrate tablets for alkaline phosphatase (Sigma Fast™ 5-Bromo-4- 
chloro-3-indoyl phosphate/nitro blue tétrazolium) or enhanced chemiluminescent 
(ECL) for horseradish peroxidase (Pierce).
2.11. In vitro binding assays.
In vitro binding reactions were caiiied out by using approximately lOpg of GST or 
GST fusion protein bound to glutathione agarose beads (Amersham Inc). Beads were 
added to equal quantities of in vitro translated product. The reaction was carried out 
in a constant 200|4l volume of reaction buffer (lOOmM Tris-HCl pH 8.0, 150mM 
NaCl2 , 0.5% Np-40, ImM PMSF, ImM DTT and a recommended dilution of 
protease inhibitor cocktail). After incubation at 4°C for 3 hours the beads were 
collected and washed four times in reaction buffer and once in PBS. Proteins were 
released in SDS-sample buffer, electrophoresed and the assay monitored by 
autoradiography. In all cases equal loading was confirmed by coomassie staining of 
GST and GST fusion proteins.
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2.12. RNA isolation.
Whole cell F9 mRNA was isolated from asynchronously growing cell cultures. Cell 
cultures were lysed in RNA extraction buffer (lOOmM NaCl, 1.5mM MgCL, lOmM 
Tris-HCl pH 8 .6 , 0.5% Np-40, ImM DTT, 1000 U RNasin, 2% SDS, 25mM EDTA). 
Proteinase K was then added at a final concentration of 2 0 0 |4 g/ml and the reaction 
left at 37°C for 1 hour. Cellular RNA was then extracted using phenol:chloroform. 
DNA digestion was completed by DNAase I (final concentration 2jag/ml) treatment 
of the RNA at 37°C for 1 hour. RNA was then extracted by phenoF.chloroform 
treatment and the RNA was ethanol precipitated and stored at -80°C in TE.
2.13. RT-PCR.
RT-PCR was carried out on whole cell RNA isolated from F9 cells or on RNA kindly 
provided by Dr Shikama. Whole cell RNA was isolated as described and subjected to 
3’ RT-PCR using a specific oligonucleotide directed against a non-coding RNA 
sequence of the C-terminal JMY message.
F9 cellular mRNA (500ng) was incubated at 90°C for 4 minutes with 50pmol of 
specific oligonucleotide (O2 ) primer directed against the 3’ non-coding sequence of 
JMY as determined by Dr Shikama. The primer sequence was 
CTCTGCCAACCCAGTGTTCTTCC-3’^ ^^^  ^ The reaction was cooled on ice and 
AMV reverse transcriptase (Avian myeloblastosis virus) added (5U) together with 
DTT to a final concentration of lOmM, RNase inhibitor (5U), 0.5mM final 
concentration of dNTP mixture, and IX reaction buffer (50mM Tris-HCl pH 8.3, 
50mM KCl, lOmM MgCL, 0.5mM Spermidine, lOmM DTT) to give a final volume 
of 50)41. cDNA synthesis was allowed to proceed at 45^C for 1 hour. The cDNA was
110
then ethanol precipitated and stored in TE (lOmM Tris-HCl pH 8.0, ImM EDTA) at 
-80°C.
2.14. cDNA amplification (PCR).
Primer pairs of 3’ JMY specific sequence were used to amplify the cDNA signal. The 
wild-type JMY sequence is encoded by bases 1-+2949 and the oligonucleotide 
sequences and positions in base pairs from the first ATG in the wild-type JMY 
coding sequence are indicated. The primer pairs used were;
PCR T m = 6 8 °C
01 ’ - AGAGC AG AGG AC ACTGG ATAGAC-3 ’
0 2 ’ -CTCTGCC A ACCC AGTGTTCTTCC-3 ’
The PCR reactions were carried out using °/c rich Taq DNA polymerase (5U) 
(Clontech). PCR was performed by the addition of 1:10^  ^of the cDNA form the RT- 
PCR reaction to a solution containing a 0.2mM dNTP mixture, IX reaction buffer, 
lOOpmol of each 5’ and 3’ specific primer pair, 5U rich taq DNA polymerase to 
give a final working volume of 20|uil. Standard PCR reaction cycles was performed 
using the stated annealing temperatures of the oligonucleotide pairs.
Nested primers from sequences within the predicted PCR products were then used to 
further amplify DNA species isolated from the 3’ of JMY. The nested primer pair 
used were;
PCR Tm = 6 8 "C
Oi ^^ ^^ y’-AGAGCAGAGGACACTGGATAGAC-3’^ ^^ ^^
0 3 +3112,^ , _ taG T  A ACCTCCCGTTTGTGCTTCC-3 ’
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PCR was carried out as for the initial amplification only 10% of the first PCR 
reaction was used as template. PCR reactions were carried out as standard and the 
oligonucleotide annealing temperature are indicated. PCR reactions (5% v/v) were 
cloned into the A/T topo cloning vector system (Novagen).
2.15. Hybridisation screening.
In order to detect JMY specific clones from 3’ RT-PCR the A/T cloning reaction was 
probed using a ^^P-a-GTP radio labeled oligonucleotide probe. The probe sequence 
was (O4 ) "^^^^y’-GAACAACTTGAATCC-3’+^ ^^  ^ Ligation reactions were 
transformed into XLl blue E. coli and colonies transfened to nitocellulose filters 
(Hybound), lysed and DNA fixed by UV crosslinking. Filters were then examined by 
hybridisation.
Hybridisation was carried out overnight at 40°C in Denhardts solution (0.02% Ficoll, 
0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin) containing 6 XSSC 
(900mM NaCl, 90mM sodium citrate pH 7.2) and 0.4% SDS. Non specific binding 
was removed by washing filters in a 6 XSSC, 0.2% SDS solution three times for 30 
minutes at 45°C. Filters were examined by autoradiography.
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3. Isoforms of JMY.
3.1. Introduction.
Eukaryotic transcription directed by RNA polymerase I, II, and III produces RNA 
that is composed of both coding and non-coding sequences. The protein coding 
sequences of genes, called exons, are spatially jumbled by non-coding intron 
sequences that range in size depending on the gene. The processing of the intron and 
exon sequences is known as splicing, and leads to the construction of transcripts 
which encode physiologically expressed proteins.
The product of gene transcription, the precursor mRNA molecule, is composed of 
both intron and exon sequences. Precursor mRNA is structurally bound by a large 
protein complex, the spliceosome, which contains of a variety of small ribonucleo- 
proteins, called snRNPs (small nuclear ribonucleoproteins). snRNP protein 
complexes are associated with a number of stable RNA molecules designated U1 to 
U12. snRNP’s specifically function in the recognition of specific donor and acceptor 
sites in the precursor mRNA molecule from where they promote the formation of the 
spliceosome. snRNP’s induce RNA strand breaks in the precursor mRNA and 
promote exon joining. Specifically the spliceosome uses ATP energy to carry out the 
accurate removal of introns (Anraku, 1997; Hartel et ah, 1997).
The splicing of mRNA is an intricate process dependent on many molecular events 
and if these events are not carried out with precision then functional coding mRNA is 
not produced. Consequently numerous studies have demonstrated that genetic 
mutations at exon and intron boundaries leads to the production of mutant non­
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functional proteins that in turn disrupt the normal pattern of cell physiology (Philips 
and Cooper, 2000).
A major evolutionary reason for the existence of splicing is the diversity of protein 
expression it allows. Alternative splicing allows the production of functionally 
distinct members of the same protein from the same gene to generate genetic 
flexibility in the cell. Interestingly, many of the key cell cycle regulatory proteins 
appear to undergo extensive splicing which increases their diversity of function.
3.2. Isolation and characteristics of JMY.
Using a yeast two-hybrid approach with pLexA-pSOO^ *^ '^ ^®"^  as bait a new p300 
binding protein, JMY was isolated (Junction-mediating and regulatory protein) 
(Shikama et aL, 1999). JMY is a llOkDa proteins that lacks any significant similarity 
to other known proteins. The protein sequence possesses a number of interesting 
features, including a central region that resembles a motif in the adenovirus E l A 
protein, a C-terminal domain rich in proline residues and an N-terminal region that 
contains a number of potential S/T-P phosphorylation sites (Figure 3.1a and 3.1b).
JMY is a particularly interesting protein given that its gene, jmy, is located on 
chromosome 5 in band 5q 13.2. Interestingly, the long arm of chromosome 5 is often 
disrupted in a wide range of malignancies, in particular, leukaemia (Shikama et a l, 
1999). Potentially, the disruption of jmy may be a prerequisite or modifier of tumour 
formation, and consequently its function may be vital in the maintenance of an 
archetypal cell. However to date no specific deletion in the mRNA of JMY has been 
detected in tumour cells (Shikama, personal communication).
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Two transcripts, a 9.5kb and less abundant 6 kb species, encode the JMY message. 
Both transcripts are expressed in a wide variety of mouse tissues apart from testis 
where a smaller 4kb transcript exists (Shikama et a l, 1999).
3.3. 3' splicing of .TMY.
As JMY is potentially a target of inactivation in malignancies it was of interest to 
determine if the transcripts encoding JMY are subject to alternative splicing. The 
analysis of the C-terminus of JMY lead to the observation that JMY was extensively 
alternatively spliced in the 3’ region. Indeed endogenous protein expression analysis 
carried out in SAOS-2 cells confirmed the presence of multiple forms of JMY protein 
(Shikama, personal communication).
Using RNA derived from F9 embryonal carcinoma cells, a number of 3’ splicing 
variant transcripts of JMY were isolated and examined. An RT-PCR approach was 
used to amplify mRNA from a region of JMY encompassing the C-terminus. Reverse 
transcription was used to synthesis cDNA, from a primer directed from a previously 
identified 3’ untranslated region of the jmy gene. Nested PCR, using oligonucleotides 
directed against the C-terminal sequence of JMY, was then performed to allow 
detection of JMY specific C-terminal encoded sequences (Figure 3.2a). After 
multiple rounds of PCR specific JMY cDNA’s were isolated, by A/T cloning, and 
their base sequence analysed and compared to wild-type JMY coding sequence 
(Figure 3.2b). Given this strategy, no variant could be isolated before the aspartic acid 
(D) residue at position 650 (Figure 3.1b).
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Sequence comparisons, of the 3’ isolated sequences with the wild-type JMY 
sequence, demonstrated not only that JMY was potentially extensively spliced but 
also that the splicing sites, donor and acceptor, were diverse (Figure 3.3a). Of the 
potential 3’ splice variants examined, three resulted from frame shifts in the reading 
frame of wild-type sequence. Interestingly no wild-type JMY sequence was detected 
in the amplified mRNA splice sequences, although its expression in F9 cells can not 
be excluded.
Notably, the detection of multiple forms of JMY 3’RNA species from F9 cells 
although suggestive of splicing in the JMY message dose not confirm such a 
conclusion. Potentially the relevance of such RNA species to the endogenous RNA 
population is merely suggestive and as such is a consideration when interpreting the 
following results. Herein the isolated RNA species and their potential protein 
products are refereed to as either splicing variants or isoforms although their 
endogenous presence requires conformation by RNA protection assays.
3.4. Splice junction of JMY
Sequence analysis of a population of JMY 3’ mRNA variants allowed the recognition 
of a number of potential splice junctions. The JMYAP isoform lacks 18 residues 
located in the C-terminal region, from residue 795 to 813, which in the wild-type 
protein contains a high proportion of proline residues (83%) (Figure 3.3b). JMYAP is 
derived as a consequence of splicing bases encoding amino acid 794P to 814P and 
remarkably possesses an almost perfect deletion of the proline rich domain (Figure 
3.3ai and 3.3ci). The in frame splicing of the JMY message also results in the 
generation of two other isoforms that are devoid of the proline rich domain, JV2 A^ ^^ '
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and The variant is generated by splicing the bases encoding
amino acid 765A (Alanine) to bases for 841G (Glycine) and the isofoim
by splicing bases encoding amino acid 739T (Threonine) to those encoding 828T 
(Threonine) (Figure 3.3aii, cii and 3.3av, cv).
In addition to the in frame splicing events detected, three other splicing variants were 
isolated that were generated as a consequence of a change in the reading frame of the 
wild-type JMY message. A splice in the JMY message from the bases encoding 
amino acid 759T (Threonine) to the bases of amino acid 98IW (Tryptophan) 
generated a C-terminally deleted JMY variant, JV4 FS'*'^ . In comparison to the wild- 
type JMY message the reading frame of JV4 pS'^  ^ is altered by +2 bases at the amino 
acid encoding 98IW (Tryptophan). This results in an isofoim that is deleted in the C- 
terminus of JMY but contains additional sequence encoded for by the 3’ un-translated 
region (Figure 3.3a iv and 3.3c iv).
The JV'sFS'*’^  ^valiant was generated by splicing the bases encoding amino acid 765A 
(Alanine) to those encoding 852A (Alanine). The splicing event results in a +1 
change in the 3’ reading frame relative to wild-type JMY that generates an internal 
stop codon (Figure 3.3avi and 3.3cvi). The JVgFS^^^ splicing isoform is terminated in 
the same reading frame as JVsFS'*'^  ^ but the splice sites are different. JV^FS^^^ is 
generated by splicing the bases encoding amino acid 739T (Threonine) to those 
encoding 844R (Arginine) and is read in the +1 reading frame relative to wild-type 
JMY (Figure 3.3aiii, 3.3ciii).
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3.5. Conclusions.
The complexity of 3’ JMY mRNA splicing is undoubtedly an important mechanism 
that regulates the function of JMY. Indeed given the selective removal of the 3’ 
proline rich region of JMY it is conceivable that the region is a major controlling 
domain in JMY function. The complexity of JMY is also further highlighted by the 
isolation of other JMY related family members, although their function is as yet 
unknown (Shikama, personal conomunication). Clearly the family status and 
extensive splicing of JMY point to its role as a highly regulated cellular molecule.
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Figure 3.1. Characteristics of JMY.
a). The sequence of the 983 amino acid protein JMY. The S/T-P motifs in the N- 
terminus (blue) are underlined, and the p300 binding domains from amino acids 1- 
119 and 469-558 are highlighted (yellow). The adenovirus E l A CR2 like motif, 
EVQFEILKCBE is indicated (red). The proline rich region is highlighted in green 
and the first potentially detectable 3’ splice amino acid, 650D (Aspartic acid), is 
shown (pink).
b). Domain structure of JMY. The N- and C-terminal p300 binding domains are 
depicted (yellow), together with the N-terminal S/T-P rich region (blue), the E l A 
like motif (red) and the C-terminal proline rich domain (green). The 3’ region studied 
for alternative splicing is indicated.
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Figure 3.2. Isolation of 3* splicing variants of .TMY.
a). Diagrammatic representation of JMY. Indicated are the N-terminal and central 
p300 binding domains (yellow), the N-terminal S/T-P rich region (blue) and the C- 
Terminal proline rich domain (green). The oligonucleotide used for cDNA synthesis 
is indicated (O2 ) together with the nested oligonucleotides used for the amplification 
of cDNA (Oi, O2  and O3 ). Also indicated is the position of the oligonucleotide used 
for colony screening (O4 ).
b). The products from the PCR reactions generated in 3.2a were loaded on an agarose 
gel and DNA levels examined by ethidium Bromide staining. PCR reactions were 
ligated into the Invitrogen A/T cloning vector, pCR 2.1, and the presence of positive 
JMY clones confirmed by probe hybridisation with ^^p-a-labelled olionucleotide 4.
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Figure 3.3. JMY 3’ splice variants.
a). Diagrammatic representation of JMY. Highlighted are the 3 ’ splice variants 
isolated from F9 embryonic carcinoma cells, i) The JMYAP variant that encompasses 
a splice event that deletes a proline rich region in the C-terminus of JMY (84%). 
Variant ii), iii), iv), v) and vi) are a representation of other 3’ splicing events that 
give rise to 3’ spliced JMY construct.
b). The variants shown in 3.3a all commonly lack the proline rich region from amino 
acids 794 to 812 of wild-type JMY. The sequence of the region is indicated.
c). Amino acid comparisons of the 3’ splicing variants depicted in 3.3a. The wild- 
type JMY sequence form amino acids 721G (Glycine) to 983N (Asparagine) is 
indicated. The splicing events are indicated -:
i) JMYAP. 794p''''''"’^ p
ii)
iii) JV3 FS+'*. 765^ 852^
I
AAG-ACT
iv) JV4PS+ .^ 7 5 9 ^  981^
4
TGG-GAG
v) 7 3 9 rjr""""""l^
vi) JVeFS^^®. 739p S44j^
I
CTC-AGC
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4. JMY, a new co-activator of the p53 
response.
4.1. Introduction.
The p300/CBP transcriptional co-activator family regulates the cell cycle by co­
ordinating the actions of transcription factors. The key cell regulatory transcription 
factor p53 is one such target of p300/CBP function (Avantaggiata et al., 1997; Gu et 
a l, 1997; Lill et al., 1997a). p300/CBP facilitates the transcription of p53 mediated 
gene expression to augment the p53 response.
The inactivation of the p53 pathway is a prerequisite for the formation of tumour cells 
and the maintenance of viral infections. p53’s ability to stall genomic replication 
allows the repair of genetic lesions that maintains a healthy cell (Levine, 1997). In 
circumstances where the genetic shock is too severe for recovery, p53 can induce cell 
death (Gottlieb and Oren, 1996). The controlling mechanisms that discriminate 
between p53’s role in cell cycle an'est and apoptosis are currently not well 
understood.
The ability of p300/CBP to co-operate with the p53 response provides a mechanistic 
control point for the p53 pathway. In addition to p300/CBP itself a number of 
molecules exist in complex with p300/CBP but their function in the regulation of p53 
is unknown. Given that JMY is a p300/CBP associated molecule that has an unknown 
function it is of clear interest to elucidate the role, if any, of JMY in the p300/CBP- 
p53 molecular pathway.
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4.2. JMY binds p300 in vivo.
Previous studies have suggested that p300/CBP forms a multi-meric complex in vivo 
and that the composition of the complex is ultimately responsible for its function 
(Eckner et al., 1996b; Roeder, 1996; Chen et al., 1997; Grossman et al., 1998; 
Korzus et al., 1998; Xu et al., 1999). Consistent with the isolation of JMY as a p300 
binding protein it was demonstrated that JMY contained at least two independent 
p300-binding domains (Shikama et al., 1999) (Figure 4.1a). In addition p300 itself 
interacts with JMY through two separate binding domains (Shikama et al., 1999) 
(Figure 4.1b). Shikama et al. (1999) also demonstrated that JMY and p300 directly 
interact in vitro. The ability of JMY, the natural splice JMYAP and a C-terminal 
truncation mutant, JMYAC, to bind p300 in vivo was therefore of interest and was 
assayed by immuno-precipitation.
Anti-HA immuno-precipitates from SAOS-2 cells overexpressing HA-JMY, HA- 
JMYAP or HA-JMYAC all contained a p300 specific component (Figure 4.1c). HA- 
JMY and HA-JMYAP immuno-precipitates contained an equivalent level of p300 
while HA-JMYAC showed a reduction in the level of in vivo complexed p300. The 
ability of endogenous p300 to be immuno-precipitated with JMY clearly 
demonstrates that the two proteins exist in an in vivo complex and that physiological 
3’ splicing of JMY in relation to the proline rich domain does not effect this 
interaction. Given that deletion of the C-terminus of JMY reduces the level of in vivo 
bound p300, even through the region is outside the previously identified binding 
domains, it is conceivable that JMY’s interaction with p300 is in part mediated by its 
C-terminus (Shikama et al., 1999).
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4.3. JMY co-activates p53 transcription.
Given that p300 and CBP are physiological co-activators of p53 and that this co­
activation leads to the enhancement of p53’s cellular function it was of interest to 
determine JMY’s ability to influence p53 transcriptional activation function 
(Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997a; Lee et al., 1998). As 
previously shown p53 efficiently activates expression from the box, mdm2, wafl and 
gaddAS promoters (Figure 4.2) (Lee et al., 1998). The box, mdm2, gadd45 and WWP 
reporters consist of promoter regions, that contain p53 DNA binding consensus sites, 
fused upstream of a luciferase reporter gene (El-Deiry et al., 1993; Chen et a l, 1995; 
Haupt et al., 1995).
The box promoter, consistent with its role in p53 mediated apoptosis, is activated 
upon the introduction of exogenous p53 expression plasmid into SAOS-2 cells and 
this transcription is in turn co-activated by the co-expression of HA-JMY (Miyashita 
et al., 1994a; Miyashita and Reed, 1995). JMY induces a two-fold stimulation of p53 
mediated box promoter driven transcription (Figure 4.2a and 4.3a). Intriguingly the 
natural splice, JMYAP, was unable to co-activate p53 driven transcription of the bax 
gene even through it retains p300 binding properties (Figure 4.2a). The JMYAC 
mutant was unable to significantly co-stimulate p53 mediated transeription of the bax 
promoter (Figure 4.3a). As JMY is unable to bind p53 directly it was assumed that 
endogenous p300 was acting as a bridging molecule in JMY’s co-activation of 
transcription (Shikama, personal communication). The reporter activity in the 
absence of p53 was unaffected by JMY, JMYAP or JMYAC indicating that JMY’s 
ability to act as a co-activator was specific for p53 in the context of bax.
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Consistent with the C-terminus of JMY being important for p53 transcriptional co­
activation and p300 binding was the observation that a C-terminal JMY deletion 
mutant, JMYA" °^ ‘^^ ®^, possessed dominant negative activity (Shikama et a l, 1999). 
The JMYA"^ ^^ '^ ^^  mutant retains the N-terminal p300 binding domain and S/T-P rich 
cluster but has lost the central p300 binding domain and C-terminal region. The level 
of transcriptional activity by p53 was significantly compromised by the co-expression 
of JMYA'^^ '^^^ ,^ presumably as a result of its ability to interfere with the endogenous 
JMY/p300 and p53/p300 interactions (Figure 4.3a). Implying that endogenous JMY 
is required for p53 mediated transcription.
An N-terminal JMY deleted mutant that binds p300 in vitro, JMYA '^^^^, still retained 
the ability to transcriptionally co-activation p53, although at a level significantly 
reduced relative to wild-type (Figure 4.3a). Implying that the C-terminus of JMY, at 
least in part, confers its ability to act as a transcriptional co-activator (Shikama et a l, 
1999). Together these results suggest that JMY’s ability to effectively co-activate p53 
mediated transcription requires not only its p300 binding capacity but also its C- 
terminal region. Furthermore, it appears that the integrity of the C-terminus of JMY 
may influence co-activation as a result of its role in p300 binding.
JMY’s ability to stimulate p53 mediated transcription in the context of Gi arrest was 
examined using the cell cycle arrest associated promoters taken from the gadd45 and 
wafl genes. The co-expression of JMY with p53 only minimally stimulated 
expression from the WWP and gadd45 promoters above the level of p53 alone 
(Figure 4.2c and 4.2d). The lack of substantial co-activation can be attributed to the
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responsiveness of the reporter constructs to the addition of p53 alone. Interestingly, 
although subtle, JMYAP was repeatedly more active than JMY in the co-activation of 
p53’s /mMj-activation of the WWP promoter (Figure 4.2c). JMYAP co-activation of 
p53-dependent transcription, driven from the gadd45 promoter, was equivalent to 
wild-type JMY which was repeatedly similar to p53 alone (Figure 4.2d).
In order to examine further the enhanced activity of JMYAP in WWP co-activation 
the artificial TGig-luc reporter, that consists of thirteen p53 consensus sites taken 
from the promoter fused upstream of a luciferase reporter gene, was
studied (Lee et al., 1998). p53 mediated transcription from the TGig-luc promoter 
was co-stimulated efficiently by JMYAP but JMY did not alter the level of p53 
mediated transcription (Figure 4.3b). Given these findings it is possible that the 
proline rich domain of JMY, that is selectively spliced, functions as a promoter 
specific p53 co-activator domain.
The p53 regulated promoter taken from the mdml gene was also marginally co­
activated by the expression of JMY and JMYAP in the presence of p53 (Figure 4.2b). 
It is of interest to note that transcription from the TGn, mdm2, WWP and gadd45 
promoters was p53-dependent as JMY and JMYAP did not alter the activity of the 
reporters constructs in the absence of p53 (data not shown and Figure 4.3b).
Together these results suggest that JMY is a physiological p53 co-activator, 
presumably as a consequence of its association with and recruitment by p300. The 
inability of JMYAP to co-activate p53 mediated transcription driven from the bax 
promoter implies that 3’ splicing of JMY produces functionally distinct variants. The
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loss of the proline rich domain confers promoter specificity on JMY as only the bax 
and WWP promoters were affected. Indeed the entire C-terminus of JMY appears to 
influence JMY’s ability to act as a transcription co-activator as some p53 promoters 
show a high level of co-activation by JMYAC while others are compromised (Figure 
4.4a and 4 .12d), further strengthening the hypothesis that the C-terminus of JMY 
confers p53’s transcriptional promoter specific properties.
Given that JMY’s ability to co-activate p53 transcription presumably stems from its 
capacity to bind p300 it was of interest to determine if JMY and p300 would co­
operate in the activation of p53 mediated transcription. The Z)a%-luciferase promoter 
construct was activated by the addition of p53 and as previously shown p53 mediated 
transcription was co-activated by the addition of exogenous p300 (Lee et ah, 1998; 
Shikama et al., 1999). JMY effectively co-activated p53-dependent transcription from 
the /?(%%-luciferase reporter and transcription was further enhanced by the addition of 
p300 (Figure 4.4a). JMY and p300 therefore effectively co-operated in the co­
activation of p53’s transcription. JMYAP was unable to co-activate the bax reporter 
and consequently did not significantly co-operate with p300 in p53 mediated 
transcription (Figure 4.4a). Interestingly, p300’s ability to stimulate p53 mediated 
transcription was unaffected in the presence of JMYAP which suggests that JMYAP 
does not dominate p300’s function as a co-activator for p53 in the context of 
apoptosis (Figure 4.4a).
As p53 mediated transcription is activated following its post-translational 
modification and stabilisation it was of significance to determine if JMY affected p53 
stability. The addition of HA-JMY, HA-JMYAP and HA-JMYAC into SAOS-2 cells
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along with p53 did not effect the expression level of p53 or p53’s stability (Figure 
4.4b). The lack of p53 stabilisation points to JMY acting as a co-activator and not 
post-translational modifier of p53.
In transient reporter assays JMY acts as a co-activator that helps stimulate p300/p53 
mediated transcription. Significantly the 3’ splicing of JMY appears to play a role in 
the promoter specificity of p53 mediated transcription and presumably p53’s role in 
cell cycle arrest and apoptosis. It is clear that the p300/CBP in vivo complex 
components, of which JMY is one, enhance the transcriptional co-activator and hence 
cellular consequences of p300/CBP action.
4.4. JMY co-activates endogenous gene expression.
Given that p53 stimulates the transcription of artificial promoters in vivo and that 
JMY acts as a co-activator of p53 transcription it was of interest to deteimine if JMY 
would stimulate the transeription of endogenous genes.
SAOS-2 cells, which lack p53, when transfected with p53 begin to express both the 
upper and lower forms of MDM2 (Figure 4.5a). Consistent with JMY’s role as a co­
activator, the co-expression of JMY and p53 stimulated the level, although only 
slightly, of MDM2 expression compared to that seen with p53 alone (Figure 4.5aiii). 
The co-activator stimulation of MDM2 protein expression mirrored the reporter gene 
activation studies. Similarly, the JMYAP 3’ splice variant behaved as wild-type JMY 
in the co-activation of MDM2 expression (Figure 4.5aiii). The activation of MDM2 
expression was p53-dependent as the over-expression of JMY or JMYAP in the 
absence of exogenous p53 did not stimulate MDM2 expression. Surprisingly the
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stimulation of MDM2 expression by JMY/p53 did not lead to a reduction in the level 
of p53 (Figure 4.5aii). The stability of p53 in the presence of high levels of MDM2 
may be explained by the sensitivity and transient nature of the experiment or may a 
consequence of JMY influencing MDM2’s function.
Given that JMY showed a preference over JMYAP in the co-activation of p53 
transcription from of the bax promoter it was of significance to determine the level of 
endogenous Bax expression. Cells transfected with p53 expressed an elevated level of 
Bax protein and JMY co-stimulated this transcription (Figure 4.5b). Interestingly and 
consistent with the inability of JMYAP to activate p53 mediated transcription of the 
bax promoter construct, no increase in p53’s induction of Bax protein was detected 
after the co-transfection of SAOS-2 cell with p53 and JMYAP (Figure 4.5b). Bax 
protein induced expression by JMY is p53-dependent, as the over-expression of JMY 
or JMYAP did not induce the co-activation of Bax expression in the absence of p53 
(Figure 4.5b).
Strikingly, and in agreement with the reporter gene assays, the transfection and over­
expression of JMYAP in U20S cells, which express endogenous p53, increased the 
level of expressed (Figure 4.5c). Both JMY and JMYAC however were
unable to increase protein levels (Figure 4.5c). These results confirm that
3’ splicing of JMY bestows promoter specific properties on JMY. In addition it 
appears that JMY’s role as a co-activator of p53-mediated transcription is gene 
specific as some genes display a higher degree of co-activation than others (Figure 
4.2 and 4.5).
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4.5. p53 translocates JMY to the nucleus.
The ability of p53 to act as a transcription factor is associated with its nuclear 
localisation. Nuclear localisation of p53 is dependent on its inherent nuclear 
localisation signal (NTS) as well as its interaction with MDM2 (Kubbutat et a l, 
1997; Haupt et al., 1997; Roth et al., 1998). Given that JMY appears to participate in 
the p53 transcriptional response it was of significance to determine if JMY cellular 
localisation conesponded to its ability to act as a p53 transcriptional co-activator.
Initially in order to address JMY sub-cellar localisation a polycolonal antibody raised 
against the N-terminus of JMY was used in the detection of the endogenous JMY 
population. In non-transfected SAOS-2 cells fluorescent staining established that in 
the majority of cells JMY was localised throughout the cell (Figure 4.6ai and 4.6aii). 
Interestingly a small population of cells displayed exclusively nuclear or cytoplasmic 
staining for JMY.
As the localisation of the 3’ splicing variant, JMYAP, could not be observed or 
discriminated directly using the N-terminal antibody, cells were transfected with HA 
tagged JMY variants prior to immuno-florescence. SAOS-2 cells were transfected 
with expression plasmids for HA-JMY, HA-JMYAP or HA-JMYAC. HA-JMY 
cellular localisation mirrored that observed with the JMY polyclonal antibody as the 
largest population of cells stained simultaneously both nuclear and cytoplasmic 
(Figure 4.6bi and 4.6bii). Again a population of cells displayed exclusively 
cytoplasmic or nuclear staining. Under the same cellular conditions HA-JMY-AP and 
HA-JMYAC displayed a similar staining pattern as wild-type JMY with the majority 
of cells staining whole cell (Figure 4.6ci, 4.6cii, 4.6di and 4.6dii), In embryonic
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fibroblast taken from p53'^' and p53'^';mdm2'^' mice an identical staining pattern as for 
SAOS-2 cells was observed for HA-JMY, HA-JMYAP and HA-JMYAC (data not 
shown).
The cellular localisation of JMY in SAOS-2 cells implied that JMY’s localisation 
was regulated. Interestingly, a large population of endogenous JMY must be in the 
transcriptionally dormant cellular compartment, the eytoplasm. Given that JMY 
activates p53 mediated transcription and that nuclear localisation is required for 
transcriptional co-activation it was of interest to determine if p53 affected JMY‘s 
cellular localisation. To this end SAOS-2 cells were co-transfected with p53 and 
either HA-JMY, HA-JMYAP or HA-JMYAC. The over-expression of p53 in SAOS-2 
cells resulted in its almost exclusively, nuclear localisation (Figure 4.7). Presumably 
cells overexpressing p53 that displayed weak cytoplasmic staining were undergoing 
p53 degradation as a consequence of MDM2’s over-expression.
The over-expression of HA-JMY and p53 lead to the observation that JMY 
localisation was altered in the presence of p53. The previously observed cytoplasmic 
population of JMY was replaced by a predominantly nuclear population (Figure 
4.7a). In an identical manner the subcellular localisation of JMYAP and JMYAC was 
also altered, becoming nuclear in the presence of p53 (Figure 4.7b and 4.7e). Given 
that p53 does not alter the expression level of JMY it is conceivable that p53 traffics 
or stimulates the trafficking of JMY from the cytoplasm to the nucleus. The ability of 
p53 to stimulate the translocation of JMY from the cytoplasm to the nucleus 
presumably contributes to JMY’s ability to stimulate p53 mediated transcription. 
Given that SAOS-2 cells contain endogenous p300 it is arguable that the translocation
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of JMY is through a p300 mediated mechanism. Interestingly p300’s intrinsic HAT 
activity appears to regulate nuclear import and export although in the context of JMY 
this mechanism of action has not been explored to date (Bannister et a l, 2000).
Although the shift in JMY’s cellular localisation in the presence of p53 was 
reproducible, in a set of assays the extent of change in JMY’s localisation in the 
presence of p53 was not uniform. It therefore appears that a feasible conclusion is 
that the JMY/p53 co-staining pattern is a cell cycle regulated event, although further 
studies are required to confirm such a hypothesis.
A N-terminal nuclear localisation signal (NLS) tagged JMY protein that is 
constitutively nuclear is less efficient than wild-type JMY in the co-activation of p53 
mediated transcription (Figure 4.3a). This suggests that it is not JMY’s nuclear 
localisation that is important for its function as a co-activator but the signals that 
trigger its localisation. In addition, p53 is not the only trigger for JMY’s nuclear 
localisation as a population of endogenous and overexpressed JMY is exclusively 
nuclear in the absence of p53 (Figure 4.6 and 5.7).
4.6. JMY is present in a DNA damage induced p53 complex.
The induction of p53 stabilisation by DNA damage stimulates cell cycle arrest and 
promotes apoptosis (Levine, 1997) (Figure 4.8a). DNA damage affects cells by 
increasing the transcription of target genes that control the cell cycle and apoptotic 
pathways (Figure 4.8a). As JMY participates in the activation of p53 mediated 
transcription it was of interest to determine if JMY was found complexed with p53 in 
vivo under conditions of p53 activation.
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Previously both JMY and p300 were shown not to be DNA damage-inducible genes 
(Shikama et al., 1999). p53 is stabilised and activated by the treatment of cells with 
the DNA damaging agent actinomycin D. In order to study the composition of the 
JMY complex under damaging conditions U20S cells treated with actinomycin D 
were examined for JMY binding polypeptides. As expected p53 was effectively 
induced following the DNA damage of U20S cells (Figure 4.8b). Given that JMY 
stimulates p53 mediated transcription it was of interest to determine if p53 was 
present in the JMY complex following DNA damage. To this end both untreated and 
treated U20S cells were immuno-precipitated with an anti-JMY N-terminal, 
polycolonal antibody and the level of p53 determined by western blot. As expected 
from the immuno-staining data, the JMY complex in asynchronous U20S cells 
contains p53 (Figure 4.8b). Interestingly, and in agreement with previously published 
data, DNA damaged U20S cells contain a significantly higher level of p53 in the 
JMY immuno-complex (Shikama et al., 1999) (Figure 4.8b). Furthermore the 
importance of the JMY/p53 in vivo complex is emphasised by the observation that 
quantitatively the JMY complex appears to contain the majority of the endogenous 
p53.
Given that JMY stimulates p53 mediated transcription it is conceivable the high level 
of p53 in the JMY complex under DNA damaging conditions corresponds to a p53 
mediated cell cycle cheekpoint arrest or apoptotic event that is associated with 
transcriptional up-regulation. As the level of JMY is unaffected following DNA 
damage it is possible that the increase in the level of p53 found in the JMY complex
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coiTesponds to an activated complex. Clearly JMY is a component of the DNA 
damage response of p53.
4.7. .TMY s role in p53 mediated cell cycle arrest.
The ability of p53 to induce a Gi arrest phenotype as a result of 
expression is well documented and understood (El-Diery et al., 1993; Gu et a l, 
1993). As JMY co-localises with p53, is present in the DNA damage induced p53 
complex and is able to co-stimulate the transcription of it was of interest
to determine the effect if any of JMY on p53’s role as a checkpoint protein.
To this end, SAOS-2 cells were transiently transfected with HA-JMY, HA-JMYAP or 
HA-JMYAC either alone or in combination with p53. Transfected populations were 
selected using CD20 staining and DNA content and cell cycle stage were assayed 
using propidium iodide (Figure 4,9).
As expected, p53’s introduction into SAOS-2 cells caused an increase in the Gi 
population of cells (Figure 4.9b and 4.10a). Under the conditions of the transient 
assay no detectable Gi/M arrest was observed in p53 overexpressing cells. The over­
expression of JMY alone did not affect the cell cycle suggesting that JMY plays a 
dormant role in the unstressed cell (Figure 4.9c and 4.10b). However in the presence 
of p53, JMY stimulated an increase in the population of Gi arrested cells by almost 2 
fold relative to p53 alone (Figure 4.9d and 4.10b). The increase in Gi arrest 
presumable correlates with an increase in p53 mediated transcription.
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Given that JMY did not alter the level of the endogenous protein but
JMYAP did, it was of merit to determine if 3’ splicing could affect p53’s ability to 
arrest cells. JMYAP like wild-type JMY did not affect the cell cycle but in 
combination with p53, JMYAP produced a striking increase in the Gi population of 
cells relative to p53 alone (Figure 4.9e, 4.9f and 4.10c). JMYAP stimulated a four­
fold increase in the p53 mediated Gi arrest population.
The over-expression of JMYAC alone resulted in an increase in the Gi population of 
cells (Figure 4.9g and 4.10d). In combination with p53, JMYAC increased the Gi 
population of cells but the p53 and JMYAC cell cycle arrest phenotype was additive 
and so non-synergistic effects can not be ruled out (Figure 4.9h and 4.10d). 
Conceivably JMYAC may be adversely effecting the normal cellular processes that 
mediates a p53 response and indirectly effecting the cell cycle profile.
Together these results suggest that JMY functions in mediating a p53 Gi arrest, but 
more significantly point to 3’ splicing of JMY as an important regulatory mechanism 
of p53 function. JMYAP clearly has an enhanced ability over JMY in the stimulation 
of p53 mediated cell cycle arrest.
4.8. JMY regulates p53-dependent apoptosis.
In addition to its role in cell cycle arrest, p53 functions as an apoptotic promoting 
gene product (Gottlieb and Oren, 1996; Levine, 1997). As JMY is present in an 
activated p53 DNA damage induced complex it is conceivable that JMY may be 
involved in p53’s ability to stimulate apoptosis. In addition JMY stimulates
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transcription of the apoptotic promoting gene product Bax in a p53-dependent 
manner.
In order to study JMY’s ability to regulate the p53 apoptotic responses cells were 
assayed for the characteristic, apoptotic, DNA fragmentation phenotype. Fluorescent 
labelled nucleotide incorporation into DNA was visualised directly by immuno­
fluorescence using the TUNEL assay. As expected the transient transfection of p53 
into SAOS-2 cells in conditions conducive to apoptosis, namely low serum, 
stimulated an apoptotie response (Figure 4.11). Populations of cells overexpressing 
p53 showed a 30% increase in the level of apoptosis relative to those not expressing 
p53. The over-expression of HA-JMY and HA-JMYAP slightly induced apoptosis in 
the absence of p53 by 5,8% and 3.7% respectively (Figure 4.11). More interestingly, 
the simultaneous over-expression of HA-JMY and p53 dramatically increased the 
population of apoptotic cells in comparison to p53 alone (Figure 4.11). The over­
expression of JMY and p53 induced a 41% stimulation in the level of apoptosis 
compared to p53 alone. However the level of apoptosis in JMYAP and p53 
overexpressing cells remained at levels equivalent to p53 alone (Figure 4.11). The 
over-expression of JMYAC produced an apoptotic phenotype identical to that of 
JMYAP in the presence of p53 (Simms, personal communication).
The ability of JMY to stimulate p53 dependent apoptosis clearly demonstrates that 
JMY can enhance p53 induced cell death. Interestingly, the inability of JMYAP to 
stimulate p53 mediated apoptosis but its ability to enhance cell cycle arrest supports 
an attractive hypothesis. The possibility that 3’ splicing of JMY generates 
functionally distinct species of JMY that confer specificity on the p53 response
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supports an attractive mechanism for controlling the switch between cell cycle arrest 
and apoptosis,
4.9. Transcription and proline rich domains.
Although Bax is a well characterised gene involved in the p53 apoptotic response a 
number of studies have demonstrated that Bax expression is dispensable for p53 
mediated apoptosis (Knudson et a l, 1995). The ability of p53 to stimulate the 
expression of the PIG3 gene may correlate with the induction of p53 mediated 
apoptosis (Polyak et ah, 1996). A vitally important domain in p53 that mediates PIG3 
expression is the N-terminal proline rich region. The poly proline domain of p53 is 
essential for PIG3 expression but dispensable for MDM2, and Bax
expression (Walker and Levine, 1996; Venot et ah, 1998). In order to confirm that 
JMY is participating in p53’s induction of cell death by co-activating the transcription 
of genes involved in apoptosis the transcription of PIG3 was examined.
In transient transfection assays p53 effectively activated the P/GJ-luciferase reporter 
construct in a dose-dependent fashion (Venot et ah, 1998) (Figure 4.12a). As 
previously shown the deletion of the polyproline domain of p53 resulted in the loss of 
transcriptional activation (Figure 4.12a). Furthermore, as expected, the co-expression 
of JMY with p53 co-stimulated p53 directed expression from the PIG3 promoter and 
the transcriptional co-activation was dependent on the p53 polyproline domain 
(Figure 4.12b). JMYAP’s ability to stimulate the transcription of the PIG3 promoter, 
as for bax, was severely compromised relative to JMY (Figure 4.12c). JMYAC ability 
to stimulate p53 mediated transcription was also compromised relative to wild-type 
JMY (Figure 4.12d). Interestingly the C-terminal deletion of JMY still retained a
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degree of transcriptional co-activation, indicating that the C-terminus of JMY is not 
absolutely essential for co-activation but a contributor. The inability of p53AP to 
transaciiyait the P1G3 promoter was unaffected by JMY, JMYAP or JMYAC (Figure 
4.12).
Taken together these results support the observation that JMY plays a role in p53 
mediated apoptosis by promoting gene expression. Furthermore they support the 
observation that 3’ splicing of JMY deteimines the switch between the cell cycle 
arrest and apoptotic functions of p53.
Previously the polyproline domain of p53 was shown to be dispensable for the 
transcription of MDM2 and In agreement with these observation p53AP
transactivated the WWP promoter at levels equivalent to wild-type p53 (Figure 
4.13a). Both JMY and JMYAP co-activated p53AP rran^activation of the pWWP 
reporter at level equivalent to those for co-activation of wild-type p53 (Figure 4.13a). 
Significantly and consistent with earlier results JMYAP was reproducibly more active 
than JMY in the co-activation of either p53 or p53AP transactivation of pWWP- 
luciferase. Indeed JMYAP's co-operation with p53AP was repeatedly greater that that 
seen with wild-type p53, further strengthening the role of proline rich domains in cell 
cycle arrest. The mdm2 promoter construct showed no transcriptional activation by 
p53AP however the addition of JMY or JMYAP resulted in a co-activation of 
expression that was independent of the presence of the proline rich domain (Figure 
4.13b). The co-activation of p53AP mdm2 promoter driven expression by JMY and 
JMYAP was equivalent to that seen with wild-type p53 (Figure 4.13b).
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Mechanistically, the polyproline domain of p53 may be a regulated region that 
controls the function of p53 whether it be apoptosis or cell cycle aiTest. Clearly the 
proline rich domain in JMY performs a similar function. Given that JMYAP and 
p53AP aie able to co-operate in the induction of WWP expression it is conceivable 
that proline rich domains in transcriptional regulatory proteins may mediate cell cycle 
arrest. The separation of cell cycle arrest and apoptotic phenotypes by proline rich 
domains may be the determining event in cell death or cell survival. The proline rich 
domains in p53 and JMY clearly perfoim similar synergistic functions in inducing 
cell death.
4.10. Conclusions.
The p53 protein utilises p300/CBP’s co-activation properties in order to 
transcriptionally activate gene expression (Avantaggiati et ah, 1997; Lill et ah, 
1997a; Gu et ah, 1997; Lee et ah, 1998). The results presented here suggest that JMY 
as a consequence of its association with p300 plays an important role in dictating p53 
mediated transcription. Given that co-activators complexes are known to play an 
important role in regulating eukaryotic transcription it is of significance to note that 
JMY appears to specifically enhance p53 ability to induce apoptosis. JMY 
specifically can upregulate p53’s transactivation of apoptotic promoting gene 
products such as Bax and PIG3.
Isoforms of JMY appear to distinguish between the cell cycle arrest and apoptotic 
properties of p53. The 3’ splicing events in JMY that specifically remove the highly 
proline rich domain compromise JMY’s ability to induce p53 mediated apoptosis. 
However JMYAP in combination with p53 is able to increase the cell cycle arrest
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phenotype induced by p53 mediated transcription. Potentially, therefore, the 
expression of a particular array of JMY isoforms could alter the characteristics of the 
p53 response via their ability to modulate gene specific transcription (Figure 4.14).
The study presented here also implies that JMY and its isoforms are themselves 
regulated proteins. Indeed p53 itself is able to stimulate the translocation of JMY and 
its isoforms into the nucleus of cells.
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Figure 4.1. JMY interacts with p300.
a). Functional Domains of JMY.
Diagrammatic representation of JMY, JMYAP and a C-terminal truncation mutant 
JMYAC. The previously mapped p300 binding domains are indicated (in yellow) at 
positions JMY '^^^  ^ and JMY"^ *^ '^^ ^^  (Shikama et a l, 1999). The N-terminus contains a 
cluster of potential phosphorylation sites for S/T-P directed kinases (blue) and the 
central region contains a motif that resembles conserved region 2 (CR2) in the 
adenovirus E lA  protein (red) (EVQFEILXCEE). The C-terminal proline rich region 
from amino acids 776-785 is highlighted (green).
b). Domains in p300.
Diagrammatic representation of p300 illustrating the cysteine/histidine rich domains 
(red), CHI, CH2, and CH3 together with the central Bromodomain (grey). The 
previously described binding regions for JMY from amino acids 611 to 1257 and 
1572 to 2283 are indicated (Shikama et a l, 1999). The amino acid residue numbers 
indicate region boundaries.
c). JMY, JMYAP and JMYAC interact with p300 in vivo.
SAOS-2 cells were transiently transfected with either a vector encoding HA-JMY 
(5pg), HA-JMYAP (5|ig) or HA-JMYAC (5p,g). Cell extracts were subjected to 
immuno-precipitation with mouse anti-HA antibody and the immuno-precipitates 
were blotted with a N-teiminal anti-p300 specific antibody. A specific 300kDa 
polypeptide coiTesponding to p300 was detected in the immuno-precipitates of all the 
JMY transfected cells. No p300 binding was detected in empty vector (pcDNA3HA) 
transfected cells (lane 1).
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Figure 4.2. JMY co-activates p53 transcription.
a). JMY drives box expression.
SAOS-2 cells were transfected with 500ng of the p53 responsive promoter consisting 
of the box gene promoter fused upstream of a luciferase reporter gene. Transcription 
factor dependent gene expression was achieved by the addition of 50ng of p53 
expression plasmid. Co-activation of the p53 response was achieved by the addition 
of 5jig of HA-JMY. The effect of JMY 3’ splicing on p53 co-activation was 
examined by the addition of 5pg of HA-JMYAP. The values shown represent the 
average of three readings and depict the relative level of luciferase to P-galactosidase 
internal control expression.
b). mdm2 expression.
SAOS-2 cells transfected with HA-JMY (5pg) and HA-JMYAP (5pg) together with 
50ng of p53 were assayed for their ability to drive expression of a luciferase reporter 
gene fused to the p53 responsive mdm2 gene promoter (Ipg). Relative activity is 
depicted by luciferase activity normalised relative to the level of a p-galactosidase 
internal control.
c). promoter diiven expression
The p53 responsive reporter gene construct, pWWP-luciferase (Ip-g) was introduced 
into SAOS-2 cells together with the expression vectors for p53 (50ng) and JMY 
(5pg) or JMYAP (5|iig). The expression of luciferase is depicted relative to that of a 
P-galastosidase internal control.
d). Regulation of the p53 target gene, gadd45.
pGADD45-luciferase (lp,g) reporter gene construct, that contains a p53 responsive 
element, was introduced into SAOS-2 cells together with the expression vectors for 
p53 (50ng) and JMY (5|ig) or JMYAP (5pg). The expression of luciferase reporter 
gene is depicted relative to that of a P-galastosidase internal control.
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Figure 4.3. Analysis of JMY s co-activation properties*
a). Mutant analysis of JMY’s ability to co-activate box expression.
SAOS-2 cells were transfected with 500ng of the reporter vector, pBax-luciferase, 
together with 50ng of p53 expression vector. The co-activation of the p53 response 
was examined by the co-transfection of 5|xg of expression vectors encoding JMY, 
JMY*^^, JMYAC, JMYA"^ ^^ '^ ^^  or JMYA '^^^ ,^ The values shown represent the relative 
level of luciferase to internal control (3-galactosidase expression,
b). Expression of the aitificial TG^-luciferase reporter.
The aitificial TGis-luciferase reporter (ijig) was introduced into SAOS-2 cells 
together with an expression vector for p53 (lOOng), In addition 5pg of either JMY or 
JMYAP expression vector were included. The expression of a luciferase reporter 
gene is depicted relative to that of a P-galastosidase internal control.
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Figure 4.4. JMY co-operates with p300 in p53 mediated transcription.
a). Co-operation between p300 and JMY.
SAOS-2 cells transfected with 500ng of the p53 Bax-luc responsive reporter 
construct were assayed for the ability of JMY to co-operate with p300 in p53 
mediated transcription. SAOS-2 cells were transfected with an activating amount of 
p53 (50ng) together with 5pg of either HA-JMY or HA-JMYAP in the presence or 
absence of 5jig of p300 expression plasmid. The values shown represent the average 
of three readings and aie the relative level of luciferase expression to that of a P- 
galactosidase internal control.
b). p53 stability.
SAOS-2 cells were transfected with 50ng of p53 alone or in the presence of HA- 
JMY (5|.ig), HA-JMYAP (5ju.g), or HA-JMYAC (5|ig). Whole cell extracts were 
immunoblotted with anti-HA antibodies to detect the expression of the different JMY 
constructs (upper panel). The effect of JMY expression on p53’s protein stability was 
determined by immunoblotting cell extracts with a anti-p53 antibody (lower panel).
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Figure 4.5. Endogenous gene expression.
a). MDM2 expression.
To assess the induction of endogenous MDM2 protein, expression vectors for wild- 
type p53 (500ng) together with HA-JMY (5pg) or HA-JMYAP (5pg) were 
transfected into SAOS-2 cells. Cell extracts from transfected cells were prepared and 
immunoblotted for exogenous HA (i) and p53 (ii) using anti-mouse HA and anti­
mouse p53 antibodies respectfully. The level of MDM2 (iii) induced gene expression 
was determined by immunoblotting with an anti-MDM2 antibody. The treatment of 
each transfected extract is indicated together with the presence of the JMY, MDM2 
and p53 specific polypeptides.
b). JMY stimulates Bax expression.
Endogenous Bax protein expression was analysed using an anti-Bax specific 
antibody on cell extracts prepared from SAOS-2 cells transfected with p53 (5|ig) 
either alone or in the presence of HA-JMY (25pg) or HA-JMYAP (25pg). Cell 
extract prepared from cells transfected with empty vector (pcDNA-3) is indicated 
and cell extract prepared from cells overexpressing HA-JMY and HA-JMYAP in the 
absence of p53 is also shown.
c). JMYAP upregulates protein expression.
The p53'^ '^  ^ cell line, U20S, was transfected with either 20pg of HA-JMY, HA- 
JMY AP or JMYAC. Cell extracts were examined for the level of endogenous 
p2 |Wafi/cipi level by immunoblotting with an anti-p21^^^^^^^^  ^ antibody. Equal
protein loading was achieved by Bradford measurement and the position of the 
p2 iWafi/cipi specific polypeptide is indicated. Cell extract transfected with empty 
vector (pcDNA-3) is indicated.
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Figure 4.6. Cellular localisation of .TMY.
a). Endogenous JMY cellular localisation.
Asynchronous SAOS-2 cells were fixed and the cellular localisation of endogenously 
expressed JMY determined by immunofluorescence with an anti-JMY antibody. A 
rabbit polycolonal JMY antibody raised against the peptide sequence Try-Ala-Arg- 
Ser-Leu-Lys-Gly-Asp-Pro-Pro-Arg-Gly-Pro-Ala-Gly-Arg-Gly corresponding to an 
N-terminal region of JMY was used. Specific immuno-reactivity was visualised with 
rhodamine conjugated anti-rabbit immnuogloblin (i) and DAPI stain was included to 
aid nuclear identification (ii).
b). HA-JMY cellulai* localisation.
SAOS-2 cells were transfected with 5pg of a HA-JMY expression vector. Following 
fixation JMY’s expression was determined by immuno-reactivity with an anti-mouse 
HA antibody and visualised by immuno-reactivity with an rhodamine conjugated 
anti-mouse immunogloblin (i). Nuclear stain DAPI was included to determine nuclei 
position (ii).
c). 3’ splicing of JMY does not effect cellular localisation.
HA-JMYAP (5pg) expression plasmid was transfected into SAOS-2 cells and the 
cellular localisation visualised using an anti-mouse HA antibody in combination with 
a rhodamine conjugated anti-mouse immunogloblin (i). DAPI stain was included to 
aid nuclear identification (ii)
d). Cellular localisation of a C-terminal tmncation mutant of JMY.
SAOS-2 cells were transiently transfected with HA-JMYAC (5pg) expression vector, 
fixed and assayed by immuno-reactivity with an anti-HA mouse antibody. Immuno- 
reactivity was visualised with rhodamine conjugated anti-mouse immunigloblin (i). 
DAPI nuclear stain was included (ii)
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Figure 4.7. p53 mediates JMY’s cellular localisation.
a). p53’s affects JMY’s cellulai- localisation.
The intracellular distribution of exogenous HA-JMY and p53 in SAOS-2 cells was 
assessed by direct immunoflorescence. 5pg of both p53 and HA-JMY were 
transfected into SAOS-2 cells and their expression visualised by staining with anti­
rabbit HA for JMY and anti-mouse p53. Anti-HA was visualised with a rhodamine 
conjugated anti-rabbit immunogloblin (ii) and p53 with a fluorescein conjugated 
anti-mouse immunogloblin (ii). Nuclear stain DAPI was included to aid nuclear 
identification (iii).
b). p53 effects JMYAP intracellular localisation.
SAOS-2 cells transfected with 5pg of HA-JMYAP and 5pg of p53 were visualised 
for expression with anti-HA (i) and anti-p53 (ii) as in figure 4.7a. DAPI was included 
as a nuclear stain (iii).
c). p53 effects JMYAC intracellulai' localisation.
SAOS-2 cells transfected with 5pg of HA-JMYAC and 5pg of p53 were visualised 
for expression with anti-HA (i) and anti-p53 (ii) as in figure 4.7a. DAPI was included 
as a nuclear stain (iii).
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Figure 4.8. JMY functionally interacts with p53.
a). p53 DNA damage response.
Schematic diagram showing the response of p53 to DNA damage. Latent p53 is 
activated in response to DNA damage, the active p53 then induces the expression of 
genes which control Gi arrest and apoptosis. The result of p53’s response to DNA 
damage is either a Gi aiTest or apoptotic phenotype.
b). JMY’s involvement in the p53 DNA damage response.
U20S cells were treated with or without the DNA damaging agent actinomycin D 
(5nM). After 24hours whole cell extracts were prepared and subjected to immuno­
précipitation. The induction of p53 gene expression was confirmed by blotting 15% 
of the cell extract for p53 with mouse anti-p53 antibody. The remaining extract was 
immuno-precipitated with the rabbit JMY specific N-terminal polycolonal antibody 
and subjected to immunoblotting with anti-p53 antibody. The presence of a p53 
specific polypeptide in JMY immuno-precipitates and input extracts is indicated. 
Actinomycin D treated samples are labelled.
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Figure 4.9. Co-operation between JMY and p53 in cell cycle arrest.
a)-h). Cell cycle profiles of JMY over-expressing cells.
Asynchronous cultures of SAOS-2 cells were transfected with the 5jag of the cell 
surface expression marker CD20 and the indicated plasmids in the doses, p53 (3p,g), 
JMY (5jig), JMYAP (5pg), or JMYAC (5|xg). Total DNA content was equivalent to 
20pg and was made up with pcDNA-3 empty vector. Transfected cells grown in 10% 
PCS were identified by staining with the anti-CD20 fluorescein conjugated 
immunogloblin and their DNA content observed using the DNA inter-chelater 
propidium iodide. Cell cycle profiles were assigned using CellQuest software.
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Figure 4.10. JMY 3' splicing induces an enhanced Gi arrest phenotype.
a). p53 induces a Gi cell cycle arrest.
The cell cycle profile for p53 from figure 4.9b was quantified using CellQuest 
software. The percentage change in cell number for Gi, S, and G%M were calculated 
relative to mock transfected cells.
b). JMY co-operates with p53.
Profiles for JMY (Figure 4.9c) and JMY in combination with p53 (Figure 4.9d) were 
calculated as percentage change from mock (Figure 4.9a).
c). JMYAP enhances a p53 Gi an est.
Profiles for JMYAP (Figure 4.9e) and JMYAP in combination with p53 (Figure 4.9f) 
were calculated as percentage change from moek (Figure 4.9a).
d). JMYAC cell cycle phenotype
Profiles for JMYAC (Figure 4.9g) and JMYAC in combination with p53 (Figure 
4.9h) were calculated as percentage change from mock (Figure 4.9a).
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Figure 4.11. JMY participates in p53 mediated apoptosis.
a). p53 and JMY increase the apoptotic cell population.
Expression vectors for p53 (5 p g )  either alone or together with HA-JMY (5 p g )  or 
HA-JMYAP (5|Lig) were introduced into SAOS-2 cells by transient transfection. Cells 
were fixed and analysed for p53 over-expression using a p53 anti-mouse antibody 
and visualised using anti-mouse rhodamine conjugated immunoglobulin. In cells 
overexpressing HA-JMY or HA-JMYAP anti-mouse HA antibody in combination 
with an anti-mouse rhodamine conjugated immunogloblin were used to visualise 
transfected cells. Immuno-staining was performed in parallel with TUNEL (TdT 
mediated dUTP nick end labelling) in order to detect apoptotic cells. Background 
levels of apoptosis were determined using empty vector transfected cells.
Cells were visualised directly and the level of apoptosis in transfected cells 
quantified relative to empty vector transfected cells. The level of apoptosis for each 
treatment is indicated as a percentage change relative to mock. Percentage 
stimulation for JMY and JMYAP in combination with p53 is calculated relative to 
p53 alone. The data represents the average of at least two independent observations.
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Figure 4.12. .TMY co-activates p53-dependent expression of PIG3.
a). p53’s proline rich domain is required for PIG3 ^raw^activation.
The 0.7kb P1G3 gene promoter (300ng) cloned upstream of a luciferase reporter 
construct was introduced into SAOS-2 cells together with p53 and p53AP in the 
quantities (+ lOOng) and (++ 300ng) respectively. p53AP corresponds to a mutant 
p53 construct deleted in amino acids 62 to 91 that contains five PXXP motifs. 
Relative activity was calculated as luciferase expression relative to the expression of 
a P-galactosidase internal control. The expression of p53 and p53AP was confirmed 
by western blotting with an anti-p53 antibody (DO-1).
b). JMY co-activates PIG3 expression by p53 but not p53AP.
SAOS-2 cells were transfected with the PIG3-\\xc reporter (300ng) together with 
either p53 or p53AP as in 4.12a. In addition the expression vector for HA-JMY was 
included (5p,g). The expression of luciferase is calculated relative to an internal p- 
galastosidase control. JMY expression was confirmed by blotting transfected cell 
extracts with an anti-HA antibody. The specific llOkDa JMY specific polypeptide is 
indicated. Activity is plotted in scale with figure 4.12a, c, and d.
c). JMYAP is impaired in fran.yactivation of P1G3 promoter driven expression. 
SAOS-2 cells were transfected as in figure 4.12b except HA-JMYAP (5|Lig) was 
included instead of HA-JMY. The values are the relative level of luciferase to P- 
galactosidase internal control expression. The expression level of HA-JMYAP was 
confiiTned by blotting with an anti-mouse HA antibody and the corresponding 
JMYAP specific polypeptide is indicated. Activity is plotted in scale with figure 
4.12a, b, and d.
d). JMYAC activates PJG3 expression.
SAOS-2 cells were transfected as in figure 4.12b except HA-JMYAC (5|Xg) was 
included instead of HA-JMY. The values shown are the relative level of luciferase to 
p-galactosidase internal control expression. The expression level of HA-JMYAC was 
confirmed by western blot with an anti-mouse HA antibody. Activity is plotted in 
scale with figure 4.12a, b, and c.
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Figure 4.13. .TMY co-activates p53 and p53AP ^ rqwyactivation.
a). p53 proline rich domain is dispensable for WWP fran^'activation.
SAOS-2 cells were transfected with lp,g of the pWWP-luciferase reporter together 
with 300ng of p53 or p53AP. In addition HA-JMY (5pg) and HA-JMYAP (5jig) 
were included. Relative activity was calculated as luciferase expression relative to 
the expression of a P-galactosidase internal control.
b). JMY co-activates mdm2 promoter driven expression driven by p53 and p53AP. 
SAOS-2 cells were transfected with HA-JMY (5jig) and HA-JMYAP (5|ig) in 
addition to 300ng of p53 or p53AP and were assayed for their ability to drive 
expression of a luciferase reporter gene fused to the p53 responsive mdm2 gene 
promoter (Ijig). Relative activity is depicted by luciferase expression normalised 
relative to the level of a p-galactosidase internal control.
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Figure 4.14. Summary diagram of .TMY function.
p53’s cellular activation has two cellular consequences, cell cycle arrest and 
apoptosis. Here I propose that JMY and the isoform, JMYAP, acting through p300 
ai’e able to co-ordinate the p53 response, with JMY being specific for an apoptotic 
response and JMYAP specific for cell cycle arrest. A potential role for the cellular 
JMY population is also in the regulation of the MDM2 pathway.
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5.1. Introduction.
The p300/CBP family of proteins function as pleiotrophic co-activators to facilitate 
activation by a wide variety of transcription factors that function as regulators of 
differentiation, signal transduction and cell cycle control (Eckner et ah, 1994; 
Shikama et al., 1997). The key cell cycle regulators, E2F and p53, are both 
physiological targets of p300/CBP action and it is by the modulation of p300/CBP 
transcriptional regulation activities that viral proteins such as E lA  and SV40 large T 
exert some of their cellular outcomes (Arany et al., 1995; Avantaggiati et al., 1996; 
Lill et a l, 1997a).
The functional inactivation, by cancerous cells, of the pRb and p53 tumour suppressor 
pathways is a major event in the disruption of normal cellular growth control and 
immortalisation. The INK4a/ARF locus is a central player in the regulation of these 
growth controlling pathways, by virtue of its ability to generate two functionally 
distant products, namely p i t h a t  functions upstream of pRb and pl4/19^^^ that 
regulates p53 stability. As the INK4a/ARF locus and its individual products are both 
frequently the target of mutational events that precede tumourigenesis their 
mechanisms of action are potentially of therapeutic interest.
Given that a major regulator of the p i4/19^^^ response is E2F and that E2F is a 
known target for p300/CBP, it is of interest to define a role for the p300/CBP
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associated factors in pl4/19^^^ function and regulation. As JMY is such a p300 
associated co-activator molecule that participates in the p53 response to cellular stress 
it is of significance to elucidate the role, if any, that JMY plays in the p 14/19^^^ 
pathway.
5.2. E2F stimulates transcription of the p l4^ ^  promoter.
Previous studies have demonstrated that the p 14/19^^^ reporter is highly sensitive to 
E2F-1 over-expression (Bates et al., 1998; Roberston and Jones, 1998; Inoue et ah, 
1999). Consistent with these observations, the over-expression of E2F-1 effectively 
activated a pl4*^^ promoter reporter construct in a dose-dependent, p53 negative 
SAOS-2 background (Figure 5.1b). The pl4^^^ luciferase reporter construct consists 
of the exon Ip promoter region, from -805 to +59 which contains four potential anti­
sense strand E2F consensus sites, fused to a luciferase reporter gene (Figure 5.1a) 
(Bates et ah, 1998; Robertson and Jones, 1998).
Given that a physiological co-activator for E2F-1 is p300/CBP it was of importance to 
determine the effectiveness of p300 in stimulating E2F-1 mediated transcription from 
the pl4**^ promoter. SAOS-2 cells transfected with the p i4^^^ luciferase reporter 
and an activating level of E2F-1 were effectively co-activated by the addition of 
exogenous p300 expression vector (Figure 5.1c). The p300 specific two-fold 
activation of E2F-1 mediated transcription from the p l4 ^ ^  reporter supports the 
previous observations that a physiological mediator of E2F-1 transcription is p300 
and furthermore suggests that pl4*^^ expression is triggered by an E2F-l/p300 
mechanism (Trouche et al., 1996) (compare Figure 5.1b and 5.1c).
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5.3. JMY transcriptionally enhances p l4^ ^  expression.
The ability of JMY to co-stimulate E2F-1 transcription from the pl4^^^ luciferase 
promoter was tested by co-transfection of HA-JMY with E2F-1 in the presence and 
absence of exogenous p300. JMY effectively co-activated, by up to eight fold, E2F-1 
dependent transcription from the p i4^^^ luciferase reporter in SAOS-2 cells, with the 
activity being further enhanced by the addition of exogenous p300 (Figure 5.1b and 
5.1c). The ability of p300 to co-stimulate the activation of E2F-1 in the context of 
JMY is consistent with its function as a bridging transcriptional co-activator. In 
addition JMY’s role as a transcriptional co-activator is also consistent with these 
results.
Given the ability of JMY to undergo 3’ splicing, and that the splicing variants 
commonly are devoid of the C-temainal proline rich region, it was of interest to note 
that the co-stimulation of E2F-1 mediated pl4*^^ transcription by JMYAP, although 
reduced relative to JMY, was still significant (Figure 5.1b). The ability of p300 to 
further enhance JMYAP stimulation was only slightly compromised compared to 
JMY (Figure 5.1c). Notably, the transcription from the pl4*^^ promoter was E2F-1 
dependent as p300, JMY and JMYAP did not alter the activity of the reporter in the 
absence of E2F-1 (data not shown and Figure 5.2a).
Together these results support the role of E2F-1 as a transcription factor that drives 
the expression of pl4^^^. Two potential physiological regulators of p l4 ^ ^  expression 
have also been identified by nature of their ability to efficiently co-activate E2F-1 
transcription, namely p300 and JMY.
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5.4. pl4^^ transcription auto-regulation.
Given that E2F-1 activates expression and that this expression is effectively
co-activated by the addition of JMY and p300 it was of interest to dissect the 
transcriptional regulation of the p i4^^^ promoter further. Previous observations have 
shown that E2F-1 is essential for Gi cell cycle progression, and that E2F’s ability to 
act as a transcriptional co-activator is efficiently blocked by hypophosphorylated pRb. 
E2F-1 over-expression studies demonstrated that E2F-1 can induce apoptosis in co­
operation with p53, although studies performed on p53'‘' and mice embryos have 
more recently demonstrated that E2F-1 can induce a p53 independent mechanism of 
apoptosis (Hass-Kogan et ah, 1995; Macleod et ah, 1996). Given that a potential 
mechanism of p53 activation by E2F may be via pl4^^^ and that this activation may 
be the trigger that predisposes cells to apoptosis it is of interest to determine the effect 
of pl4**^ on activated transcription. The observation that pl4*^^ can induce pRb 
hypophosphorylation indicates a potential autoregulatory mechanism whereby p i4 ^ ^  
may regulate its own expression (Labaer et ah, 1997; Kurokawa et a l, 1999).
PI4 ARF over expression in SAOS-2 and U20S cells did not alter the basal 
transcription of the exon ip-luc reporter nor of the internal control derived from g- 
galactosidase (data not shown. Figures 5.2a and 5.2b). However transcription of the 
exon ip  reporter by E2F-1 in SAOS-2 cells was effectively repressed by pl4^^^ in a 
pRb and p53 independent manner (Figure 5.2a). The level of expression driven from 
the E2F site within the exon ip  promoter was reduced by 2.5 fold in the presence of 
p i4"^ ^^  (Figure 5.2c). Similarly the co-activated expression of exon Ip by JMY was 
reduced by 2.7 fold in the presence of pl4^^^ (Figure 5.2a and 5.2c).
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In order to determine the specificity of the transcriptional repression ability of pl4^^^ 
the transcriptional activity of p53 was studied. In order to study p53 transcription the 
promoter taken from the box gene that encodes a protein that facilitates apoptosis and 
responds to p53 was used (Miyashita and Reed, 1995; Friedlander et ah, 1996). The 
box promoter was effectively induced in the presence of exogenous p53 in SAOS-2 
cells (Figure 5.2b). As expected p53-dependent transcription of the box promoter was 
increased by the co-expression of JMY. The addition of p i4^^^ into the activated box 
promoter driven transcription although repressive was not as great as that seen for 
E2F-1, with transcription of both the p53 and p53/JMY mediated transcription being 
reduced by only 1.3 and 1.4 fold respectively (Figure 5.2c). Interestingly unlike 
previous studies p i4^^^ was unable to stabilise p53 under these cellular condition, 
presumably as a consequence of the transient nature of the assay (Figure 5.2d).
The ability of pl4^^^ to repress transcription in a transcription factor dependent 
fashion clearly indicates a new mechanism of pl4^^^ regulation. Significantly, the 
preference of p i4"^ ^^  for E2F-1 was demonstrated by the increased repression seen 
over p53. Potentially the ability of p i4^^^ to auto-regulate its own expression 
provides a possible insight into a novel function of pl4^^^ .
5.5. interacts with JMY.
The ability of p i4 ^ ^  to interact directly with MDM2 has previously been shown to 
be a deteimining factor in pl4^^^ ability to influence the p53 pathway (Zhang et a l, 
1998; Weber et a l, 1999; Zhang and Xiong, 1999). To examine the possibility that 
p i4^^^ transcription and function is regulated by JMY it was of interest to determine 
the ability of the two proteins to interact. Thus using a pull-down approach in a cell
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free system the ability of in vitro translated JMY, the natural splice JMYAP and a C- 
terminal truncation mutant, JMYAC, to interact with a bacterially purified GST- 
protein was examined (Figure 5.3a, 5.3b and 5.3c).
JMY and JMYAP bound weekly to bacterially expressed and purified GST-pl4^^^ 
whereas JMYAC, a mutant devoid of the C-terminal 215 amino acids of JMY, bound 
with a similar efficiency as MDM2 (Figure 3c, upper panel). The specificity of JMY 
and JMYAP binding to GST-pl4^^^ was confirmed by the inability of a non-specific 
luciferase control protein to bind. In all cases GST alone failed to bind to any of the in 
vitro translated products (Figure 5.3c, lower panel). Confirming that, although 
weekly, JMY and its natural splice JMYAP were capable of interacting with pl4^*^^ in 
vitro. Given that a C-terminal deletion, JMYAC, showed an enhanced affinity for 
GST-pl4^^^ it is possible that the C-terminus of JMY plays an inhibitory role in the 
pl4^^^ interaction.
In order to further map the interaction region of JMY with pl4^^^ a panel of JMY 
deletion mutants were used (Figure 5.4a). Initial mapping results indicated that the C- 
terminal region of JMY played an inhibitory role in the interaction of p l4 ^ ^  with 
JMY. A construct encompassing the C-terminus, JMY^^ '^^^ ,^ that is devoid of a p300 
binding domain failed to bind pl4^^^ (Figure 5.4aii and 5.4b). However a mutant of 
JMY^^ '^^^  ^ which retained the central p300 binding capacity was capable of 
interacting with pl4^^^ (Figure 5.4ai and 5.4b). As p300 is a potential bridging 
mediator in the interaction seen between pl4^^^ and JMY it was of relevance to 
determine the ability of the two previously identified p300 binding domains in JMY 
to influence pl4"^^^ binding. An N-teiminal construct of JMY^ '^ "^  ^that is devoid of the
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central p300 binding domain, but contains the N-terminal binding domain, still 
retained the ability to bind p l4 ^ ^  (Figure 5.4aiii and 5.4b). Given the link between 
MDM2 and p300 it was then of curiosity to determine whether the interaction of 
was solely confined to the regions in JMY responsible for p300 binding. 
Using a mutant devoid of p300 binding namely, JMY^ ^®'"^ ^^  it was determined that 
p l 4 ^Rp , although weakly, was still capable of binding to JMY in the absence of p300 
(Figure 5.4a iv and 5.4b).
Taken together these results point to at least two pl4^^^ interaction domains in JMY, 
one encompassed from amino acids 118 to 403 and a second from amino acids 502 to 
683 that overlap’s the central p300 binding domain in JMY. These results also 
confirm that the pl4^^^ interaction with JMY is at least in part outside the p300 
binding function of JMY (Figure 5.4a).
5,6, p14^^ and JMY are present in a complex in vivo.
The ability of JMY to interact with pl4^^^ in vitro strongly suggests that such a 
physical complex may occur in mammalian cells. It was therefore of relevance to 
determine whether JMY and pl4^^^ were present in the same complex in vivo. Given 
that pl4^^^ physiologically targets MDM2 it is also of interest to determine if JMY 
influences the ability of MDM2 to associate with pl4^*^ .^
Previously pl4^^^ was shown to physically associate with p53 in the absence of 
MDM2 so in order to rule out a p53/p300 dependent mechanism of interaction p53'^' 
;Rb'^ ~ SAOS-2 cells were used (Kamijo et al., 1998). HA-JMY and HA-JMYAP 
together with p l4 ^ ^  were transiently transfected into SAOS-2 cells, p i4^^^, HA-
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JMY and HA-JMYAP were all overexpressed in SAOS-2 cells (Figure 5.5a, upper 
and lower panels). The immuno-precipitation of cell extracts with anti-HA followed 
by immunoblotting with anti-pl4^^^ revealed that a specific 14 kDa polypeptide 
corresponding to pl4^*^^ was present in the JMY in vivo complex (Figure 5.5b). 
Strangely, given its ability to interact in vitro, JMYAP failed to immuno-precipitate 
PI4 ARF ^pjgm-g 5 _5 p) However the significance of the in vivo interaction assay in 
relation to JMYAP is undermined, potentially due to its sensitivity, given that JMYAP 
behaved as wild-type in all the other assays performed.
In order to determine the functional significance of the pl4^^^/JMY interaction on the 
previously described pl4^^^/MDM2 interaction, SAOS-2 cells transfected with 
MDM2 and either HA-JMY or HA-JMYAP were assayed for MDM2 binding 
to p i4^^^. In cells overexpressing either JMY or JMYAP no detectable pl4^^^ 
polypeptide was present in the MDM2 immuno-precipitates, whereas cells, not 
overexpressing JMY, efficiently immuno-precipitated p l4 ^ ^  with an MDM2 
antibody (Figure 5.5c and 5.5d). Given that JMY and JMYAP over-expression did 
not affect the stability of either MDM2 or pl4^^^ a loss in interaction due to stability 
can be ruled out (Figure 5c and 5d). Interestingly cells overexpressing MDM2 and 
p l 4 ^ ^  showed a higher moleculai* weight polypeptide corresponding to pl4^^^ in 
MDM2 immuno-precipitates (Figure 5.5d).
Taken together these results suggest a physiological interaction occurs between JMY 
and pl4^^^, and that the splicing of the 3’ of JMY may affects this interaction. The 
inability of p l4 ^ ^  to bind to MDM2 under conditions of JMY, or JMYAP over­
expression raises the possibility that JMY influences the cellular interactions of
162
It is also evident that the MDM2 in complex with p i4^^^ affects pl4^*^  ^
mobility and presumably either stability or post translation modification.
5.7. JMY regulates p l4^ ^  nuclear localisation.
The ability of p l4 ^ ^  to act as a regulator of p53 is closely associated with its 
characteristic nucleolar localisation pattern (Tao and Levine, 1999b; Zhang and 
Xiong, 1999). Tumour mutations mapping to the nucleolar localisation signal in exon 
2 of p i4^^^ are known to prevent the p i4^^^ mediated stabilisation of p53 (Soufir et 
al., 1998; Holland et al., 1999). Potentially, p i4^^^ ability to regulate the cell cycle 
may invoke its capability to be localised in the nucleolus and given that JMY 
influences pl4^^^‘s capacity to interact with MDM2 it was of interest to determine 
the influence of JMY on p i4 ^ ^  cellular localisation.
To address the role of JMY on the intracellular localisation of p l4 ^ ^  heamagglutin 
(HA) tagged JMY, JMYAP and JMYAC were expressed together with pl4^^^ by 
transient transfection in SAOS-2 cells. JMY, JMYAP and JMYAC in the absence of 
p53, as previously shown, are predominantly localised throughout the cell with both 
the cytoplasm and nucleus showing an equal intensity of staining (Figure 5.7 b, d, and 
f). In cells overexpressing pl4^^^ the characteristic nucleolar localisation pattern 
previously observed was visible, with a small population expressing nuclear p i4^^^ 
(Figure 5.6a and Figure5.7a). Under the conditions of the assay endogenous pl4^^^, 
which is expressed in SAOS-2 cells, could be occasionally visualised. Given that 
SAOS-2 lack p53 and pRb it can be assumed that a major regulatory pathway 
involved in pl4^*^^ expression has been lost in these cells (Stott et a l, 1998). In order
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to focus on the effects of exogenous JMY and p l4 ^ ^  the protein sub-cellular 
localisation of only the transfected population of cells was examined.
The over-expression of JMY in SAOS-2 cells produced a characteristic whole cell- 
staining pattern, with 6 6  % of cells showing both nuclear and cytoplasmic staining 
(Figure 5.7b). In JMY and pl4^^^ overexpressing cells the subcellular localisation of 
JMY remained unaffected, however pl4^^^ localisation shifted (Figure 5.6b). Only 
40% of JM Y /pl4^^ overexpressing cells displayed the characteristic nucleolar 
PI4 ARF localisation, with 40% now displaying a nuclear pattern for pl4^^^. 
Interestingly in these cells a population of pl4^^^ was also relocalised to the 
cytoplasm (7%) and a group of cells showed the characteristic whole cell localisation 
(13%) predominately visualised with JMY alone (Figure 5.6b and Figure5.7c).
Even though an in vivo interaction between JMYAP and pl4^^^ was undetected a 
similar relocalisation pattern of pl4^^^ staining was observed with JMYAP over­
expression (Figure 5.6c). Although the retention of p l4 ^ ^  in the nucleolar speckles 
(52%) was greater in the presence of JMYAP, a shift in 48% of cells was observed. 
Over-expression of JMYAP shifted 32% of p i4^^^ nuclear and 6 % cytoplasmic 
(Figure 5.6c and Figure 7e). Similarly to JMY no detectable shift in JMYAP 
subcellular localisation was observed in the presence of p i4^^^ (Figure 5.6c).
JMYAC was more effective in the translocation of the p i4^^^ nucleolar signal (Figure 
5.6d). As JMYAC was more effective at binding pl4^^^ in vitro it is interesting that 
over 6 8 % of cells observed a shift in pl4^^^ signal upon JMYAC introduction into 
cells. JMYAC shifted the p i4"^^ signal with 41% of cells staining nuclear, 5%
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cytoplasmic and 22% whole cell (Figure 5.6d and Figures 5.7g). Again in the 
presence of p i4^^^ the cellular localisation of JMYAC remained unchanged (Figure 
5.6d).
Given that the ability of p i4^^^ to act as a cell cycle regulator is closely linked to its 
ability to translocate into nucleolar speckles it is interesting to observe that JMY, 
JMYAP and JMYAC significantly disrupted pl4^^^ nucleolar staining (Figure 5.6 and 
Figure 5.7). Translocation of pl4^^^ by JMY resulted in an increase in p l4 ^ ^  
stability, transcription or translation as cells in which p i4^^^ localisation had been 
altered showed a definite increase in the level of the pl4^^^ signal (Figure 5.1 and 
5.6). Together these observations provide a clue as to a potential physiological role of 
JMY in p i4^^^ function.
5.8. p l4^ ^  in cell cycle regulation.
The ability of pl4^^^ to induce a p53-dependent cell cycle Gi an'est is well 
documented. As previously shown JMY is known to participate in the cellular 
response to DNA damage by inducing p53-dependent transcription and apoptosis. 
The ability of JMY to disrupt pl4^^^ nucleolar localisation suggests that JMY may 
function as a regulator of pl4^^^. Given these observations a fundamental question is 
the effect of JMY on p i4^^^ mediated cell cycle arrest.
To this end, SAOS-2 cells were transiently transfected with a combination of pl4^^^, 
JMY and p53. The cell cycle stages of transfected SAOS-2 cells were monitored by 
FACS analysis in cells showing positive expression of a transfected cell surface CD20 
marker. Propidium Iodide was used to monitor the cellular DNA content.
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As previously shown the introduction of p53 into SAOS-2 cells caused a Gi arrest 
(Figure 5.8a). Introduction of JMY produced a slight increase in the number of cells 
in Gi (Figure 5.8c). In agreement with others the introduction of p i4 ^ ^  into SAOS-2 
cells, in a p53 negative background, had little or no effect on the population of Gi 
cells (Stott et ah, 1998) (Figure 5.8b). As previously shown JMY and p53 co-operated 
in p53 mediated Gi arrest (Figure 5.8d). p l4 ^ ^  and p53 co-operated in the induction 
of Gi arrest presumably as a result of increased p53 stabilisation (Figure 5.8f). p i4^^^ 
did not alter the effect of JMY on the level of Gi aiTested cells as the same level of 
cells were observed in the presence of JM Y /pl4^^as with JMY alone (Figure 5.8e). 
The re-introduction of p53 into the JM Y /pl4^^ expressing cells restored the 
dominant p53/JMY Gi arrest phenotype (Figure 5.8g).
Notably, cells overexpressing p53, pl4^^^ and JMY simultaneously, displayed a 
higher proportion of cells in S-phase than those expressing p53 and pl4^^^, pl4^^^ 
and JMY or p53 and JMY (Figure 5.8). The level of S-phase seen in p53, pl4"^^^ and 
JMY overexpressing cells was equivalent to that observed in p53 overexpressing cells 
(Figure 5.8a). However the in my hands the measurement of S-phase by flow 
cytometry proved inconsistent and variable and so although notable, no clear 
eonclusions can be drawn from the levels of S-phase at present (Figure 4.10 and 
Figure 5.8).
Together these results confirm earlier findings that JMY’s cell cycle regulatory effect 
is dominant over pl4^^^. Interestingly JMY and pl4^^^ were unable to co-operate in
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the p53 induction of Gi arrest implying that the JMY’s and pl4^^^ mechanisms of 
inducing a p53 response are similar.
5.9. Conclusions.
stands at the nexus of the MDM2/p53 regulatory pathway. The ability of 
p%4 R^R to bind and sequester MDM2 into nuclear bodies is believed to be a major 
cellular controlling event in the release of p53 regulation (Zhang and Xiong, 1999), 
Evidence presented here supports that of others in that E2F transcriptionally regulates 
p i4^^^ expression (Bates et aL, 1998; Roberston and Jones, 1998). In addition p i4^^^ 
itself appeal's to down-regulate E2F mediated transcription and hence it’s own 
transcription.
The results presented here implicate JMY in the transcriptional up-regulation of E2F 
responsive genes and specifically p i4^^^, potentially through its ability to bind p300. 
Functionally JMY can physically interact with pl4"^^ and is present in the p i4"^ ^^  in 
vivo complex. Over-expression studies have demonstrated that JMY can affect pl4^^^ 
function as a consequence of its ability to sequester pl4"^^ from nuclear bodies in to 
the nucleus. A potential consequence of JMY’s actions on pl4^^^ function is the 
abolishment of pl4"^^ ability to bind MDM2. In addition MDM2 specifically binds to 
as yet unknown forms of p i4^^^ (Figure 5.9).
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Figure 5.1. Activation of the ExonlB reporter.
a). Organisation of the human pl4^^^exon ip  luciferase reporter promoter eonstruct. 
Putative transcription factor binding sites for Spl (•) and the four potential anti-sense 
strand E2F(—) sites within the exon p l4 ^ ^  ip  promoter region from +59 to -805 
are indicated. The E2F sites at -265 and +27 are good matches to the binding 
consensus site for E 2 F (-TTTCCCGCC^/t^/t-) whereas the sites at -249 and -69 are 
poor matehes. The indieated initiation codon for luciferase expression is located at 
+59 and the previously mapped transcriptional start site within the p l4 ^ ^  reporter is 
defined as position +1 (Mao et al., 1995). The previously described E2F-1 responsive 
site at -275 to -261 is highlighted (Bates et a l, 1998). The promoter has an observed 
CpG content of 0.85 over a 2400bp region downstream from the Initiator element 
(+1) (Robertson and Jones, 1998).
b). JMY Iran^activation of the p 14^^ promoter.
SAOS-2 cells were transfected with lug of exon Ip luciferase reporter vector 
together with lOOng of the E2F-1 transcription factor expression vector. Co­
activation of expression was achieved with the addition of increasing amounts of 
JMY and JMYAP expression vectors in the quantities lp,g (+), 3pg (++) and 5p,g 
(+++) respectively. Relative activity is depicted by luciferase normalised relative to 
the level of a P-galactosidase internal control.
c). Co-activation of p l4 ^ ^  transcription by p300.
SAOS-2 cells were transfected with exon ip  luciferase (lug) together with the 
activator E2F-1 (lOOng) and increasing quantities of JMY or JMYAP vectors as 
described in figure 5.1b. In addition 5|xg of the expression vector for p300 was 
included. The values shown are the average of duplicate readings and represent the 
relative level of luciferase to a p-galactosidase internal control. The relative 
expression seen in figure 5.1b is plotted in scale with figure 5.1c.
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Figure 5.2. Self regulation of pl4"'^expression.
a), p i4^^^transcriptional regulation.
Exon ip  luciferase reporter (Ijiig), E2F-1 (lOOng), and JMY (2|ag) expression vectors 
were introduced separately and in combination as indicated into SAOS-2 cells by 
transient transfection. The regulatory effect of p i4 ^ ^  was studied by the 
introduction of a pl4^^^ expression vector at 5pg into each treatment. Relative 
activity represents the level of transcription of luciferase to a p-galactosidase internal 
control.
b). Specificity of p i4 ^ ^  transcription regulation.
The p53 responsive reporter construct, pBax-luciferase (500ng) was introduced into 
SAOS-2 cells together with expression vectors for p53 (50ng) and JMY (2]Lig). 
Relative transcriptional activity of the reporter was measured in the presence and 
absence of 5p,g of p l4 ^ ^  expression vector. The expression of luciferase was 
normalised to an internal p-galactosidase control gene.
c). Quantification of pl4"^^^ transcriptional effect.
Activity levels from figure 5.2a and figure 5.2b were quantified relative to basal 
reporter activity and calculated as a fold induction or repression. Fold activity 
represents the increase in expression relative to the unstimulated reporter, where 
reporter alone equals one. Fold repressions by p l4 ^ ^  were calculated relative to the 
addition of the relevant component to the reporter.
d). pI4^^^ effect on p53 stability.
SAOS-2 cells were transfected with the expression vectors for p53 (50ng) and 
PI4 ARF as indicated. Cell extracts were immunoblotted with an anti-p53
antibody and a specific 53kDa polypeptide was detected as indicated.
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Figure 5.3. JMY interacts with 014"^^.
a). GST-pl4^^^purification.
10% SDS PAGE coomassie stained gel of bacterially expressed and purified GST 
(500ng) and G ST-pl4^^ (500ng). As indicated, pull-down assays were performed 
with 500ng of GST or GST-pl4^^^.
b). Translation products.
JMY, JMYAP, JMYAC, luciferase, and MDM2 were all expressed and ^^ S 
methionine labelled in vitro from a promoter containing a T7 polymerase site 
(Promega). A 10 % SDS PAGE gel shows 20% of the input level of each protein 
used for binding assays to GST and GST-pl4^^^.
c). pl4^^^ specifically binds JMY.
Either GST-pl4^^^, upper panel or GST protein alone, lower panel were incubated 
with in vitro translated JMY, JMYAP, JMYAC, MDM2, or luciferase from figure 
5.3b. The bound products were separated and loaded on a 10% SDS PAGE gel. After 
separation the binding was assayed by autoradiography. The presence of JMY 
specific in vitro products is represented by (•). The binding of MDM2, which acts as 
a known pl4^^^ partner is indicated
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Figure 5.4. Region of .TMY required for the interaction with p l4^^ .
a). Diagrammatic summary of functional domains in JMY.
Diagrammatic representation of JMY, JMYAP and the truncation mutants used for in 
vitro domain mapping. The proline rich region in the C-terminus is highlighted 
(green) together with the location of potential N-terminal S/T-P motif (blue). The 
E l A CR2 like central motif is indicated (red) as well as the two, N-terminal^'^^^ and 
central"*^^ '^^ ,^ p300 binding domains (yellow). Indicated is the p300 binding capacity 
of each of the constructs determined previously (Shikama et aL, 1999) together with 
a representation of the pl4**^ binding data. The two identified p l4 ^ ^  binding 
regions in JMY are highlighted, at and
b). Specific domains in JMY mediates its p i4 ^ ^  interaction.
JMY constructs coiTesponding to i, ii, iii and iv from figure 5.4a were in vitro 
translated using the Promega T7 TNT coupled system. 20 % of each construct was 
loaded as a control (IN). GST-pl4^^^ (500ng) was used to determine the binding 
efficiency of each of the JMY truncation mutants and GST alone (500ng) was used 
to control for non-specific binding. JMY^^ '^^^  ^ and JMY^ '^ "^  ^ bound to GST-pl4"^^ 
with similar efficiencies, at a level corresponding to 2 0 % of input, while JMY^ ^^ '"^ ®^  
showed a low affinity for GST-pl4^^^ at a level of approximately 5% input.
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Figure 5.5. JMY physically associates with p 14^^ in mammalian cells.
a). Over-expression of JMY and
SAOS-2 cells were transiently transfected with vectors encoding pl4"^^ (5pg) and 
either HA-JMY (Spg) or HA-JMYAP (5|iig). Immunoblot analysis was performed 
with mouse anti-HA(ll) and mouse anti-pl4^^^. The position of the llOkDa HA- 
JMY and 105kDa HA-JMYAP polypeptides is indicated together with the 14kDa 
specific polypeptide. The level of endogenous p l4 ^ ^  was too low for 
detection.
b). pl4**^ interacts with JMY in vivo
Protein extracts were immuno-precipitated with mouse anti-HA antibody. Following 
separation the immuno-precipitates were analysed for p l4 ^ ^  binding using a mouse 
anti-p 14^^^ specific antibody. A specific 14kDa p l4 '^^  polypeptide is indicated in 
the immuno-precipitate from JMY overexpressing cells. No p l4 ^ ^  was detected in 
the immuno-precipitates from non-transfected or JMYAP overexpressing cells.
c). JMY prevents the pl4^^/M DM 2 interaction in vivo.
SAOS-2 cells were transfected with 5|Hg of pl4^^^ and 5p,g MDM2 together with 
either 5|Ltg of JMY or JMYAP. The levels of MDM2 and pl4*^^ expression were 
monitored using mouse anti-MDM2 and mouse anti-pl4^^^ antibodies. The immuno­
précipitation of pl4**^ with a mouse anti-MDM2 antibody was performed and the 
level of pl4*^^ detected by immunoblotting with an anti-pi4^^^ antibody.
d). MDM2 binds a distinct form of pl4"^^^.
SAOS-2 cells transfected with 5ug of pl4^^^ and 5pg of MDM2 were immuno- 
precipitated with either 1: anti-pl4^^ or 2: anti-MDM2 antibodies. The immuno- 
precipitates were resolved on a 10% SDS gel and subjected to immunoblotting with 
an anti-pl4^^^ antibody. A higher mobility form of p l4 ^ ^  was resolved in MDM2 
immuno-precipitates and is indicated by **. The level of MDM2 and pl4^^^ over­
expression was detected using anti-MDM2 and anti-pl4^^ specific antibodies
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Figure 5.6. JMY mediates d14 ' cellular localisation.
a). The cellular localisation of p l4 ^ ^  in SAOS-2 cells.
SAOS-2 cells were transiently transfected with 5pg of pl4"^^ expression vector, 
fixed and assayed by inununo-reactivity with an anti-p l4^^ antibody. Immuno- 
reactivity was visualised with a fluorescein conjugated anti-mouse immunogloblin 
(i). DAPI staining was included in order to confirm the position of nuclei (ii).
b). JMY effects p l4 ^ ^  intracellulai* localisation.
The intracellular distribution of exogenous HA-JMY and p i4 ^ ^  in SAOS-2 cells 
was assessed by direct immunoflorescence. 5pg of both p i4 ^ ^  and HA-JMY were 
transfected into SAOS-2 cells and their expression visualised by staining with anti­
rabbit HA for JMY and anti-mouse pl4^^^. Anti-HA was visualised with a 
rhodamine conjugated anti-rabbit immunogloblin (ii) and pl4"^^^ with a fluorescein 
conjugated anti-mouse immunogloblin (ii). Nuclear stain DAPI was included to 
confirm the position of nuclei (iii).
c). Effect of JMYAP on p 14^^ intracellular localisation.
SAOS-2 cells transfected with 5pg of HA-JMYAP and 5|ig of p l4 ^ ^  were 
visualised for expression with anti-HA (i) and anti-p l4^^ (ii) as in figure 5.6b. 
DAPI was included as a nuclear stain (iii).
d). Effect of JMYAC on pl4"^^ intracellular localisation.
The distribution of p i4^^^ was monitored as above with the exception that 5p,g of 
JMYAC (i) expression vector was transfected into SAOS-2 cells with p l4 ^ ^  (ii). 
Again DAPI was included for nuclear visualisation (iii).
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Figure 5.8. Effect of d14^^ and .TMY on cell cycle arrest.
a)-g). Cell cycle effects of JMY, p53 and p i4"^^.
Flow cytometry was performed on asynchronous cultures of SAOS-2 cells 
transfected with the CD20 expression vector (5pg) together with p53 (3jig), JMY 
(5|ig), pl4^^^ (5 jig) or mixtures therein. Total DNA content was equivalent to 23jig 
and excess was made up with pcDNA-3. Transfected cells grown in 10% FCS were 
identified by staining with the anti-CD20 fluorescein conjugated immnuogloblin. 
The treatment of each cell cycle profile is indicated. Cell cycle events were 
quantified using CellQuest softwaie. The percentage change in cell number for Gi, S 
and G2/M were calculated as percentage change against mock transfected cells.
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Figure 5.9. Summary diagram of .TMY’s regulation of p l4^^.
JMY impacts on p l4 ^ ^  in a number of ways. JMY induces the transcription of 
p l 4 ^RP yia its association with p300 and their action on E2F-1 transactivation. JMY 
promotes the movement of p l4 ^ ^  from the nucleolus to the nucleus and prevents 
p l 4 ^^^ physiological association with the oncogene MDM2. In addition pl4"^^^ 
downregulates the transcription driven by E2F-1 acting on the exon ip  promoter 
suggesting an auto-regulatory feedback loop for p i4 ^ ^  expression.
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6. Transcriptional repression and 
activation by pRb.
6.1. Introduction.
The pRb tumour suppressor protein acts as a “master regulator” of cellulai' growth as 
a consequence of its ability to regulate the activities of transcription factors (Sellers 
and Kaelin, 1996). The key cell cycle controlling transcription factor family, E2F, is a 
physiological target of pRb’s repressive function and it is the destruction of this 
regulatory pathway that viral oncoproteins use to exhibit their growth promoting 
activities (Vousden, 1995; Dyson, 1998).
The pRb pathway is frequently inactivated by mutations in tumour cells that have 
become immortal. Specifically the pRb protein is susceptible to mutational events 
that destroy its tumour suppressor function primarily due to a loss in its ability to 
regulate gene transcription by E2F.
Recently a number of studies have highlighted that functional cross-talk occurs 
between pRb and the tumour suppressor p53. It is becoming apparent that growth 
regulators, such as p53 and pRb, are not individually responsible for the phenotypes 
that they induce but rather it is the concerted effect of multiple cellular proteins that 
determines a cells fate. In particular it appears that the oncogene MDM2 and 
transcriptional co-activator family p300/CBP are key to pRb’s role in the regulation 
of the cell cycle.
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Given the conductor like role of pRb in cellular control it is of clear significance to 
elucidate the mechanisms of transcriptional repression that it employs. In addition 
pRb’s ability to cross-talk with the transcriptional apparatus is undoubtedly an 
important mechanism by which pRb function is controlled.
6.2. pRb's repression and chromatin modulation.
A well characterised target of pRb repressive activity is the S-phase promoting 
transcription factor E2F (La Thangue, 1994; Dyson, 1998). The over-expression of a 
Gal4-E2F-1^^^"'^^  ^ fusion protein, that physiologically binds to pRb, effectively 
activates transcription from a promoter gene construct containing Gal4 DNA binding 
consensus sequences (Figure 6.1 and 6.2). The Gal4-E2F-1^^ '^"^^  ^ fusion protein 
consists of a Gal4 DNA binding domain fused to the fransactivation domain region of 
E2F-1 from amino acid 380 to 437 (Lee et aL, 1998). As expected pRb when 
overexpressed with Gal4-E2F-1^^‘^ ''^ ^^  was able to dose-dependently repress Gal4- 
E2F-1^^^’'^ ^^  ?ran.sactivation (Figure 6.1b).
Given that transcriptional repression correlates with DNA condensation and 
nucleosome formation it was of interest to determine the effect of nucleosome 
modifications on gene transcription. Acétylation is one such nucleosome modification 
that is believed to act by relaxing the histone/DNA interaction to facilitate the access 
of the transcriptional apparatus and rraw^activation (Brownell and Allis, 1996). The 
opposite of acétylation is the removal of acetly groups from hi stone tails and is 
teimed deacetylation. Deacetylation is effectively inhibited by the naturally occurring 
Streptomyces compound trichostatin A (Figure 6.1a).
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The treatment of cells with trichostatin A increases the level of basal gene 
transcription presumably as a result of a gross relaxation in chromatin structure 
(Figure 6.1 and 6.2). Interestingly the ability of pRb to repress E2F mediated 
transcription was completely abolished in the presence of trichostatin A (Figure 6.1c). 
Significantly it appears that pRb repression of E2F-1 transcriptional activation is at 
least in part mediated by a gross chromatin structural change that is potentially 
signalled through deacetylation.
Given that transcriptional upregulation by co-activators is associated with a relaxed 
chromatin structure and that the co-activator p300 contains an intrinsic HAT activity 
it was of interest to examine p300’s role in pRb’s repression of E2F mediated 
transcription. As expected and in agreement with previously published work, p300 
effectively activated Gal4-E2F-1^^^ "^ ^^ mediated transcription in a transient reporter 
assay (Trouche et ah, 1996; Lee et aL, 1998) (Figure 6 .Id). The ability of pRb to 
repress co-activated Gal4-E2F-1^^^"'^^  ^ transcription was un-compromised in the 
presence of p300, suggesting that pRb’s function in E2F-1 transcriptional repression 
is dominant over that of p300 co-activation (Figure 6 . Id). The treatment of cells with 
trichostatin A did not affect the level of co-activated transcription seen with p300 and 
Gal4-E2F-1^® '^"^^  ^ but completely abolished pRb’s repressive function (Figure 6 . le). 
Interestingly the level of Gal4-E2F-1^^°"'^^  ^ fran^activation was unaffected in the 
presence of trichostatin A suggesting that activated transcription employs maximal 
chromatin relaxation in terms of inhibition of deacetylation. In addition p300’s ability 
to co-activate transcription was unaffected by the induction of hyperacetylation, by 
trichostatin A treatment, implying that co-activation in the context of p300 acting on 
the artificial promoter is outside its HAT function or that the level of acétylation is
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maximal upon p300 treatment of cells. An explanation for the inability of 
hyperacetylation to stimulate activated and co-activated transcription is that artificial 
promoters are not correctly condensed into nucleosomes.
These results suggest that pRb’s ability to repress E2F-1 mediated transcription is in 
part dependent on the chromatin structural changes. More specifically pRb’s 
repressive effect overrides the activating effects of the p300 co-activator implying 
that the loss of repression is absolutely vital in transcriptional co-activation.
6.3. HDAC-1 enhances pRb^s repressive function.
The active repression of gene transcription is carried out by a number of co-repressor 
complexes. Co-repressor complexes such as SIN3 and NCo-R act as muti-subunit 
platforms that are specifically targeted to gene promoters where they silence 
transcription. A component of the co-repressor complexes are the histone deacetylase 
family of enzymes (HDAC’s). Histone deacetylases are families of proteins that help 
repress transcription by promoting the association of histones and DNA into 
nucleosomes. Enzymatically HDAC’s as a result of their intrinsic histone 
deacetylation activity are able to remove the acetyl groups from histone lysine tails to 
promote nucleosome assembly and chromatin condensation. The deacetylation 
activity of HDAC’s links their cellular role to one as global transcriptional repressors. 
Some HDAC’s also contain a putative LXCXE motif that suggests a pRb interface 
(Kaelin, 1999).
The co-repressor complex, SIN3, interestingly also contains the pRb binding proteins 
pRbAp46 and pRbAp48. Given that the stimulation of hyperacetylation, by
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trichostatin A treatment, resulted in a loss in pRb repressive function it was 
conceivable that pRb’s ability to recruit and use histone deacetyl ase enzymes was 
responsible at least in part for their ability to repress transcription. To this end, the 
transcriptional activity of Gal4-E2F-1^^°''^^^ in combination with pRb was studied by 
the co-expression of HDAC-1. Interestingly in SAOS-2 cells, that lack pRb, HDAC-1 
had no effect on the level of E2F-1 mediated transcription or basal transcription 
(Figure 6.2). However the co-expression of pRb and HDAC-1 reduced the level of 
Gal4-E2F-1^^ '^"^^  ^mediated transcription to a level below that seen with pRb (Figure 
6.1b and 6.2a), It is evident that pRb’s ability to repress transcription is therefore 
specifically enhanced by HDAC-1 co-expression.
Given HDAC-l’s ability to heighten pRb’s ability to repress E2F mediated 
transcription it was of interest to determine if this affect was due to HDAC-1 intrinsic 
histone deacetylase activity. The deacetylase inhibitor trichostatin A completely 
abolished pRb mediated repression of E2F in the presence of HDAC-1 (Figure 6.2b). 
It therefore appears that HDAC-1’s ability to reduce the level of E2F mediated 
transcription in the context of pRb corresponds to its function as a deacetylase. 
Interestingly HDAC-1’s enhanced repression of pRb/E2F-l was never complete; 
suggesting that pRb’s physiological repressive function is not only through its 
recruitment of HDAC-1 but also relies on its previously described functions (La 
Thangue, 1994; Weintraub e ta l,  1995; Dyson et aL, 1998; Ross etaL, 1999).
p300’s ability to activate E2F-1 mediated transcription was unaffected in the presence 
of HDAC-1 and absence of pRb (Figure 6.2c), pRb’s repression of E2F-1 
transaciivsLtion in the presence of p300 and HDAC-1 was equivalent to that seen in
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the absence of exogenous HDAC-1 (Figure 6 . Id and 6.2c). The treatment of HD AC- 
1, p300 and pRb overexpressing cells with trichostatin A resulted in a level of 
transcription by Gal4-E2F-1^^®''^^  ^ equivalent to that seen by the treatment of cells 
with p300 (Figure 6 . le  and 6 .2d).
Together, these results show that pRb repressive function is enhanced by HDAC-1. In 
particular, other groups have demonstrated that pRb binds directly to HDAC’s in 
order to transiently repress transcription (Brehm et aL, 1998; Luo et aL, 1998; 
Magnaghi-Jaulin et aL, 1998; Brehm and Kouzarides, 1999). In addition it appears 
that p300’s function in the co-activation of E2F-1 transcription is directly affected by 
pRb, as pRb’s effect dominates p300 function. pRb’s effect on p300 is however 
dependent on deacetylation and presumably occurs via HDAC. p300 directly 
promotes ^mna'activation while HDAC-1 appears to promote ?ran.srepression. 
Competition between these two factors helps determine pRb’s ability to repress E2F- 
1  mediated transcription.
6.4. pRb co-operates in transcriptional activation.
pRb’s role as a transcriptional repressor is well characterised, however its ability to 
activate transcription is poorly understood (Sellers and Kaelin, 1996). The ability of 
pRb, in certain circumstances, to upregulate transcription has been associated with 
the integrity of the pocket region and so may also play a role in pRb’s suppression of 
tumourigenesis. An interesting feature of JMY is its ability to bind directly to pRb 
(Shikama, personal communication). It was therefore of interest to study the role of 
pRb in the JMY/p300/p53 response.
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JMY in combination with p53 showed its characteristic up-regulation of the p53 
responsive promoter bax (Figure 6.3a). Interestingly, pRb co-operated with p53 in the 
induction of pBax promoter driven expression implying that pRb possesses the 
properties of a transcriptional activator for p53 in the context of Bax expression 
(Figure 6.3a). The induction of p53 driven expression by pRb was further enhanced 
by the addition of exogenous JMY suggesting that pRb co-operates in JMY’s 
function as a p53 co-activator (Figure 6.3a). The level of co-activation was over three 
fold of that seen either with JMY/p53 or with p53/pRb implying a degree of co­
operation between the three proteins. Furthermore, the pRb tumour derived mutant 
devoid of exon 22, RbA22, retained the able to drive p53 mediated transcription and 
equally co-operated with JMY (Figure 6.3a). Given that pRbA22 has lost its ability to 
act as a Gi/S phase repressor it is interesting to speculate that the activation of the 
Bax promoter by pRb is a mutational event that occurs in tumour cells that prevents 
the proliferation of cells with deregulated growth control.
As Bax is not the only p53 responsive promoter it was of significance to study the 
pRb effect on another p53 responsive promoter. The promoter is
effectively co-activated by p53 expression however JMY does not significantly co- 
activate p53 mediated transactivaMon in the context of (Figure 6.3b). pRb
alone or in combination with JMY was unable to rraw^activate p53 expression of the 
promoter (Figure 6.3b). The pRbA22 mutant is also unable to co-operate 
in p53 mediated transacûvaûon of the promoter (Figure 6.3b). The ability
of pRb to co-operate with both p53 and JMY in the co-activation of the p53 response 
is therefore specific to the Bax promoter.
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The co-activation of the p53 response was further analysed using mutants in both pRb 
and JMY. As the pRbA22 mutant is devoid of a region of the pocket it was of interest 
to examine the affect if any of the N-terminus of pRb. To this end a pRb mutant, 
pRb^^ '^^^  ^ that is deleted in the N-terminal 378 amino acids was used and scored in 
the reporter assay. The pRb ' mutant was significantly reduced compared to wild- 
type pRb and pRBA22 in the activation of p53 mediated transcription and similarity 
the co-operation between JMY and pRb^^ '^^^  ^in activation was also reduced relative 
to wild-type pRb and pRbA22 (Figure 6.3a and 6.4a). Together these results imply 
that the N-terminus of pRb is essential for maximal co-operation in the upregulated 
p53 transac\.\\a\xon of Bax.
Furthermore, a JMY dominant negative mutant that represses p53 mediated 
transcription was examined for its ability to co-operate with pRb in p53 mediated 
transcription. As previously shown the JMY*'"^ ^^  mutant effectively represses p53 
mediated transcription (Shikama et ah, 1999) (Figure 6.4b). Significantly the 
repressive effect of JMY^ ""^ ^^  was dominant over pRb activating effect as the co­
transfection of pRb and JMY^ '"^ ^^  reduced the level of pRb/p53 mediated transcription 
(Figure 6.4b). Given that JMY^ '"^ ^^  potentially interferes with the endogenous 
p300/p53 interaction it is conceivable that pRb’s activating potential is signalled 
through p300. Significantly the repressive activity of JMY^ '"^ ^^  was further enhanced 
by the co-tranfection of the pRb^ ^^ "^ ^^  mutant to levels representing basal reporter 
activity (Figure 6,4b). Together these results suggest that both pRb and JMY can co­
operate in p53 mediated fra«.sactivation and that a potential intermediary molecule in 
this pathway is p300.
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6.5. pRb influences .TMY s cellular localisation.
The ability of p53 to influence JMY’s cellular localisation is potentially an intregal 
point in JMY’s ability to co-activate p53 mediated transcription. As pRb co-operates 
with JMY in p53 mediated rraw^activation it was of interest to determine if JMY 
nucleai* localisation was affected by pRb.
The over-expression of p53 and JMY resulted in their characteristic co-nuclear 
staining pattern (Figure 6.5a). pRb over-expression in SAOS-2 cells did not alter the 
characteristic whole cell staining pattern of JMY and pRb was as expected 
exclusively nuclear (Figure 6.5b). Interestingly the over-expression of p53, pRb and 
JMY did not affect p53 nuclear localisation but JMY’s nuclear staining pattern in the 
presence of p53 was disrupted and a cytoplasmic staining population of JMY was 
clearly visible in cells overexpressing pRb (Figure 6.5c).
These results suggest that pRb interrupts p53’s ability to influence the cellular 
localisation, at least in part, of JMY. Given that pRb and JMY co-operated in p53’s 
transaciivaXion it was expected that a nuclear complex between all three proteins 
would be visible. However the disruption of JMY’s nuclear pattern by pRb suggests 
that the enhanced rraw^activation of p53 is mediated through a cytoplasmic 
intermediary path. An intriguing possibility is that pRb removes JMY to the 
cytoplasm where it receives the necessary signals that stimulate its function as a co­
activator, a hypothesis supported by the reduced ability of JMY^^® to activate p53 
mediated transcription (Figure 4.3a). Although supportive many other possibilities 
can not be ruled out.
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6.6. Conclusions.
The ability of pRb to repress transcription is clearly associated with its role and 
ability to bind E2F-1. Interestingly it appears that pRb in addition to its ability to 
directly repress E2F-1 rratt^sactivation is also able to utilise chromatin modulators 
such as HDAC-1 to bring about its repressive function. Given that co-activators such 
as p300 aie believed to functionally upregulate the activity of transcription factors it 
is of significance to note that the repressive function of pRb is dominant over that of 
the co-activators. In addition p300’s HAT activity was maximal in the activation of 
E2F-1 and was unaffected by the induction of hyperacetylation.
In addition to its role in transcriptional repression pRb possesses a transcriptional 
activating potential. Specifically pRb co-operated in JMY’s ability to co-activate p53 
fraii^activation of the bax promoter and interestingly this activity was independent of 
a region of the pocket in pRb. Given that a naturally found mutant form of pRb 
behaved as wild-type in the co-operation of the p53 response it is interesting to 
speculate that tumour cells that have lost pRb function as a gene repressor retain its 
ability to functionally activate transcription and so is important in its role as a tumour 
suppressor.
In particular the co-operation in transacûvaûon of the p53 response between JMY 
and pRb alters the cellular localisation of JMY. The JMY/p53 nuclear population is 
disrupted and in particular JMY is shifted to the nucleus. The exact functional 
significance of JMY localisation is however unknown.
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Figure 6.1. pRb mediated repression.
a). Trichostatin A.
The structure of the deacetylase inhibitor trichostatin A is shown.
b). pRb represses E2F-1.
SAOS-2 cells were transiently tansfected with the pG5-Elb luciferase vector (Ipig) 
together with lOOng of Gal4-E2F-1^^® '^ ^^ . Repression was achieved by the over­
expression of the pCMV-Rb expression vector in the quantities Ipg (+) and 2pg 
(++). The values shown represent the average of two readings of luciferase 
expression relative to the expression of an internal P-galastosidase control vector.
c). pRb uses deacetylases to repress E2F-1 rra/î^yactivation.
SAOS-2 cells were transfected as in figure 6.1b. Trichostatin A was added to 
transfected cells at a final concentration of 150nM 10 hours prior to harvesting. 
Reading represents the expression level of luciferase relative to that of an internal p- 
galactosidase control gene.
d). p300 and pRb repression.
SAOS-2 cells transfected with pG5-Elb luciferase (Ipg), lOOng Gal4-E2F-1^^®''^^  ^
and pRb at Ipg (+) and 2pg (++), In addition the expression vector for pCMV-p300 
(5pg) was included. The relative level of luciferase and internal p-galastosidase 
expression was measured and plotted as relative activity.
e). Trichostatin A treatment.
SAOS-2 cells were transfected as in figure 6 . Id. Trichostatin A was added to 
transfected cells at a final concentration of 150nM 10 hours prior to harvesting. 
Reading represents the expression level of luciferase relative to that of an internal p- 
galactosidase control gene.
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Figure 6.2. HDAC-1 enhances pRb mediated transcriptional repression.
a). pRb repression of E2F-1 is enhanced by HDAC-1.
SAOS-2 cells were transiently tansfected with the pG5-Elb luciferase vector (Ijig) 
together with lOOng of Gal4-E2F-1^^^*'^^ .^ Repression was achieved by the over­
expression of pCMV-Rb expression vector in the quantities Ipg (+) and 2pg (++) 
respectfully. In addition 2|iig of the expression vector for HDAC-1 was included. The 
values shown represent the average of two readings of luciferase expression relative 
to the expression of an internal P-galastosidase control vector.
b). pRb/HDAC-1 repressive activity is overcome by trichostatin A.
SAOS-2 cells were transfected as in figure 6.2a except trichostatin A was added to 
transfected cells at a final concentration of 150nM 10 hours prior to harvesting. 
Reading represents the expression level of luciferase relative to that of an internal P- 
galactosidase control gene.
c). p300 and pRb/HDAC-1 repression.
SAOS-2 cells were transiently tansfected with pG5-Elb luciferase vector (Ifxg) 
together with lOOng of Gal4-E2F-1^^^"'^^ .^ Repression was achieved by the over­
expression of pCMV-Rb expression vector in the quantities I jL ig  (+) and 2pg (++) 
respectfully. In addition 2p,g of the expression vector for HDAC-1 and 5|Lig of 
pCMV-p300 encoding vectors were included. The values shown represent the 
average of two readings of luciferase expression relative to the expression of an 
internal p-galastosidase control vector.
d). Trichostatin A treatment.
SAOS-2 cells were transfected as in figure 6.2c except trichostatin A was added to 
transfected cells at a final concentration of 150nM 10 hours prior to harvesting. 
Reading represents the expression level of luciferase relative to that of an internal p- 
galactosidase control gene.
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Figure 6.3. Co-operation between p53 and pRb in .TMY co-activation.
a). p53 and pRb co-operate in transcription.
SAOS-2 cells were transfected with 500ng of the p53 responsive promoter pBax- 
luciferase together with 50ng of p53 and 5p,g of pRb or RbA22 expression vectors. In 
addition 5pg of JMY expression vector was added to the indicated treatments. 
Relative expression is depicted noimalised relative to the level of (3-galastosidase 
internal control.
b). p53, pRb and JMY do not co-operate in co-activation.
SAOS-2 cells were transfected with the WWP-luciferase (Ipg) reporter vector 
construct together with a p53 vector (50ng). In addition either CMV-pRb (5pg) or 
pCMV-pRbA22 (5pg) were added. The expression vector for JMY (5p,g) was added 
to the indicated treatments. Relative expression is depicted normalised relative to the 
level of p-galastosidase internal control.
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Figure 6.4. Mutational analysis of the p53, pRb and JMY co-activation affect.
a). Requirement for pRb N-terminus in ïran^activation by p53.
The pBax luciferase (500ng) reporter vector together with a p53 (50ng) expression 
vector were transfected into SAOS-2 cells. In addition the expression vector for 
pRb^^ '^^^  ^ (5p.g) was added either alone or in combination with a JMY (5pg) 
expression vector. Relative expression is depicted normalised relative to the level of 
p-galastosidase internal control.
b). Behaviour of a dominant negative JMY in transcriptional activation
The pBax luciferase (500ng) reporter vector together with a p53 (50ng) expression 
vector were transfected into SAOS-2 cells. In addition the expression vector for 
pRb^^ '^^^  ^ (5|ig) was added either alone or in combination with a JMY^ ""^ ®^  (5pg) 
expression vector. Relative expression is depicted normalised relative to the level of 
P-galastosidase internal control.
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Figure 6.5. Cellular localisation effects of pRb and p53 on JMY.
a). p53’s affects JMY’s cellular localisation.
The intracellular distribution of exogenous JMY and p53 were examined by direct 
immunoflorescence. 5pg of HA-JMY and p53 expression vectors were transiently 
transfected into SAOS-2 cells and their localisation visualised by staining with an 
anti-mouse HA antibody for JMY and an anti-rabbit antibody for p53. Anti-HA 
binding was detected using a rhodamine conjugated anti-mouse immunogloblin (i) 
and p53 using an anti-rabbit fluorescein conjugated antibody (ii). DAPI was included 
to stain nuclei (iii).
b). pRb’s and JMY localisation.
The intracellulai* distribution of exogenous JMY and pRb were examined by direct 
immunoflorescence. 5pg of HA-JMY and pRb expression vectors were transiently 
transfected into SAOS-2 cells and their localisation visualised by staining with an 
anti-rabbit HA antibody for JMY and an anti-mouse antibody for pRb. Anti-HA 
binding was detected using a fluorescein conjugated anti-rabbit immunogloblin (i) 
and pRb using an anti-mouse rhodamine conjugated antibody (ii). DAPI was 
included to stain nuclei (iii).
c). JMY, p53 and pRb.
The intracellular distribution of exogenous JMY and p53 were examined by direct 
immunofluorescence in cells that were also overexpressing exogenous pRb (5p,g). 
5pg of HA-JMY and p53 expression vectors were transiently transfected into SAOS- 
2  cells and their localisation visualised by staining with an anti-mouse HA antibody 
for JMY and an anti-rabbit antibody for p53. Anti-HA binding was detected using a 
rhodamine conjugated anti-mouse immunogloblin (i) and p53 using a fluorescein 
anti-rabbit conjugated antibody (ii). DAPI was included to stain nuclei (iii).
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7. Discussion.
7.1. Transcriptional co-activation bv p300.
The biological activity of the p300/CBP family is at least in part dependent on their 
ability to augment the function of a variety of transcription factors such as, c-Jun, 
MyoD, CREB and E2F-1/DP-1 (Chrivia et a l, 1993; Arias et al., 1994; Eckner et al., 
1996b; Perkins et al., 1997; Shikama et al., 1997; Lee et al., 1998; Torchia et al., 
1998). Indeed E lA ’s ability to perturb the cell cycle by blocking differentiation and 
transcriptional control has been associated with its ability to directly interfere with 
p300/CBP’s function as a co-activator of p53 (Avantaggiati et al., 1997; Gu et al., 
1997; Li 11 et al., 1997a; Lee et al., 1998; Shikama et al., 1997).
Specifically, here I demonstrated, in a fashion similar to others, that p300 acts as a 
transcriptional co-activator for both p53 and E2F-1 (Trouche et a l, 1996; 
Avantaggiati et al., 1997; Lee et al., 1998) (Figure 7.1). The phosphorylation of p53 
in response to cellular stress is arguably a mechanism that controls its stability and 
activity (Siliciano et al., 1997). p300 functionally acetylates p53 and increases the 
sequence specific binding activity of p53 (Gu and Reeder, 1997; Sakaguchi et al., 
1998). In addition transa.ctiv3.tion domain phosphorylation of p53 stimulates its 
binding to p300 and consequently an increase in the level of p53 acétylation (Lambert 
et al., 1998). Recent evidence has also demonstrated that the acétylation of E2F-1 by 
p300 directly influences E2F-1 DNA binding activity and stability (Martfnez-Balbas 
et al., 2000). An intriguing possibility is that the p300 co-activator complex co­
ordinates and regulates the p53 and E2F-1 cellular responses.
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7.2. JMY enhances p53-dependent transcription.
Evidence from mammalian cells has implicated the p300 co-activator complex as 
having a significant role in mediating transcription. p300’s co-activator function is 
known to be regulated by its association with a number of proteins such as PCIP, 
P/CAF, and SRC-1 (Yang et aL, 1996; Chen et al., 1997; Spencer et ah, 1997). Given 
that JMY physically associates with p300 and that p300 functionally co-activates p53 
it was considered that JMY would modulate the activity of the p300/p53 response.
Analysis of a series of p53 responsive promoters demonstrated that JMY significantly 
co-operated with p300 in the co-activation of p53 (Shikama et ah, 1999). 
Significantly, JMY exhibited the properties of a gene specific co-activator as the box 
and PIG3 promoters were efficiently co-activated upon JMY over-expression. In 
contrast the mdm2 and wafl p53 responsive promoters were largely unaffected by 
increased levels of JMY. It appears that JMY may show promoter specific effects in 
vivo as the co-activation of the endogenous mdm2, box and wafl genes mirrored that 
seen with artificially reporters. Thus this study suggests that JMY performs a 
physiological role in co-activating the p53 response and importantly demonstrates 
that JMY’s co-activation is more pronounced on a selective sub-group of p53 target 
genes (Figure 7.1).
The differential regulation of the p53 response by JMY is identical to results that 
demonstrate that p300 itself regulates the specificity of the p53 response for certain 
p53 responsive promoters (Lee et a l,  1998). Indeed the viral E l A oncogene has been 
shown to specifically target p300’s co-activation of MDM2 expression (Thomas and 
White, 1998). It therefore appears that JMY behaves in a similar manner to its
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partner, p300, in order to differentially regulate the p53 response. In fact it is 
conceivable that JMY’s mechanism of action may account for the differential 
regulation of p53 inducible genes by p300.
7.3. JMY arguments p53-dependent apoptosis.
p53’s ability to induce apoptosis correlates with both transcriptional dependent and 
independent mechanisms (Caelles et al., 1994; Haupt et al., 1995). The over­
expression of Bax effectively induces apoptosis and the inactivation of p300/CBP 
can, in certain situations, prevent p53-dependent apoptosis (Oltavi et at., 1993; 
Miyashita and Reed, 1995; Lill et al., 1997a). p53’s induction of the PIG subset of 
genes also correlates with the induction of apoptosis (Polyak et a l, 1996). In 
particular it appears that the induction of apoptosis following the ïran^activation of 
specific target genes by p53 is cell type specific, which may correlate with the 
presence of specific amounts of additional effector molecules, such as JMY.
Fibroblasts derived from p300'^' embryos display a profile of transcriptional defects 
including a defective proliferation phenotype, implying that p300 is essential for cell 
proliferation and development (Yao et a l, 1998). It therefore appears that JMY’s 
ability to transcriptionally activate p53 gene expression may be dependent on its 
association with p300.
JMY efficiently co-activated box and PIG3 expression, and significantly co-operated 
with p53 in the induction of apoptosis. The induction of p53-dependent apoptosis by 
JMY is independent of p300’s over-expression and interestingly p300 over 
expression itself is insufficient to induce p53 apoptosis (Lee et a l,  1998; Shikama et
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al., 1999). Rather it appears that JMY acts together with p300 to promote p53- 
dependent apoptosis and implies that JMY is the physiological effector in the 
induction of apoptosis. Furthermore, since JMY could argument apoptosis without 
the addition of p300 it suggests that JMY rather than p300 is the limiting partner in 
p53’s induction of apoptosis. These results directly imply that effector molecules 
such as JMY regulate the p53 response through their association with p300 (Figure
7.1).
In agreement with JMY being important in p53’s induction of apoptosis it was 
demonstrated that the JMY in vivo complex contains a very high level of p53. It is 
interesting to speculate that through its promoter specific co-activator effects JMY 
acts downstream of p53’s activation in the induction of apoptosis. Clearly p300 and 
JMY co-operate in the promoter specific activation of p53 responsive genes but their 
ability to bias gene expression is not yet fully understood.
p53’s cellular level helps determining p53’s role in cell cycle arrest and apoptosis 
(Macleod et ah, 1996; Polyak et al., 1996). However JMY’s ability to up-regulate 
p53-dependent apoptosis is independent of p53 post-translational stabilisation as 
JMY itself does not post-translationally activate p53. It therefore appears that a 
controlling factor in p53’s role in apoptosis and cell cycle arrest is the presence and 
activity of JMY, and factors that mimic JMY’s function.
7.4. The importance of 3’ isoforms of JMY.
As many of the vitally important cell cycle regulators, such as the p53 family, are 
extensively spliced it was of significance to observe that the JMY mRNA was
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alternatively spliced. Specifically the 3’ region of the JMY mRNA showed diverse 
splicing and, in particular, the proline rich domain was a common region lost as a 
result of splicing. Given JMY’s ability to co-activate p53’s apoptotic response it was 
of considerable interest to observe that the splice isoform, JMYAP, displayed 
properties that were functionally distinguishable from wild-type JMY. JMYAP was 
unable to co-activate the box promoter but, significantly, showed a preference over 
JMY in the co-activation of the wafl promoter. In agreement, the JMYAP splice 
variant showed a dramatic increase in the endogenous induction of 
protein levels in a p53-dependent manner.
p53’s induction of cell cycle arrest is closely associated with the induction of 
p2 ]^ wafi/cipi block of E2F transcription (El-Diery et al., 1993). It was therefore 
notable that JMYAP was able to significantly co-operate with p53 in the induction of 
a Gi cell cycle arrest. Conversely, JMYAP did not affect the level of p53-dependent 
apoptosis. Given that p300 is required for p21^^^^^ '^^  ^expression but is insufficient to 
induce p53-dependent apoptosis (Lee et al., 1998) it has been proposed that apoptosis 
occurs when the level of p300 is not rate limiting. Here I propose that a second 
controlling event in the mediation of a p53-dependent Gi arrest is the presence of 
specific JMY isofoims (Figure 7.1).
7.5. JMY controls the p53 response.
Transcriptionally inactive p53 can induce apoptosis (Caelles et al., 1994; Haupt et al., 
1995). Here I demonstrated that the co-activation of p53 by JMY correlates well with 
transactivation and apoptosis. It is believed that the controlling switch between p53 
function in apoptosis and cell cycle anest relates to the cellular level of p53 (Gottlieb
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and Oren, 1996; Bums and El-Deiry, 1999), here I clarify such an issue by 
demonstrating that a second controlling switch is the p300/JMY co-activator 
complex. Specifically p53 bound to p300/JMY will co-activate apoptotic genes, 
whilst p53 bound to p300/JMYAP can induce the expression of cell cycle arrest 
associated genes (Figure 7.1). Even through JMY acts downstream of p53 to co- 
activate gene expression, it is conceivable that the signals that simulate cell cycle 
an'est and apoptosis also impact directly on JMY, controlling the relative intensities 
and activities of the JMY population.
Results presented in this study are consistent with p53’s role in apoptosis and cell 
cycle arrest and underline the dependence of p300 in these processes. In addition it is 
evident that p300/CBP co-activator complex components, such as JMY, are key 
molecular switches that control the p53 response. The p53 family member, p73, is 
known to possess promoter specific transacMvaixon properties and to directly interact 
with p300 in order to carry out its cellular functions (Lee et al., 1999). Whether JMY 
is part of this complex is an interesting but as yet unanswered question.
Interestingly, the association of p300 with MDM2 has been linked with the regulation 
of MDM2 cellular function. Indeed, MDM2 forms a ternary complex with p53 and 
p300 and it appears that the inclusion of p300 is essential for MDM2’s ability to 
mediate degradation of p53 (Grossman et a l, 1998). Thomas and White (1998) 
proposed that p300’s co-activation and regulation of p53 mediated transcription of 
the mdm2 gene is in fact an important determinant in the physiological response of 
p53 (Thomas and White, 1998). Hypothetically, JMY may be a mediator in this
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pathway; in such a way that competition for p300 by JMY and MDM2 may augment 
and define the p53 response.
7.6. Translocation of TMY.
The nuclear localisation of transcription factors and co-activator molecules is 
essential for their effective rraw^activation. Since transcriptional co-activators exeit 
their effects on gene transcription in the nucleus, the control of their intra-cellular 
localisation must be an important regulatory mechanism. JMY is predominantly a 
whole cell protein but in the presence of p53 the JMY signal is predominantly nuclear 
(Figure 7.1). However, the nuclear localisation of JMY appears not to be important 
for its function as a co-activator, as a constitutive nuclear JMY^^^ protein is less 
active than wild-type JMY in transcriptional co-activation. It therefore appears that it 
is signals that trigger JMY’s translocation into the nucleus from the cytoplasm, or 
those which effect nuclear import or export, that are vital in regulating its role as a 
co-activator. Indeed it is interesting to speculate that the cellular signals that govern 
cell cycle arrest and apoptosis are individually responsible for the translocation of 
specific JMY isoforms from the cytoplasm to the nucleus. Whether JMY’s 
localisation is signalled through the mitogenic or oncogenic pathways is unknown.
7.7. Proline rich domains and transcription.
The p53 tumour suppressor has been implicated in the regulation of multiple cellular 
anti-proliferative pathways including those that lead to transient cell cycle arrest as 
well as those that lead to permanent cell death. p53’s accumulation leads to Gi arrest, 
however the co-expression of cells with E2F-1 or c-Myc forces Gi arrested cells to 
undergo apoptosis (Martinez et a l, 1991; Wu and Levine, 1994). Therefore p53
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mediated events in a cell are able to detect and respond appropriately to signals 
generated from a variety of nuclear signal transduction pathways to mediate the 
appropriate cellular outcome.
Several studies have demonstrated that there are discrete classes of p53 responsive 
genes that determine the functional outcome of p53 activation (Friedlander et al., 
1996; Ludwig et al., 1996). It appears that the proline rich domain, located between 
the transactivation and DNA binding domain in p53, helps discriminate the 
rra/î.yactivation function of p53 (Walker and Levine, 1996; Venot et a l, 1998; Zhu et 
a l,  1999). The importance of the proline rich domain of p53 is highlighted by the 
inability of Li-Fraumeni syndrome suffers, that display mutational events within the 
proline domain, to undergo a normal p53 response (Sun et a l, 1996).
Strikingly, several studies have demonstrated that the proline rich domain of p53 
imparts promoter specific functions in an identical manner to those observed for 
JMY. Here I have confirmed that the proline rich domain of p53 is essential for the 
transcriptional activation of PIG3 but is dispensable for MDM2 and p21^^^ ^^ '^^  ^
expression. Taken together the results presented in this thesis suggest a hypothesis in 
which proline rich domains in transcriptional activating proteins play a vital role in 
promoter specificity and co-ordination of the cellular response.
Studies relating to the proline rich domain of p53 have suggest a number of potential 
roles for such a domain, all of which have a relevance in the understanding of JMY’s 
function. The proline rich domain in p53 mediates an activity that is critical for its 
tumour suppressor function in vivo and demonstrates that transcriptional activation by
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p53 can be uncoupled from its apoptotic growth suppression function (Walker and 
Levine, 1996; Venot et ah, 1998; Zhu et a l, 1999). Given that a p53AP mutant 
responds to DNA damage it is conceivable that in the case of p53 that this domain is 
responsible for signalling a subset of p53’s downstream anti-proliferative signals that 
ultimately promote apoptosis (Walker and Levine, 1996). Furthermore, Zhu et a l  
(1999) conclude that the proline rich domain of p53 as a consequence of its ability to 
regulate p53’s activation of PIG3, p85, MDM2, and P IG ll, is required for activating 
genes that participate directly in the signalling pathways which control apoptosis. In 
fact p85 is involved in the apoptotic response to oxidative stress and PIG3 produces 
reactive oxygen species that degrade the mitochondria and subsequently stimulate 
apoptosis (Polyak et a l, 1997; Yin et a l, 1998). Similarly, the proline rich domain in 
JMY is also responsible for the co-activation of p53 responsive genes that are 
specifically involved in apoptosis.
The promoter specificity of the proline rich domain of p53 has been linked with the 
binding of p53 to low affinity DNA binding sites (Walker and Levine, 1996). Venot 
et a l  (1998) demonstrated that the production of reactive oxygen species is 
dependent on the proline rich domain in p53 and that the binding of p53 to low 
affinity DNA binding sites is mediated by the proline rich domain. It is therefore 
conceivable that the proline rich domain of p53 functions structurally to regulate the 
activity of p53. In an identical manner the C-terminus of p53 is known to regulate the 
sequence specific binding of p53 (Hupp et a l, 1992). However, in the case of JMY 
the binding of JMY to its known partner, p300, is unaffected by the deletion of the 
proline rich domain. Given that prolines are hydrophobic residues that induce bends 
in protein structures it is conceivably that the proline rich domain in JMY may
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influence the tertiary structure of JMY and the association of other p300/JMY co­
activator complex components.
Walker and Levine (1996) proposed that the proline rich domain in p53 mediates the 
ability of p53 to interact with SH3 domain containing proteins and that this allows the 
integration of signals that specifically induce transcriptional activation of a subset of 
genes. In fact the proline rich domain of p53 that contains five repeats of the P-X-X-P 
motif theoretically forms a left handed polyproline type II helix that creates a binding 
site for SH3 domains (Yu et al., 1994). In agreement, the murine polyproline rich 
domain in p53 is a known docking site for the transmission of G asl’s dependent anti­
proliferative signals and mutations within the proline rich domain abolish p53 
mediated transaciivaiion independent growth arrest induced by Gas 1 (Ruaro et al.,
1997). Additionally, the SH3 domain containing c-Abl protein stimulates a p53- 
dependent cell cycle arrest (Goga et al., 1995). Interestingly, antibodies directed 
against epitopes close to the proline rich domain in p53 have been shown to modulate 
the DNA binding activity of p53 which lends support to the idea that this domain is a 
docking site for activating factors that structurally influence p53’s activity 
(Wolkowicz et ah, 1995; Friedlander et al., 1996).
In some cell types several reports have demonstrated that cytokines are influential in 
the life/death decision by p53 (Gottlieb and Oren, 1996; Ko and Prives, 1996). It is 
therefore speculative to associate proline rich domains with docking to SH3  
containing proteins and the separation of the life and death signals by p53 and JMY. 
The identification of such hypothetical SH3 bearing proteins that impact on p53 and
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JMY, via their proline rich domains, will greatly help decipher and separate the 
signals that control cellular life and death.
The repressive function of p53 may accelerate the induction and progression of 
apoptosis. In agreement the WTl and ElB proteins that prevent p53 mediated 
apoptosis have been shown to inhibit p53’s ability to repress transcription 
(Maheswaran et al., 1995; Sabbatini et al., 1995a; Mui-phy et al., 1996). The absence 
of the proline rich domain in p53 also severely compromises p53’s ability to repress 
transcription (Venot et at., 1998), which strengthens the idea that repression is 
important for p53’s apoptotic function. In the case of JMY, however, mutants devoid 
of the proline rich domain do not affect p53’s ability to stimulate transcription or 
induce apoptosis. It therefore appears that the proline rich domain in JMY 
discriminates its co-activator function and plays no role in the direct down-regulation 
of transcription.
An intriguing possibility is that proline rich domains are regulated by post- 
translational phosphorylation. p53’s regulation by phosphorylation is well 
documented and is known to influence the differential binding of p53 to various 
consensus sites (Wang and Prives, 1995; Lohrum and Scheidtmann, 1996). The 
possibility that the proline rich domains in JMY and p53 are regulated by 
phosphorylation is an intriguing if unconfirmed possibility.
Zhu et al. (1999) highlighted that p53’s activation of transient reporter genes differs 
from that of endogenous genes, given that transiently transfected promoters are not 
correctly packaged in to chromatin. Zhu et al. (1999) also imply that the proline
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promoter specific functions of p53 are reminiscent to those of MyoD, that acts as a 
chromatin modulator and shows differential activation of transfected promoters in 
transient reporter assays. Consequently they propose that the proline rich domain of 
p53 may be necessary for chromatin remodelling events that counteracts the 
chromatin mediated repression of some p53 cellular target genes. However in the 
case of co-activation by JMY, endogenous gene regulation was identical to that 
observed in transient reporter assays implying that although not excludable that 
chromatin modulation is not the primary function of JMY’s proline rich domain.
7.8. JMY co-activates expression of the p 14^^ gene.
The expression of the p l4 ^ ^  tumour suppressor protein is initiated from a specific 
exon (Ip) within the INK4a locus (Sharpless and DePinho, 1998). E2F-1 over­
expression effectively induces expression from the exon ip  promoter (Bates et a l, 
1998; Roberston and Jones, 1998; Inoue et a l, 1999) and I demonstrated that this 
rran^activation is effectively co-activated by p300. Results presented here also 
demonstrated that the transcriptional co-activator JMY (Shikama et a l, 1999), 
potentially as a consequence of its association with p300 up-regulates E2F-1 
mediated expression of the p i4^^^ promoter (Figure 7.1). It therefore appears that 
JMY behaves in an identical synergistic manner as p300 in that it is able to co- 
activate both p53 and E2F-1 mediated transcription. Consequently, the results 
presented in this thesis are consistent with the p300 co-activator complex being a 
vital component in the communication between the E2F and p53 growth controlling 
pathways.
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p l 4 ^Rp’s ability to elicit a p53 response is manifested by an increase in expression of 
a number of p53 responsive genes as a result in the loss of MDM2 function (Kamijo 
et at., 1998; Pomerantz et aL, 1998; Stott et al., 1998; Zhang et al., 1998). JMY’s 
ability to up-regulate p i4^^^ expression will hypothetically induce p53’s cellular 
function and therefore potentially supports a role for JMY acting not only as a p53 
co-activator but also as an up-stream activator. The E2F-1 and p53 proteins are key 
cell cycle regulators and the balance between their activities is likely to be critical in 
cell survival. JMY clearly impacts on both pathways and is a potential molecule that 
mediates the cross-talk between the two growth controlling pathways.
E2F-1 and p53 are known to functionally co-operate in the induction of apoptosis 
(Qin et al., 1994; Wu and Levine, 1994; Kowalik et al., 1995; Lee et al., 1998). 
Indeed E2F-1 can induce apoptosis in the absence of p53 although this apoptotic 
function is to some extent transcriptionaly independent and may reflect an alleviation 
of transcriptional repression by E2F-1 (DeGregori et a l, 1997; Hsieh et a l, 1997; 
Phillips et a l, 1997; Lee et a l, 1998). Furthermore, p l 4 ^  is a potentially an 
essential intermediate in E2F-1 induced apoptosis as arf^' cells are resistant to E2F-1 
induced apoptosis (Zindy et a l, 1998). However, p300 has been shown to enhance 
E2F-1 mediated apoptosis and E2F-1 is a known transactivatQ the Drosphila cell 
death regulator reaper (Asano et a l, 1996). In addition E lA  requires the capacity to 
bind both pRb and p300 in order to induce apoptosis and so it is possible that 
p 14/19^^^ activation is essential in apoptosis (de Stanchina et a l,  1998). Here I 
demonstrated that a potential mediator of co-operation between E2F-l’s up- 
regulation of p53 mediated apoptosis is JMY, through its ability to up-regulate 
p i 4^^^ expression.
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Interestingly the cellular level of p300 is believed to be rate limiting (Yao et ah,
1998), and results presented here potentially associate the rate limiting effects of 
p300 with a reduced level of p300’s recruitment of JMY to promoters and 
consequently a reduction in transcription. Whether JMY is involved in the co­
activation of other E2F-1 tai'get genes that are associated with apoptosis and cell 
cycle anest events is at present unknown
The regulation of pl4"^^^ expression is poorly understood but here I demonstrated 
that pl4^^^ itself is able to regulate its own expression in a manner reminiscent to 
that of p53’s regulation of pl4^^^ (Robertson and Jones, 1998; Stott et al., 1998). The 
over-expression of p i4^^^ reduces E2F-l’s rmn.sactivation of the pl4^^^ promoter 
and the auto-regulatory loop is seemingly specific for the exon ip  reporter as the p53 
responsive promoter, box, expression was largely unaffected by pl4^^^ over­
expression. Given the ability to pl4^^^ to impact on the cells fate it is not surprising 
that the level of p i4"^ ^^  is tightly regulated and that p i4^^^ itself regulates its own 
expression. Data presented here demonstrated that pl4^^^ itself regulates its own 
expression in a mechanism reminiscent for that of p53/MDM2, in which p i4^^^ 
expression is repressed by over-expression of p i4 ^ ^  (Figure 7.1).
The repressive effect of pl4"^^ does not require pRb as the affect was observed in 
SAOS-2 cells that contain no functional pRb. It is therefore conceivable that the 
repression of the p l4 ^ ^  promoter by pl4^^^ occurs through a component of the E2F- 
1 co-activator complex and such a potential component is JMY. The ability of pl4^^^ 
to negatively regulate the proliferation of murine embryonic fibroblasts
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independently of p53 also agrees with the data presented in this thesis (Camero et ah, 
2000).
E2F-1 is responsible for the transition between Gi and S and although pl4^^^ 
represses E2F-1 transcription of the exon Ip promoter no change in the Gi population 
of cell was visible in cells overexpresssing pl4^^^. It therefore appears that pl4^^^’s 
inhibitory effect is specific for E2F-1 in the context of the p i4^^^ promoter. In 
agreement Stott et al. (1998) presented identical findings, in that p l4 ^ ^ ’s over­
expression in SAOS-2 cells does not alter the population of cells in the different 
stages of the cell cycle.
7.9. Functional interaction between JMY and pl4^^.
A potential target for pl4^^^’s inhibitory function is JMY as the two proteins 
physically associate in vitro and in vivo. pl4^*^^‘s primary function in cells appears to 
be the sequestration of MDM2 from the p53 regulatory pathway (Stott et al., 1998) 
and JMY’s function is in the up-regulation of p53 ?ra«.yactivation (Shikama et a l,
1999). Both JMY and p i4"^ ^^  are therefore regulators of potentially the same 
functional outcome. However JMY appears to prevent the association of MDM2 with 
m vivo.
Given that JMY physically impacts on the M D M 2/pl4^^ interaction it was 
interesting to observe that JMY actually relocalised pl4^^^ from the nucleolus to the 
nucleus. The nucleolar' localisation of p i9 ^ ^  conesponds to its ability to bind 
MDM2 and release p53 while pl4"^^^ actually sequesters MDM2 into nuclear bodies 
(Tao and Levine, 1999b; Weber et a l, 1999; Zhang and Xiong, 1999). It is therefore
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conceivable that JMY interferes with the MDM2/pl4'^^^ interaction by directly de- 
localising pl4^^^ to the nucleus. In agreement with others it therefore appears that 
pl4^^^‘s cellular localisation determines its function and it appears that JMY directly 
affects such a function via its ability to sequester pl4^*^ into the nucleus and prevent 
the formation of nuclear bodies. An interesting possibility is that JMY actually 
enhances the p l4 ^ ^  effect by localising it to the nucleus from where it can directly 
associate with MDM2 upon the appropriate signals, and thereby release p53. 
Conceivably the movement of pl4^^^ out of the nucleolus is a prerequisite for its 
formation of nuclear bodies, and a candidate protein that posses such a function is 
JMY.
The nuclear localisation of p53 is essential for its function as a transcription factor 
(Gannon and Lane, 1991; Shaulsky et a l, 1991; Kamijo et al., 1998; Roth et al., 
1998). In cells that express high levels of pl9^^^ high molecular weight forms of p53 
are detected that likely conespond to poly-ubiquitinated forms (Pomerantz et al., 
1998). So it has been suggested that p i9^^^ may not inhibit the ubiquitation of p53 by 
MDM2 but rather may prevent the degradation of ubiquitated p53 (Kamijo et al.,
1998).
Here I demonstrated that the over-expression of pl4^^^ and MDM2 in SAOS-2 cells 
results in the binding of a high molecular weight form of pl4^^^ to MDM2. The 
functional significance of such a species of p i4^^^ is unknown however given that 
MDM2 modifies p53 by ubiquation it is interesting to speculate that MDM2 may also 
be regulating pl4^^^ cellular levels in an identical manner. Similarly, Kurokawa et al. 
(1999) observed similar high mobility forms of p i9^^^ in fibroblasts prior to Gi arrest
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and they postulate that such species conespond to either degradation intermediates or 
post-translational intermediates. The post-translation modification of p l4 ^ ^  by other 
mechanisms can not be ruled out and a known regulatory mechanism of the 
p53/MDM2 interaction is phosphorylation. Whether the specific species of pl4^^^ in 
the MDM2 complex corresponds to a similar regulated interaction remains to be 
elucidated. It is also interesting to note that MDM2’s stability when complexed with 
pl^ARF reduced (Zhang et al., 1998; Kurokawa et al., 1999; Zhang and Xiong,
1999).
Interestingly, p53’s regulation of the level of pl4^^^ (Roberston and Jones, 1998; 
Stott et al., 1998) is also evident as p53 deficient cells display an elevated level of 
PI4 ARF (Quelle et al., 1995; Kamijo et al., 1997). The repressive effect of p53 is not 
however specific for the ARF locus as p53 represses a variety of other cellular 
promoters such as c-fos, c-Jun, PCNA and interleukin-6 . Whilst the p l4 ^ ^  promoter 
is regulated by p53 and JMY it is interesting to speculate that JMY’s functional 
association with p i4^^^ may impact on these mechanisms of regulation. The auto- 
regulatory feedback loop observed for pl4"^^^ is potentially the mechanism that 
regulates the steady state level of pl4^^^ and the reason why pl4^^^ is a short-lived 
cellular protein. Whether JMY’s association with pl4^^^ is responsible for the down- 
regulation of p i4^^^ expression is unknown although it is possible that such an 
association is one mechanism by which p i4"^ ^^  achieves its auto-regulation.
The up-regulation of p21^ ^^ ^^ *^ '^  ^ can induce a premature senescence phenotype in 
human fibroblasts (McConnell et al., 1998) and E2F-1 is also able to induce a 
sensecence like phenotype in a p53 and p i4^^^ dependent manner (Kamijo et al..
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1999a; Dimri et al., 2000). Clearly JMYAP co-operates with p300 in the induction of 
p2 j^ wafi/cipi pl4/19^^^’s release of p5 3 ’s activity will presumably also induce 
p 2 1 ^afi/cipi expression. These observations suggest that JMY may be involved in the 
fail-safe program that curtails tumourigenesis and age related pathologies, although 
no experimental evidence exists to date.
7.10. pRb transcriptional repression.
pRb’s functional repression of E2F-1 mediated transcription has been directly 
associated with its ability to bind and prevent the function of the fraws'activation 
domain of E2F-1 (Weintraub et ah, 1995). Here I demonstrated results in that the pRb 
repressive function is also dependent on its ability to utilise the histone deacetylase 
family of enzymes in the transient repression of E2F-1 transactivation (Brehm et al., 
1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Brehm and Kouzarides, 1999). 
In fact I demonstrated that HD AC-1 over-expression directly enhances pRb’s 
repressive function (Figure 7.1).
Since p300/CBP co-activates E2F-1 transcription it is possible that pRb overrides this 
transcription by blocking the interaction of p300/CBP with E2F-1 (Trouche et al., 
1996; Luo et al., 1998). Previous studies have demonstrated that pRb and p300 
compete for binding to the transaciivaiion domain of E2F-1 (Helin et al., 1993; Lee 
et al., 1998). However the ability of HDAC-1 to facilitate pRb repression is not 
explained by the overriding of p300 co-activation potential. It therefore appears that 
pRb ability to bind HDAC-1 allows the negation of the histone acetylase activity of 
p300/CBP associated with E2F and results in an active transcriptional repression 
complex.
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Several studies have demonstrated that pRb can associate with E2F-1 and HDAC-1 
simultaneously but the role of other associated proteins such as pRbAp46 and 
pRbAp48 can not be excluded in these assays. Luo et al. (1998) demonstrated that 
pRb efficient repression of E2F transcription is dependent on its association with 
HDAC but it also is evident that the repressive function of pRb is also as a result of 
its direct interaction with E2F. Interestingly, pRb’s ability to bind and recruit histone 
deacetylases is independent of pRb’s role in cell cycle arrest although further studies 
are required to clarify this point (Chan et a l, personal communication). Given that 
pRb associates with the chromatin modulators, BRGl, TAFn250 and Caf-1 via 
RbAp48 its ability to influence transcription by the modulation of chromatin structure 
is almost unquestionable (Hassig et a l, 1997; Hassig and Schrieber, 1997). 
Consistently I demonstrated that the block of chromatin condensation leads to an up- 
regulation of transcription and a loss in pRb’s repressive function presumably as a 
result in the loss of its function, or those of its associated partners, in the modulation 
of chromatin.
7.11. Cross talk between p53 and pRb through JMY.
Numerous studies have demonstrated that pRb has the properties of a transcriptional 
activator and that this function is pocket dependent (Kim et a l,  1992; Dunaief et a l, 
1994; Singh et a l, 1995; Chen et a l, 1996b; Need et a l, 1998). The activator 
potential of pRb although poorly understood is believed to be vital for its tumour 
suppressor function (Sellers and Kaelin, 1996). In agreement pRb’s ability to 
augment MyoD dependent gene expression has been associated with its role in
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tumour suppression and ability to induce differentiation (Gu et al., 1993; Sellers et 
a l, 1998).
Here 1 demonstrated that pRb activates p53-dependent transcription of the box 
promoter and furthermore that pRb co-operated with JMY in this co-activation 
(Figure 7.1). The activating potential of pRb is specific for Bax in the context of p53 
fransactivation and relies, at least in part, on the N-terminus of pRb. Given that the 
N-terminus of pRb has few prescribed functions it appears that in the case of tax  
activation to stabilise the co-activator complex as loss of this region drastically 
reduces pRb activating potential. Whether this reduction in the effectiveness of pRb 
corresponds to a structurally related event or loss of a functional domain is unknown. 
Interestingly, E lA  stimulates the binding of pRb to p300 (Wang et a l, 1995a) but as 
yet the influence of such an interaction on JMY’s function is unknown.
Whereas the pocket region of pRb is vital in its ability to function as a transcriptional 
repressor it is apparent that the pocket region encoded by exon 2 2  is dispensable for 
its function as a p53 activator (Weinberg, 1995). The tumour derived mutant pRbA22 
behaved like wild-type pRb in the activation and co-operation of p53 fran^activation. 
Results presented here imply that the ability of pRb to augment JMY activity is 
exerted independently of pRb dependent growth arrest, which is known to require the 
integrity of the pocket (Weinberg, 1995).
Given that JMY’s cellular localisation appears to be vitally important for its function 
as a co-activator it is intriguing to note that pRb actually displaces a population of 
JMY to the cytoplasm in the presence of p53. Given that JMY is potentially a
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regulated protein it is interesting to assume that the induction of cytoplasmic JMY by 
pRb corresponds to an activation of JMY in a cytoplasmic dependent fashion in 
response to pRb’s anti-proliferative signals. Whether the cytoplasmic population of 
JMY coiTesponds to a dormant, dead or active complex remains unclear.
Interestingly, rb' '^ cells undergo E2F-1 mediated apoptosis and pRb is a direct target 
for TNF induced apoptosis as a functional consequence of inhibition of MDM2 
function (Qin et aL, 1994; Reinder et a l,  1996; Hsieh et al., 1997; Phillips et a l, 
1997; Hsieh et al., 1999). E2F-1 induced apoptosis is overcome by pRb expression in 
an E2F-1 dependent manner (Hsieh et al., 1997). A physiological rationale for the 
actions of pRb on JMY function may be relevant as a process that allows the 
induction of apoptosis upon the inactivation of pRb’s pocket caused, for example, by 
mutational events or the action of viral oncoproteins during tumourigenesis. Cells 
mutated in pRb that are defective in cell cycle arrest would presumably undergo E2F- 
1 apoptosis and additionally would be able to increase p53’s transcriptional activation 
of Bax which would functionally lead to the elimination of potentially neoplastic 
cells.
pRb is also known to promote p53 apoptosis function as a consequence of inhibition 
of MDM2’s function (Hsieh et al., 1999). Hypothetically therefore JMY may be a 
mediator of the apoptotic functions of pRb as a consequence of MDM2’s loss of 
function.
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7.12. Overall conclusions.
Results presented in this thesis provide information that relates to the mechanistic and 
physiological role of the p300 complex in the regulation of the p53 response. In 
particular the data presented here demonstrate that JMY physically and functionally 
co-operates with p300 and moreover implies that splicing of JMY is a vitally 
important event in the discrimination of p53’s role in cell cycle arrest and apoptosis. 
In particular I have demonstrated that the proline rich domain in JMY is a region that 
can functionally control JMY’s cellulai* function.
This study has also identified JMY as a potential regulator of the p i4"^ ^^  tumour 
suppressor pathway. Moreover that analysis of pRb’s role as a transcriptional 
activator has suggested a potentially novel role for pRb in the suppression of 
tumourigenesis, and have also implicated JMY in such a pathway (Figure 7.1).
In order to fully understand the individual roles of the JMY isofoims in gene 
expression and cell cycle control, it will be necessary to document the cellular factors 
that associate with specific isoforms under specific growth conditions. Here I have 
suggested a number of potential mechanisms whereby JMY is able to elicit a specific 
p53 response however to date the actual mechanistic pathway is unknown (Figure
7.1). The understanding and separation of the roles of the individual JMY isoforms 
may well prove productive in the design of anti-tumour reagents and the fight against 
cancer.
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Figure 7.1. Summary of .TMY’s cellular role.
JMY lies at the nexus of the p53 and E2F growth control pathways, by nature of its 
ability to bind p300. The JMY cellular population acts positively via p300 to 
promote either p53 mediated cell cycle arrest or apoptosis. p53 itself plays a 
regulatory role in mediating the actions of the JMY population.
The overexpression of the tumour suppressor p l4 ^ ^ , that stimulates p53’s cellular 
activity by releasing MDM2’s control, is also governed by JMY. JMY stimulates 
p l4 ^ ^  expression, that also regulates, in an auto-regulatory loop, its own expression. 
Surprisingly JMY appears to deteimine the specificity for the pl4^^/M DM 2 
interaction.
In this study, it was also demonstrated that the histone deacetylase family of 
enzymes, HD AC’s, help mediate pRb’s repressive function. pRb, in the context of 
tumour derived mutations is able to stimulate p53 fraw^activation, and intriguingly 
co-operate with JMY in the stimulation of p53 mediated BAX protein expression. 
These findings imply a mechanism whereby tumour cells, that have lost pRb’s 
growth control, have acquired a death mediated pathway, and that JMY is an 
important mediator in this pathway.
Clearly JMY’s ability to influence two of the major growth controlling pathways is 
an indicator as to its cellulai* importance.
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